fluorouracil has been researched along with Vomiting in 299 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Vomiting: The forcible expulsion of the contents of the STOMACH through the MOUTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate whether adding aprepitant to palonosetron and dexamethasone can further prevent the incidence and severity of nausea and vomiting caused by FOLFIRI (fluorouracil, leucovorin, and irinotecan) or FOLFOX (fluorouracil, leucovorin, and oxaliplatin) chemotherapy regimens among women with gastrointestinal cancer at higher risk." | 9.41 | Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial. ( Fong, WP; Hu, MT; Jin, Y; Li, YH; Luo, HY; Peng, JW; Qiu, MZ; Ren, C; Tan, Q; Wang, DS; Wang, FH; Wang, SB; Wang, ZQ; Zou, QF, 2021) |
| "To investigate whether palonosetron is better than granisetron in preventing chemotherapy-induced nausea and vomiting (CINV) in a three-drug combination with dexamethasone and fosaprepitant (Fos) in patients with breast cancer who are placed on anthracycline and cyclophosphamide (AC-based regimen)." | 9.34 | A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophospham ( Aogi, K; Baba, M; Chiba, Y; Fujiwara, K; Hirano, G; Imamura, CK; Imoto, S; Matsumoto, K; Matsuura, K; Miyazaki, C; Naito, Y; Osaki, A; Saeki, T; Sato, K; Takahashi, M; Takano, T; Tamura, K; Tokunaga, S; Yanagihara, K, 2020) |
| "Chemotherapy-induced nausea and vomiting (CINV) causes significant morbidity among colorectal cancer patients, receiving fluorouracil, oxaliplatin, and leucovorin (FOLFOX) chemotherapy even with standard antiemetic prophylaxis." | 9.27 | Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer. ( Blanke, C; Bubalo, JS; Chen, E; Edwards, MS; Fisher, A; Herrington, JD; Lopez, CD; Palumbo, A; Takemoto, M; Williams, C; Willman, P, 2018) |
| "The granisetron transdermal system (GTS) showed non-inferior efficacy to oral granisetron to control chemotherapy-induced nausea and vomiting (CINV) during multiday chemotherapy." | 9.20 | A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients. ( Ahn, JS; Hong, YS; Kim, JE; Kim, KP; Kim, TW; Lee, J; Lee, JL; Park, SJ; Park, YS; Shin, DB; Sym, SJ, 2015) |
| "The aprepitant therapy was more effective than the control therapy for prevention of CINV in colorectal cancer patients receiving an oxaliplatin-based regimen." | 9.20 | Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. ( Doki, Y; Fukunaga, M; Fukuzaki, T; Hata, T; Ide, Y; Kudo, T; Miyake, Y; Mizushima, T; Mori, M; Morita, S; Nakata, K; Nezu, R; Nishimura, J; Ohno, Y; Sakai, D; Satoh, T; Sekimoto, M; Takemasa, I; Takemoto, H; Uemura, M; Yamamoto, H; Yasui, M, 2015) |
| "Adverse events associated with 5-fluorouracil (5FU) based adjuvant therapy in colorectal cancer (CRC) patients may predict survival." | 9.19 | Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity? ( André, T; Bono, P; de Gramont, A; Hermunen, K; Österlund, P; Poussa, T; Quinaux, E; Soveri, LM, 2014) |
| "We report the long-term results of a randomised trial comparing tamoxifen with tamoxifen plus cyclophosphamide, methotrexate and fluorouracil (CMF) in postmenopausal high-risk breast cancer patients." | 9.17 | One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer. ( Andersen, J; Andersson, M; Cold, S; Ejlertsen, B; Elversang, J; Jensen, MB; Mouridsen, HT; Nielsen, DL; Rasmussen, BB, 2013) |
| "The safety and efficacy of neratinib monotherapy were compared with that of lapatinib plus capecitabine in patients with human epidermal growth factor receptor-2-positive (HER2+), locally advanced/metastatic breast cancer and prior trastuzumab treatment." | 9.17 | A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. ( Awada, A; Bonneterre, J; Germa, C; Geyer, CE; Ito, Y; Kim, SB; Lang, I; Martin, M; Ro, J; Vermette, J; Wang, K, 2013) |
| "To evaluate the maximum tolerated dose (MTD) and pharmacokinetic profile of a chronomodulated, dose-intensified regimen of capecitabine in combination with oxaliplatin (XELOX) in metastatic colorectal cancer (mCRC)." | 9.16 | Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer. ( Chen, X; Choo, SP; Chowbay, B; Farid, M; Koo, WH; Ong, SY; Ramasamy, S; Tan, SH; Toh, HC, 2012) |
| "To compare the efficacy and feasibility of neoadjuvant chemoradiotherapy with docetaxel plus cisplatin or with cisplatin plus fluorouracil in the treatment of local advanced esophageal squamous cell carcinoma." | 9.16 | [Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma]. ( Chen, MY; Chen, Z; Luo, JC; Wei, L; Wu, S, 2012) |
| "This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable metastatic colorectal cancer." | 9.14 | Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. ( Brezault, C; Cals, L; Husseini, F; Loos, AH; Nippgen, J; Peeters, M; Raoul, JL; Rougier, P; Van Laethem, JL, 2009) |
| "Gastric cancer patients with cytologically confirmed malignant ascites were treated with cycles of oxaliplatin at 85 mg/m(2) plus leucovorin 20 mg/m(2) on the first day of treatment, followed by 5-fluorouracil (5-FU) via a 400 mg/m(2) bolus and a 22 h continuous infusion of 600 mg/m(2) 5-FU on Days 1-2 at 2-week intervals." | 9.12 | A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. ( Jang, JS; Jeong, JS; Kim, HJ; Kim, MC; Kim, SH; Kwon, HC; Lee, DM; Lee, S; Oh, SY; Yoo, HS, 2007) |
| "To evaluate the toxicity and efficacy of concurrent chemoirradiation with cisplatin followed by adjuvant ifosfamide, 5-fluorouracil and leucovorin in patients with stage IVb nasopharyngeal carcinoma (NPC) PATIENTS AND METHODS: Between October 1998 and August 2001, 35 Chinese patients with stage IVb NPC (N3a:12, N3b:23) were treated with by concurrent chemoirradiation using cisplatin 100 mg/m2 on days 1, 22, and 43 of radiotherapy, followed by adjuvant chemotherapy with 1." | 9.11 | A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma. ( Au, GK; Chua, DT; Sham, JS, 2004) |
| "The purpose is to determine the plasma pharmacokinetics, the maximum-tolerable dose and to preliminary evaluate the antitumor activity of irinotecan administered as a 7-day continuous infusion every 21 days in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed." | 9.11 | A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. ( Allegrini, G; Barbara, C; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G, 2004) |
| "To verify the effectiveness of oral 1-hexylcarbamoyl-5-fluorouracil (HCFU) in improving the surgical cure rate in advanced colorectal cancer, a multicenter randomized comparative study was conducted." | 9.11 | A multicenter randomized study comparing 5-fluorouracil continuous infusion (ci) plus 1-hexylcarbamoyl-5-fluorouracil and 5-FU ci alone in colorectal cancer. ( Kodaira, S; Kotake, K; Koyama, Y; Ohashi, Y, 2005) |
| "Alprazolam, a newer benzodiazepine, may be useful in the control of nausea and vomiting in breast cancer patients." | 9.11 | Alprazolam significantly improves the efficacy of granisetron in the prophylaxis of emesis secondary to moderately emetogenic chemotherapy in patients with breast cancer. ( Abali, H; Guler, N; Oyan, B, 2005) |
| "To assess the feasibility and activity of a combination schedule with irinotecan (CPT-11), oxaliplatin (L-OHP), brief infusional fluorouracil (5-FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer (MCC) patients." | 9.11 | An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial. ( Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Pasinetti, N; Rangoni, G; Simoncini, E; Valcamonico, F; Vassalli, L, 2005) |
| "To evaluate the feasibility and a possible activity range of combination irinotecan (CPT-11), oxaliplatin, and 5-FU in advanced colorectal cancer (ACC)." | 9.10 | Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study. ( Aramendía, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; González-Cao, M; Martín-Algarra, S; Martínez-Monge, R; Rodríguez, J; Salgado, JE, 2002) |
| " once every 3 weeks was assessed in 60 patients with advanced colorectal cancer (CRC) showing failure to 5-fluorouracil (5-FU) treatment." | 9.10 | Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. ( Abad, A; Antón, A; Aranda, E; Balcells, M; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fenández-Martos, C; Gallén, M; Huarte, L; Marcuello, E; Massutti, B; Sastre, J, 2003) |
| "The inhibitory effect of ramosetron hydrochloride (Ram), a 5-HT3 receptor antagonist, on nausea and vomiting occurring in CMF or CEF therapy as a pre- or postoperative adjuvant chemotherapy or chemotherapy for recurrent cancer was evaluated in 34 patients with breast cancer." | 9.09 | [Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer]. ( Hojo, S; Noguchi, S; Shiba, E; Taguchi, T; Takamura, Y; Tsukamoto, F; Watanabe, T; Yoneda, K, 1999) |
| "The aim of our single-center, prospective, randomized, open study was to evaluate the antiemetic efficacy and tolerability of a regimen based on a single oral dose of ondansetron 8 mg in comparison with a metoclopramide-based regimen, for prevention of acute FAC (fluorouracil, doxorubicin and cyclophosphamide) chemotherapy-induced emesis." | 9.09 | High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer. ( Bosnjak, SM; Mitrovi, LB; Nesković-Konstantinović, ZB; Radulović, SS; Susnjar, S, 2000) |
| "We have reported that an alternating regimen of bolus and continuous infusion 5-fluorouracil (FU) was superior to bolus FU in terms of response rate and progression-free survival in advanced colorectal cancer." | 9.09 | 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. ( Aschele, C; Caroti, C; Cirillo, M; Cortesi, E; Frassineti, GL; Gallo, L; Grossi, F; Guglielmi, A; Labianca, R; Pessi, MA; Ravaioli, A; Recaldin, E; Sobrero, A; Testore, P; Turci, D, 2001) |
| "The purpose of this study was to evaluate the activity and safety of oxaliplatin and protracted venous infusion of 5-fluorouracil (PVI 5-FU) in patients with advanced or relapsed 5-FU pretreated colorectal cancer." | 9.09 | Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. ( Chau, I; Cunningham, D; Hill, M; Massey, A; Norman, A; Waters, JS; Webb, A, 2001) |
| "The comparative study among granisetron alone and granisetron combined with hydroxyzine hydrochloride or dexamethasone was undertaken for the prevention of nausea and vomiting during chemotherapy including cisplatin in patients with advanced head and neck carcinomas." | 9.08 | [Comparison of granisetron alone and granisetron plus dexamethasone or hydroxyzine hydrochloride for the prevention of nausea and vomiting during chemotherapy including cisplatin]. ( Enomoto, H; Furukawa, M; Ikema, Y; Kawai, S; Kohno, H; Kubota, A; Makino, Y; Matsuda, H; Tsukuda, M; Yago, T, 1995) |
| "To determine whether a combination chemotherapy regimen that contains epirubicin (fluorouracil, epirubicin, and cyclophosphamide [FEC]) is superior to the standard cyclophosphamide, methotrexate, and fluorouracil (CMF) combination in premenopausal women with axillary node-positive operable breast cancer." | 9.08 | Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collab ( Aapro, M; Amadori, D; Bliss, JM; Chilvers, CE; Coombes, G; Coombes, RC; Espié, M; Ferreira, EP; Gambrosier, P; Marty, M; McArdle, C; Morvan, F; Pérez-López, FR; Richards, M; Vassilopoulos, P; Villar-Grimalt, A; Wils, J; Woods, EM, 1996) |
| "Both the biochemical modulation and the continuous administration of 5-fluorouracil (5-FU) have achieved promising results in patients with gastric carcinoma." | 9.08 | Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group. ( Belón, J; Blanco, E; Espinosa, E; Feliu, J; García-Alfonso, P; García-Girón, C; Garrido, P; Gómez-Navarro, J; González Barón, M; Ordónez, A; Zamora, P, 1996) |
| "A crossover clinical trial between granisetron alone and granisetron combined with methylprednisolone (MPL) was undertaken for the prevention of nausea and vomiting during chemotherapy, including cisplatin, in 12 patients with advanced primary and metastatic lung cancer." | 9.08 | [Comparative trial of granisetron alone and granisetron plus methylprednisolone for prevention of nausea and vomiting during cancer chemotherapy]. ( Fujishima, H; Hisano, C; Masumoto, N; Nakamura, M; Nakano, S; Niho, Y; Okuma, K, 1996) |
| "The aim of this open, nonrandomized, monocentric study was to evaluate the efficacy of a single daily dose of 8 mg oral ondansetron in the prophylaxis of acute nausea and vomiting in chemotherapy-naive breast cancer patients receiving their first cycle of chemotherapy with 5-fluorouracil, doxorubicin and cyclophosphamide (FAC)." | 9.08 | Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting. ( Bosnjak, SM; Jovanovic-Micic, DJ; Mitrovic, LB; Neskovic-Konstantinovic, ZB; Radulovic, SS, 1996) |
| "Azasetron, a selective 5-HT3 receptor antagonist, has been previously shown to be highly effective in the prophylaxis of nausea and vomiting induced by anticancer drugs, and is widely used in the clinical setting in Japan." | 9.08 | [Clinical effect of two azasetron treatment methods against nausea and vomiting induced by anticancer drugs including CDDP]. ( Kimura, E; Niimi, S; Tanaka, T; Watanabe, A, 1997) |
| "Efficacy of combination of ondansetron injection and tablet on CAF (cyclophosphamide, adriamycin, 5-fluorouracil) induced emesis were investigated in 10 breast cancer patients (33 courses)." | 9.08 | [Efficacy of combination of ondansetron injection and tablet in CAF-induced emesis in breast cancer patients]. ( Furukawa, T; Kurihara, N; Machimura, T; Nemoto, Y; Nishihori, H; Shinohara, H; Urakami, H; Yonekawa, H, 1998) |
| " A sample of 43 patients with breast cancer was accrued from September to November 1992 in a phase II study to assess the efficacy of granisetron in patients receiving FEC (5-FU, epirubicin, cyclophosphamide)." | 9.07 | Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide. ( Ang, PT; Khoo, KS; Tan, EH, 1994) |
| "The combination of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) is a widely used chemotherapy regimen in breast cancer patients." | 9.07 | Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study. ( Aapro, MS; Bauer, J; Brunner, KW; Buser, KS; Cavalli, F; Haefliger, JM; Joss, RA; Jungi, WF; Obrist, R; Piquet, D, 1993) |
| " To address its use with a widely used but less emetogenic regimen, we performed a double-blind, randomized clinical trial comparing ondansetron with dexamethasone and metoclopramide in patients with breast cancer receiving chemotherapy with cyclophosphamide, methotrexate, and fluorouracil." | 9.07 | Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. ( Latreille, J; Levitt, M; Lofters, WS; Perrault, DJ; Potvin, M; Rayner, HL; Warner, E; Warr, D; Wilson, KS; Yelle, L, 1993) |
| " 97 female breast cancer patients who received their first two FEC courses (epirubicin 50-75 mg/m2, 5-fluorouracil 500 mg/m2, cyclophosphamide 500 mg/m2) entered this randomised crossover study (76 had previously received an adjuvant treatment); tetracosactrin was administered intramuscularly and methylprednisolone intravenously immediately before chemotherapy administration." | 9.07 | Tetracosactrin vs. methylprednisolone in the prevention of emesis in patients receiving FEC regimen for breast cancer. ( Bastit, P; Bonneterre, J; Cappelaere, P; Chevrier, A; Fargeot, P; Geyer, G; Kerbrat, P; Metz, R; Roche, H; Tubiana-Hulin, M, 1991) |
| "The efficacy of the serotonin antagonist ondansetron (GR 38032F) was evaluated in the prevention of nausea and vomiting induced by CMF chemotherapy in 29 breast cancer patients." | 9.07 | Oral ondansetron (GR 38032F) for the control of CMF-induced emesis in the outpatient. ( Campora, E; Cetto, GL; Fosser, V; Mammoliti, S; Marangolo, M; Oliva, C; Rosso, R, 1991) |
| "Seventy-five breast cancer patients scheduled to receive a first course (in a new cycle) of cyclophosphamide, fluorouracil, and doxorubicin (FAC) or epirubicin (FEC) participated in a double-blind crossover study to compare the antiemetic efficacy and safety of ondansetron (GR38032), a 5-hydroxytryptamine3 (5-HT3) receptor antagonist, and metoclopramide." | 9.06 | A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. ( Bonneterre, J; Bons, J; Chevallier, B; Fargeot, P; Metz, R; Paes, D; Pujade-Lauraine, E; Spielmann, M; Tubiana-Hulin, M, 1990) |
| "Thirty patients with advanced breast cancer, previously treated with anthracycline and 5 fluorouracil in bolus administration, were evaluated with a chemotherapy regimen generally used in head and neck cancer." | 9.06 | [Phase II trial as 2nd line chemotherapy with 5 fluorouracil and cisplatin (5FU-CDDP) for advanced breast cancer]. ( Bastit, P; Bugat, R; Cappelaere, P; Chauvergne, J; Fumoleau, P; Horner, D; Metz, R, 1990) |
| " cyclophosphamide, methotrexate, and 5-fluorouracil (CMF), 25 women with stage II breast cancer were entered into this study." | 9.06 | Effective control of CMF-related emesis with high-dose dexamethasone: results of a double-blind crossover trial with metoclopramide and placebo. ( Giannarelli, D; Marolla, P; Nardi, M; Pinnaró, P; Pollera, CF; Terzoli, E, 1989) |
| "The antiemetic effectiveness of haloperidol plus dexamethasone was compared with that of prochlorperazine plus dexamethasone in a prospective study of patients receiving chemotherapy for breast cancer." | 9.06 | A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer. ( Carpenter, JT; Conolley, C; Lee, J; Silvey, L; Wheeler, RH, 1988) |
| "Sixty-eight breast cancer patients for outpatient adjuvant chemotherapy (CT) with cyclophosphamide, methotrexate, and fluorouracil (CMF) on a 1-day schedule entered a randomized trial comparing the antiemetic-efficacy of different doses of methylprednisolone (MPN)." | 9.06 | Methylprednisolone for the control of CMF-induced emesis. ( Bruzzi, P; Campora, E; Chiara, S; Lionetto, R; Rosso, R, 1987) |
| " CMF were included in a double-blind comparative study aimed at evaluating the efficacy of 3 different drugs (methylprednisolone (MP), metoclopramide (MTC), and domperidone (DMP) in preventing chemotherapy-induced nausea and vomiting." | 9.06 | Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF. ( Ballatori, E; Basurto, C; del Favero, A; Minotti, V; Roila, F; Tonato, M, 1987) |
| "The antiemetic efficacy and toxicity of methylprednisolone (MP) and metoclopramide (MTC) in prevention of nausea and vomiting in breast cancer patients receiving intravenous cyclophosphamide methotrexate 5-fluorouracil (CMF) chemotherapy has been evaluated in a double-blind trial." | 9.06 | Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized study. ( Ballatori, E; Basurto, C; Del Favero, A; Minotti, V; Roila, F; Tonato, M, 1988) |
| "Patients with visceral patterns of metastatic breast cancer were stratified according to dominant metastatic site and performance status and then randomized to therapy with cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) or CAF alternating with a "cell-cycle active" regimen including cytosine arabinoside, methotrexate with leucovorin rescue, and oncovin ( CAMELEON )." | 9.05 | Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project. ( Carpenter, J; Fishkin, E; Krauss, S; Moore, MR; Raab, S; Raney, M; Smalley, RV; Stagg, M; Velez-Garcia, E; Vogel, CL, 1984) |
| "To determine the incidence of anticipatory vomiting (AV) and postchemotherapy nausea and vomiting (PCNV) in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma, we studied 52 women randomized to two regimens (standard-dose and low-dose) of CMF." | 9.05 | Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma. ( Abeloff, MD; Fetting, JH; Nettesheim, KM; Wilcox, PM, 1982) |
| "Data on 162 women (90 premenopausal and 72 postmenopausal) with metastatic breast cancer randomized to receive cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF) on two Eastern Cooperative Oncology Group (ECOG) protocols were analyzed." | 9.05 | The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Carbone, PP; Cummings, FJ; Falkson, G; Falkson, HC; Gelman, RS; Tormey, DC, 1985) |
| "As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF)." | 9.05 | A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Bennett, JM; Byrne, P; DeConti, R; Desai, A; Doroshow, J; Krementz, E; Muggia, F; Plotkin, D; Vogel, C; White, C, 1985) |
| "One hundred and sixteen patients with advanced and metastatic adenocarcinoma of the pancreas were randomized to treatment with combined Streptozotocin and 5-fluorouracil or combined Streptozotocin and cyclophosphamide." | 9.04 | Treatment of advanced adenocarcinoma of the pancreas with combinations of streptozotocin plus 5-fluorouracil and streptozotocin plus cyclophosphamide. ( Carbone, PP; Douglas, HO; Hanley, J; Moertel, CG, 1977) |
| "An electronic search was undertaken to identify randomized controlled trials comparing raltitrexed-based regimen to 5-fluorouracil-based regimen in patients with advanced colorectal cancer." | 8.90 | Raltitrexed-based chemotherapy for advanced colorectal cancer. ( Hong, W; Huang, Q; Liu, Y; Sun, X; Wu, J; Wu, W, 2014) |
| " A phase III randomized trial, Xeloda in Adjuvant Colorectal Cancer Treatment, demonstrated that treatment with single-agent capecitabine was equivalent to bolus 5-fluorouracil with leucovorin with respect to disease-free survival and overall survival, with significantly less diarrhea, stomatitis, neutropenia, nausea and vomiting, and alopecia." | 8.83 | Capecitabine: a new adjuvant option for colorectal cancer. ( Berg, DT, 2006) |
| " This study evaluated the percentages of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) undergoing second-line therapy with 5-fluorouracil (5-FU)-based regimens that experienced AEs during treatment and received medication to manage those AEs." | 8.12 | Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma. ( Cockrum, P; Kim, G; Surinach, A; Wainberg, Z; Wang, S, 2022) |
| "Although efficacy of aprepitant for suppressing emesis associated with single-dose cisplatin has been demonstrated, there are limited data on the antiemetic effect of this oral neurokinin-1 receptor antagonist during daily administration of cisplatin." | 7.80 | Efficacy of aprepitant for nausea in patients with head and neck cancer receiving daily cisplatin therapy. ( Ishimaru, K; Kaneko, K; Katsura, M; Takahashi, H; Takano, A; Yamaguchi, N, 2014) |
| "To evaluate the efficacy of reduction of dexamethasone with a single-dose of palonosetron in preventing acute and delayed nausea and vomiting in patients receiving highly emetogenic chemotherapy (HEC) for early breast cancer." | 7.79 | Single-dose palonosetron and dose-reduced regimen of dexamethasone in preventing nausea and vomiting by anthracycline-including chemotherapy in patients with early breast cancer. ( Cardillo, FD; Cognetti, F; Evangelista, S; Fabi, A; Fattoruso, SI; Pacetti, U; Veltri, E, 2013) |
| " In this retrospective study, we assessed the efficacy of palonosetron versus granisetron for the incidence of CINV induced by mFOLFOX6 and FOLFIRI in patients with advanced colorectal cancer." | 7.78 | [Antiemetic effect of palonosetron in advanced colorectal cancer patients receiving mFOLFOX6 and FOLFIRI: a retrospective survey]. ( Hayakawa, Y; Muro, K; Noma, H; Okamoto, H; Sato, Y; Tatematsu, M, 2012) |
| "The aim of the study was to evaluate the role of ramosetron for the prevention of chemoradiotherapy-induced nausea and vomiting (CRINV) in patients receiving upper abdominal irradiation with concurrent 5-fluorouracil chemotherapy." | 7.75 | Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer. ( Bang, YJ; Chie, EK; Ha, SW; Im, SA; Jang, JY; Kim, K; Kim, SW; Kim, TY; Oh, DY, 2009) |
| "Short-term infusion of 5-fluorouracil with leucovorin in combination with irinotecan or oxaliplatin has been considered as standard treatment for metastatic colorectal cancer." | 7.74 | Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan. ( Boku, N; Fukutomi, A; Hasuike, N; Hironaka, S; Machida, N; Ono, H; Onozawa, Y; Yamaguchi, Y; Yamazaki, K; Yoshino, T, 2007) |
| "The antiemetic efficacy of granisetron in repeated CAF chemotherapy after breast cancer operation was investigated." | 7.69 | [Antiemetic efficacy of granisetron in repeated CAF chemotherapy after breast cancer operation]. ( Hatano, Y; Kato, N; Okuyama, N; Park, Y; Sasamoto, S; Yamazaki, S, 1997) |
| "A total of 60 patients with advanced breast cancer were treated with a combination of prednimustine (P: 110 mg/m2, days 1-5), mitoxantrone (M: 12 mg/m2, day 1) and 5-fluorouracil (F: 500 mg/m2, day 1) (PMF)." | 7.68 | Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer. ( Dusleag, J; Kasparek, AK; Lechner, P; Pfeiffer, K; Samonigg, H; Schmid, M; Smola, M; Steindorfer, P; Stöger, H, 1991) |
| "Twenty-nine patients with metastatic breast cancer were treated with fluorouracil, adriamycin, cyclophosphamide (FAC), and methotrexate (MTX), with or without leukovorin rescue." | 7.67 | Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate. ( Aboud, A; Blumenschein, GR; Buzdar, AU; Hortobagyi, GN; Yap, HY, 1984) |
| "Thirty patients with advanced breast cancer, not pretreated with chemotherapy, received a polychemotherapy regimen containing mitoxantrone, fluorouracil and cyclophosphamide at the dose of 10 mg/m2, 500 mg/m2 and 500 mg/m2 i." | 7.67 | Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer. ( Canova, N; Ercolino, L; Martoni, A; Pannuti, F; Rani, P, 1988) |
| "Forty-six outpatients with breast cancer who had experienced severe emesis as a result of chemotherapy were evaluated for the antiemetic efficacy of high-dose metoclopramide (HD-MCP) and dexamethasone (DXM)." | 7.67 | High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second study. ( Ben-Baruch, N; Ben-Yosef, R; Biran, S; Brufman, G; Gez, E; Uziely, B; Warner-Efraty, E; Yitzhaki, N, 1987) |
| "In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose." | 7.67 | Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer. ( Armand, JP; Cappelaere, P; Delgado, M; Grimbert, J; Keiling, R; Mathe, G; Metz, R; Misset, JL; Prevot, G, 1985) |
| "In mouse models of pancreatic cancer, IPI-926, an oral Hedgehog inhibitor, increases chemotherapy delivery by depleting tumor-associated stroma." | 6.82 | A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. ( Catenacci, DV; Chang, WC; Kantoff, E; Kate Kelley, R; Kindler, HL; Ko, AH; Lewis, S; LoConte, N; Tempero, MA; Vannier, MW; Venook, AP; Walker, EJ, 2016) |
| "Survival time for metastatic breast cancer (MBC) can be substantially improved by combination chemotherapy in the adjuvant setting." | 6.75 | A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines. ( Alexopoulos, A; Ardavanis, A; Ioannidis, G; Kandylis, C; Malliou, S; Orphanos, G; Rigatos, G; Stavrakakis, J, 2010) |
| "Grade 4 leukopenia was observed in 1 case and grade 3 to 4 thrombocytopenia was observed in two cases, respectively." | 6.68 | The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD). ( Antón-Torres, A; Aranda, E; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fernández-Martos, C; Massutí, T, 1996) |
| "The outbreak of coronavirus disease 2019 (COVID-19) has affected the treatment of cancer patients, with particular regard to the management of both chemotherapy and side effects." | 5.62 | NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study. ( Caputo, V; Cicero, G; De Luca, R; Ferrera, G; Mistretta, O; Paci, R; Rosati, G; Volpe, C, 2021) |
| "Among the advanced colorectal cancer patients who received treatment with FOLFOX or FOLFIRI at Koyama Memorial Hospital, patients older than 65 years of age were selected in order to assess the effectiveness of aprepitant as an antiemetic supportive therapy." | 5.43 | [Study of the Efficacy of Aprepitant in FOLFOX/FOLFIRI for Elderly Patients with Advanced Colorectal Cancer]. ( Hanaka, J; Nakayama, H; Takahashi, M; Terashima, T, 2016) |
| "To evaluate whether adding aprepitant to palonosetron and dexamethasone can further prevent the incidence and severity of nausea and vomiting caused by FOLFIRI (fluorouracil, leucovorin, and irinotecan) or FOLFOX (fluorouracil, leucovorin, and oxaliplatin) chemotherapy regimens among women with gastrointestinal cancer at higher risk." | 5.41 | Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial. ( Fong, WP; Hu, MT; Jin, Y; Li, YH; Luo, HY; Peng, JW; Qiu, MZ; Ren, C; Tan, Q; Wang, DS; Wang, FH; Wang, SB; Wang, ZQ; Zou, QF, 2021) |
| "Aprepitant is a very active antiemetic drug for the prevention of delayed nausea and vomiting induced by mFOLFOX6 regimen." | 5.36 | [Clinical usefulness of oral aprepitant for alleviation of delayed nausea and vomiting induced by mFOLFOX6--report of a case]. ( Abe, T; Hachiro, Y; Kunimoto, M, 2010) |
| "To investigate whether palonosetron is better than granisetron in preventing chemotherapy-induced nausea and vomiting (CINV) in a three-drug combination with dexamethasone and fosaprepitant (Fos) in patients with breast cancer who are placed on anthracycline and cyclophosphamide (AC-based regimen)." | 5.34 | A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophospham ( Aogi, K; Baba, M; Chiba, Y; Fujiwara, K; Hirano, G; Imamura, CK; Imoto, S; Matsumoto, K; Matsuura, K; Miyazaki, C; Naito, Y; Osaki, A; Saeki, T; Sato, K; Takahashi, M; Takano, T; Tamura, K; Tokunaga, S; Yanagihara, K, 2020) |
| "Chemotherapy-induced nausea and vomiting (CINV) causes significant morbidity among colorectal cancer patients, receiving fluorouracil, oxaliplatin, and leucovorin (FOLFOX) chemotherapy even with standard antiemetic prophylaxis." | 5.27 | Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer. ( Blanke, C; Bubalo, JS; Chen, E; Edwards, MS; Fisher, A; Herrington, JD; Lopez, CD; Palumbo, A; Takemoto, M; Williams, C; Willman, P, 2018) |
| "Diphenhydramine was administered intramuscularly 30 minutes before and 5 hours after chemotherapy." | 5.27 | [The prevention of CDDP-induced emesis with a combination regimen including metoclopramide, dexamethasone, droperidol and diphenhydramine]. ( Arihiro, T; Dozono, H; Morimoto, O; Ochiai, K; Sasaki, H; Takahashi, S; Terashima, Y; Tsuruoka, M; Yasuda, M; Yokoyama, S, 1987) |
| "Sixteen patients with advanced colo-rectal cancer were treated with the combination methyl-CCNU, vincristin, 5-fluorouracil and streptozotocin (MOF-Strepto)." | 5.26 | [The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma]. ( Cavalli, F; Sessa, C; Togni, P; Varini, M, 1982) |
| "The purpose of this phase II study was to explore the efficacy and safety of an alternating regimen consisting of folinic acid, 5-fluorouracil (5-FU) and oxaliplatin (mFOLFOX6) plus bevacizumab, and folinic acid, 5-FU and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer." | 5.22 | Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801). ( Akagi, Y; Emi, Y; Higashi, H; Ishikawa, H; Kusumoto, T; Maehara, Y; Matsuda, H; Miwa, K; Ogata, Y; Oki, E; Saeki, H; Samura, H; Sueyoshi, S; Tanaka, T; Tokunaga, S; Touyama, T, 2016) |
| "The granisetron transdermal system (GTS) showed non-inferior efficacy to oral granisetron to control chemotherapy-induced nausea and vomiting (CINV) during multiday chemotherapy." | 5.20 | A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients. ( Ahn, JS; Hong, YS; Kim, JE; Kim, KP; Kim, TW; Lee, J; Lee, JL; Park, SJ; Park, YS; Shin, DB; Sym, SJ, 2015) |
| "The aprepitant therapy was more effective than the control therapy for prevention of CINV in colorectal cancer patients receiving an oxaliplatin-based regimen." | 5.20 | Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. ( Doki, Y; Fukunaga, M; Fukuzaki, T; Hata, T; Ide, Y; Kudo, T; Miyake, Y; Mizushima, T; Mori, M; Morita, S; Nakata, K; Nezu, R; Nishimura, J; Ohno, Y; Sakai, D; Satoh, T; Sekimoto, M; Takemasa, I; Takemoto, H; Uemura, M; Yamamoto, H; Yasui, M, 2015) |
| "Adverse events associated with 5-fluorouracil (5FU) based adjuvant therapy in colorectal cancer (CRC) patients may predict survival." | 5.19 | Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity? ( André, T; Bono, P; de Gramont, A; Hermunen, K; Österlund, P; Poussa, T; Quinaux, E; Soveri, LM, 2014) |
| "We report the long-term results of a randomised trial comparing tamoxifen with tamoxifen plus cyclophosphamide, methotrexate and fluorouracil (CMF) in postmenopausal high-risk breast cancer patients." | 5.17 | One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer. ( Andersen, J; Andersson, M; Cold, S; Ejlertsen, B; Elversang, J; Jensen, MB; Mouridsen, HT; Nielsen, DL; Rasmussen, BB, 2013) |
| "The safety and efficacy of neratinib monotherapy were compared with that of lapatinib plus capecitabine in patients with human epidermal growth factor receptor-2-positive (HER2+), locally advanced/metastatic breast cancer and prior trastuzumab treatment." | 5.17 | A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. ( Awada, A; Bonneterre, J; Germa, C; Geyer, CE; Ito, Y; Kim, SB; Lang, I; Martin, M; Ro, J; Vermette, J; Wang, K, 2013) |
| "To evaluate the maximum tolerated dose (MTD) and pharmacokinetic profile of a chronomodulated, dose-intensified regimen of capecitabine in combination with oxaliplatin (XELOX) in metastatic colorectal cancer (mCRC)." | 5.16 | Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer. ( Chen, X; Choo, SP; Chowbay, B; Farid, M; Koo, WH; Ong, SY; Ramasamy, S; Tan, SH; Toh, HC, 2012) |
| "To compare the efficacy and feasibility of neoadjuvant chemoradiotherapy with docetaxel plus cisplatin or with cisplatin plus fluorouracil in the treatment of local advanced esophageal squamous cell carcinoma." | 5.16 | [Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma]. ( Chen, MY; Chen, Z; Luo, JC; Wei, L; Wu, S, 2012) |
| "This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable metastatic colorectal cancer." | 5.14 | Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. ( Brezault, C; Cals, L; Husseini, F; Loos, AH; Nippgen, J; Peeters, M; Raoul, JL; Rougier, P; Van Laethem, JL, 2009) |
| "A single-institution Phase I clinical trial was conducted to determine the maximum tolerated dose (MTD) and define the safety profile of temozolomide and capecitabine when used in combination to treat brain metastases from breast cancer." | 5.12 | Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. ( Arun, B; Broglio, K; Buchholz, T; Francis, D; Groves, M; Hortobagyi, GN; Meyers, C; Rivera, E; Valero, V; Yin, G, 2006) |
| "Gastric cancer patients with cytologically confirmed malignant ascites were treated with cycles of oxaliplatin at 85 mg/m(2) plus leucovorin 20 mg/m(2) on the first day of treatment, followed by 5-fluorouracil (5-FU) via a 400 mg/m(2) bolus and a 22 h continuous infusion of 600 mg/m(2) 5-FU on Days 1-2 at 2-week intervals." | 5.12 | A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. ( Jang, JS; Jeong, JS; Kim, HJ; Kim, MC; Kim, SH; Kwon, HC; Lee, DM; Lee, S; Oh, SY; Yoo, HS, 2007) |
| "To evaluate tolerance and toxicity of high-dose epirubicin regimen CEF-100 as adjuvant therapy for breast cancer." | 5.12 | [Comparison of tolerance and toxicity of CEF-100 regimen versus CEF-60 regimen as adjuvant therapy for breast cancer]. ( Hao, XM; Hui, R; Zhang, J; Zhang, M, 2007) |
| "To evaluate the toxicity and efficacy of concurrent chemoirradiation with cisplatin followed by adjuvant ifosfamide, 5-fluorouracil and leucovorin in patients with stage IVb nasopharyngeal carcinoma (NPC) PATIENTS AND METHODS: Between October 1998 and August 2001, 35 Chinese patients with stage IVb NPC (N3a:12, N3b:23) were treated with by concurrent chemoirradiation using cisplatin 100 mg/m2 on days 1, 22, and 43 of radiotherapy, followed by adjuvant chemotherapy with 1." | 5.11 | A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma. ( Au, GK; Chua, DT; Sham, JS, 2004) |
| "The purpose is to determine the plasma pharmacokinetics, the maximum-tolerable dose and to preliminary evaluate the antitumor activity of irinotecan administered as a 7-day continuous infusion every 21 days in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed." | 5.11 | A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. ( Allegrini, G; Barbara, C; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G, 2004) |
| "To verify the effectiveness of oral 1-hexylcarbamoyl-5-fluorouracil (HCFU) in improving the surgical cure rate in advanced colorectal cancer, a multicenter randomized comparative study was conducted." | 5.11 | A multicenter randomized study comparing 5-fluorouracil continuous infusion (ci) plus 1-hexylcarbamoyl-5-fluorouracil and 5-FU ci alone in colorectal cancer. ( Kodaira, S; Kotake, K; Koyama, Y; Ohashi, Y, 2005) |
| "Alprazolam, a newer benzodiazepine, may be useful in the control of nausea and vomiting in breast cancer patients." | 5.11 | Alprazolam significantly improves the efficacy of granisetron in the prophylaxis of emesis secondary to moderately emetogenic chemotherapy in patients with breast cancer. ( Abali, H; Guler, N; Oyan, B, 2005) |
| "To assess the feasibility and activity of a combination schedule with irinotecan (CPT-11), oxaliplatin (L-OHP), brief infusional fluorouracil (5-FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer (MCC) patients." | 5.11 | An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial. ( Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Pasinetti, N; Rangoni, G; Simoncini, E; Valcamonico, F; Vassalli, L, 2005) |
| "To evaluate the feasibility and a possible activity range of combination irinotecan (CPT-11), oxaliplatin, and 5-FU in advanced colorectal cancer (ACC)." | 5.10 | Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study. ( Aramendía, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; González-Cao, M; Martín-Algarra, S; Martínez-Monge, R; Rodríguez, J; Salgado, JE, 2002) |
| " once every 3 weeks was assessed in 60 patients with advanced colorectal cancer (CRC) showing failure to 5-fluorouracil (5-FU) treatment." | 5.10 | Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. ( Abad, A; Antón, A; Aranda, E; Balcells, M; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fenández-Martos, C; Gallén, M; Huarte, L; Marcuello, E; Massutti, B; Sastre, J, 2003) |
| " Chemotherapy naive women with stage I or II breast cancer scheduled to intravenous cyclophosphamide, fluorouracil and methotrexate or cyclophosphamide, epirubicin and fluorouracil every 3 weeks were included." | 5.09 | Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy. ( Andersen, LJ; Dombernowsky, P; Havsteen, H; Herrstedt, J; Kjaer, M; Kjaerbøl, AG; Langer, SW; Lund, H; Sigsgaard, T, 1999) |
| "The inhibitory effect of ramosetron hydrochloride (Ram), a 5-HT3 receptor antagonist, on nausea and vomiting occurring in CMF or CEF therapy as a pre- or postoperative adjuvant chemotherapy or chemotherapy for recurrent cancer was evaluated in 34 patients with breast cancer." | 5.09 | [Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer]. ( Hojo, S; Noguchi, S; Shiba, E; Taguchi, T; Takamura, Y; Tsukamoto, F; Watanabe, T; Yoneda, K, 1999) |
| "The aim of our single-center, prospective, randomized, open study was to evaluate the antiemetic efficacy and tolerability of a regimen based on a single oral dose of ondansetron 8 mg in comparison with a metoclopramide-based regimen, for prevention of acute FAC (fluorouracil, doxorubicin and cyclophosphamide) chemotherapy-induced emesis." | 5.09 | High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer. ( Bosnjak, SM; Mitrovi, LB; Nesković-Konstantinović, ZB; Radulović, SS; Susnjar, S, 2000) |
| "We have reported that an alternating regimen of bolus and continuous infusion 5-fluorouracil (FU) was superior to bolus FU in terms of response rate and progression-free survival in advanced colorectal cancer." | 5.09 | 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. ( Aschele, C; Caroti, C; Cirillo, M; Cortesi, E; Frassineti, GL; Gallo, L; Grossi, F; Guglielmi, A; Labianca, R; Pessi, MA; Ravaioli, A; Recaldin, E; Sobrero, A; Testore, P; Turci, D, 2001) |
| "The purpose of this study was to evaluate the activity and safety of oxaliplatin and protracted venous infusion of 5-fluorouracil (PVI 5-FU) in patients with advanced or relapsed 5-FU pretreated colorectal cancer." | 5.09 | Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. ( Chau, I; Cunningham, D; Hill, M; Massey, A; Norman, A; Waters, JS; Webb, A, 2001) |
| "The comparative study among granisetron alone and granisetron combined with hydroxyzine hydrochloride or dexamethasone was undertaken for the prevention of nausea and vomiting during chemotherapy including cisplatin in patients with advanced head and neck carcinomas." | 5.08 | [Comparison of granisetron alone and granisetron plus dexamethasone or hydroxyzine hydrochloride for the prevention of nausea and vomiting during chemotherapy including cisplatin]. ( Enomoto, H; Furukawa, M; Ikema, Y; Kawai, S; Kohno, H; Kubota, A; Makino, Y; Matsuda, H; Tsukuda, M; Yago, T, 1995) |
| "To determine whether a combination chemotherapy regimen that contains epirubicin (fluorouracil, epirubicin, and cyclophosphamide [FEC]) is superior to the standard cyclophosphamide, methotrexate, and fluorouracil (CMF) combination in premenopausal women with axillary node-positive operable breast cancer." | 5.08 | Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collab ( Aapro, M; Amadori, D; Bliss, JM; Chilvers, CE; Coombes, G; Coombes, RC; Espié, M; Ferreira, EP; Gambrosier, P; Marty, M; McArdle, C; Morvan, F; Pérez-López, FR; Richards, M; Vassilopoulos, P; Villar-Grimalt, A; Wils, J; Woods, EM, 1996) |
| "Both the biochemical modulation and the continuous administration of 5-fluorouracil (5-FU) have achieved promising results in patients with gastric carcinoma." | 5.08 | Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group. ( Belón, J; Blanco, E; Espinosa, E; Feliu, J; García-Alfonso, P; García-Girón, C; Garrido, P; Gómez-Navarro, J; González Barón, M; Ordónez, A; Zamora, P, 1996) |
| "We undertook a randomized trial in patients with advanced colorectal cancer, comparing 5-fluorouracil and leucovorin versus combination of these agents with additional cisplatin." | 5.08 | [Evaluation of chemotherapy in the treatment of advanced colorectal cancer--pilot study of 5-FU by biochemical modulation]. ( Katsumata, K; Ohno, M; Shibata, K; Yamamoto, K; Yamashita, S, 1996) |
| "A crossover clinical trial between granisetron alone and granisetron combined with methylprednisolone (MPL) was undertaken for the prevention of nausea and vomiting during chemotherapy, including cisplatin, in 12 patients with advanced primary and metastatic lung cancer." | 5.08 | [Comparative trial of granisetron alone and granisetron plus methylprednisolone for prevention of nausea and vomiting during cancer chemotherapy]. ( Fujishima, H; Hisano, C; Masumoto, N; Nakamura, M; Nakano, S; Niho, Y; Okuma, K, 1996) |
| "The aim of this open, nonrandomized, monocentric study was to evaluate the efficacy of a single daily dose of 8 mg oral ondansetron in the prophylaxis of acute nausea and vomiting in chemotherapy-naive breast cancer patients receiving their first cycle of chemotherapy with 5-fluorouracil, doxorubicin and cyclophosphamide (FAC)." | 5.08 | Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting. ( Bosnjak, SM; Jovanovic-Micic, DJ; Mitrovic, LB; Neskovic-Konstantinovic, ZB; Radulovic, SS, 1996) |
| "Azasetron, a selective 5-HT3 receptor antagonist, has been previously shown to be highly effective in the prophylaxis of nausea and vomiting induced by anticancer drugs, and is widely used in the clinical setting in Japan." | 5.08 | [Clinical effect of two azasetron treatment methods against nausea and vomiting induced by anticancer drugs including CDDP]. ( Kimura, E; Niimi, S; Tanaka, T; Watanabe, A, 1997) |
| " The combination chemotherapy with CDDP and 5-fluorouracil (5-FU), which has great efficacy for head and neck cancer, induces nausea and vomiting as side effects." | 5.08 | [Comparison of effects between single vs five-day injection of granisetron for combination chemotherapy with cisplatin and 5-fluorouracil for head and neck cancer]. ( Fujii, M; Imanishi, Y; Kanke, M; Kanzaki, J; Ohno, Y; Tokumaru, Y, 1997) |
| "Efficacy of combination of ondansetron injection and tablet on CAF (cyclophosphamide, adriamycin, 5-fluorouracil) induced emesis were investigated in 10 breast cancer patients (33 courses)." | 5.08 | [Efficacy of combination of ondansetron injection and tablet in CAF-induced emesis in breast cancer patients]. ( Furukawa, T; Kurihara, N; Machimura, T; Nemoto, Y; Nishihori, H; Shinohara, H; Urakami, H; Yonekawa, H, 1998) |
| "The antiemetic efficacy of dexamethasone (Dexaven) was examined in patients with breast cancer during chemotherapy CMF (cyclophosphamide, methotrexate and 5-fluorouracil) in comparison with patients treated identically but without dexamethasone." | 5.07 | [Use of dexamethasone as an antiemetic in patients with breast cancer treated with the CMF regimen]. ( Domaradzka-Woźniak, A; Dziewulska-Bokiniec, A; Wojtacki, J, 1994) |
| " A sample of 43 patients with breast cancer was accrued from September to November 1992 in a phase II study to assess the efficacy of granisetron in patients receiving FEC (5-FU, epirubicin, cyclophosphamide)." | 5.07 | Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide. ( Ang, PT; Khoo, KS; Tan, EH, 1994) |
| "The combination of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) is a widely used chemotherapy regimen in breast cancer patients." | 5.07 | Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study. ( Aapro, MS; Bauer, J; Brunner, KW; Buser, KS; Cavalli, F; Haefliger, JM; Joss, RA; Jungi, WF; Obrist, R; Piquet, D, 1993) |
| " To address its use with a widely used but less emetogenic regimen, we performed a double-blind, randomized clinical trial comparing ondansetron with dexamethasone and metoclopramide in patients with breast cancer receiving chemotherapy with cyclophosphamide, methotrexate, and fluorouracil." | 5.07 | Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. ( Latreille, J; Levitt, M; Lofters, WS; Perrault, DJ; Potvin, M; Rayner, HL; Warner, E; Warr, D; Wilson, KS; Yelle, L, 1993) |
| "The antiemetic response and side effects resulting from treatment with methylprednisolone (MPA) given on two different dose schedules were evaluated in 20 women with breast cancer who were undergoing chemotherapy consisting of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)." | 5.07 | Methylprednisolone as antiemetic treatment in breast-cancer patients receiving cyclophosphamide, methotrexate, and 5-fluorouracil: a prospective, crossover, randomized blind study comparing two different dose schedules. ( Cass, Y; Edelmann, DZ; Gez, E; Strauss, N; Vitzhaki, N, 1992) |
| " 97 female breast cancer patients who received their first two FEC courses (epirubicin 50-75 mg/m2, 5-fluorouracil 500 mg/m2, cyclophosphamide 500 mg/m2) entered this randomised crossover study (76 had previously received an adjuvant treatment); tetracosactrin was administered intramuscularly and methylprednisolone intravenously immediately before chemotherapy administration." | 5.07 | Tetracosactrin vs. methylprednisolone in the prevention of emesis in patients receiving FEC regimen for breast cancer. ( Bastit, P; Bonneterre, J; Cappelaere, P; Chevrier, A; Fargeot, P; Geyer, G; Kerbrat, P; Metz, R; Roche, H; Tubiana-Hulin, M, 1991) |
| "The efficacy of the serotonin antagonist ondansetron (GR 38032F) was evaluated in the prevention of nausea and vomiting induced by CMF chemotherapy in 29 breast cancer patients." | 5.07 | Oral ondansetron (GR 38032F) for the control of CMF-induced emesis in the outpatient. ( Campora, E; Cetto, GL; Fosser, V; Mammoliti, S; Marangolo, M; Oliva, C; Rosso, R, 1991) |
| "Seventy-five breast cancer patients scheduled to receive a first course (in a new cycle) of cyclophosphamide, fluorouracil, and doxorubicin (FAC) or epirubicin (FEC) participated in a double-blind crossover study to compare the antiemetic efficacy and safety of ondansetron (GR38032), a 5-hydroxytryptamine3 (5-HT3) receptor antagonist, and metoclopramide." | 5.06 | A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. ( Bonneterre, J; Bons, J; Chevallier, B; Fargeot, P; Metz, R; Paes, D; Pujade-Lauraine, E; Spielmann, M; Tubiana-Hulin, M, 1990) |
| "Thirty patients with advanced breast cancer, previously treated with anthracycline and 5 fluorouracil in bolus administration, were evaluated with a chemotherapy regimen generally used in head and neck cancer." | 5.06 | [Phase II trial as 2nd line chemotherapy with 5 fluorouracil and cisplatin (5FU-CDDP) for advanced breast cancer]. ( Bastit, P; Bugat, R; Cappelaere, P; Chauvergne, J; Fumoleau, P; Horner, D; Metz, R, 1990) |
| " cyclophosphamide, methotrexate, and 5-fluorouracil (CMF), 25 women with stage II breast cancer were entered into this study." | 5.06 | Effective control of CMF-related emesis with high-dose dexamethasone: results of a double-blind crossover trial with metoclopramide and placebo. ( Giannarelli, D; Marolla, P; Nardi, M; Pinnaró, P; Pollera, CF; Terzoli, E, 1989) |
| "Nineteen women receiving their first cycle of adjuvant chemotherapy for early breast cancer were randomized between two antiemetic drugs: methylprednisolone (MPN) 125mg and metoclopramide (MCP) 20mg, both given by intravenous push as a single dose." | 5.06 | Methylprednisolone versus metoclopramide as antiemetic treatment in patients receiving adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) chemotherapy: a randomized crossover blind study. ( Biran, S; Cass, Y; Gera, C; Gez, E; Nathan, S; Ochayon, L; Rubello, E; Sulkes, A, 1989) |
| "Two hundred sixty-three patients with advanced breast cancer were randomized to two treatment regimens consisting of fluorouracil, 500 mg/m2; cyclophosphamide, 500 mg/m2; and either epirubicin (Farmorubicin, Farmitalia Carlo Erba SpA, Italy), 50 mg/m2 (FEC); or doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH), 50 mg/m2 (FAC), administered intravenously (IV) every 3 weeks." | 5.06 | A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group. ( , 1988) |
| "The antiemetic effectiveness of haloperidol plus dexamethasone was compared with that of prochlorperazine plus dexamethasone in a prospective study of patients receiving chemotherapy for breast cancer." | 5.06 | A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer. ( Carpenter, JT; Conolley, C; Lee, J; Silvey, L; Wheeler, RH, 1988) |
| "Sixty-eight breast cancer patients for outpatient adjuvant chemotherapy (CT) with cyclophosphamide, methotrexate, and fluorouracil (CMF) on a 1-day schedule entered a randomized trial comparing the antiemetic-efficacy of different doses of methylprednisolone (MPN)." | 5.06 | Methylprednisolone for the control of CMF-induced emesis. ( Bruzzi, P; Campora, E; Chiara, S; Lionetto, R; Rosso, R, 1987) |
| " CMF were included in a double-blind comparative study aimed at evaluating the efficacy of 3 different drugs (methylprednisolone (MP), metoclopramide (MTC), and domperidone (DMP) in preventing chemotherapy-induced nausea and vomiting." | 5.06 | Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF. ( Ballatori, E; Basurto, C; del Favero, A; Minotti, V; Roila, F; Tonato, M, 1987) |
| "The antiemetic efficacy and toxicity of methylprednisolone (MP) and metoclopramide (MTC) in prevention of nausea and vomiting in breast cancer patients receiving intravenous cyclophosphamide methotrexate 5-fluorouracil (CMF) chemotherapy has been evaluated in a double-blind trial." | 5.06 | Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized study. ( Ballatori, E; Basurto, C; Del Favero, A; Minotti, V; Roila, F; Tonato, M, 1988) |
| "Patients with visceral patterns of metastatic breast cancer were stratified according to dominant metastatic site and performance status and then randomized to therapy with cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) or CAF alternating with a "cell-cycle active" regimen including cytosine arabinoside, methotrexate with leucovorin rescue, and oncovin ( CAMELEON )." | 5.05 | Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project. ( Carpenter, J; Fishkin, E; Krauss, S; Moore, MR; Raab, S; Raney, M; Smalley, RV; Stagg, M; Velez-Garcia, E; Vogel, CL, 1984) |
| "To determine the incidence of anticipatory vomiting (AV) and postchemotherapy nausea and vomiting (PCNV) in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma, we studied 52 women randomized to two regimens (standard-dose and low-dose) of CMF." | 5.05 | Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma. ( Abeloff, MD; Fetting, JH; Nettesheim, KM; Wilcox, PM, 1982) |
| "One-hundred-ninety-four eligible and evaluable patients with histologically confirmed locally unresectable adenocarcinoma of the pancreas were randomly assigned to therapy with high-dose (6000 rads) radiation therapy alone, to moderate-dose (4000 rads) radiation + 5-fluorouracil (5-FU), and to high-dose radiation plus 5-FU." | 5.05 | Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. ( Barkin, J; Bateman, J; Brooks, J; Chaffey, J; Childs, DS; Corson, JM; Douglas, HO; Frytak, S; Hahn, RG; Holbrook, MA; Kalser, M; Knowlton, A; Lavin, PT; Lessner, H; Livstone, E; Lokich, J; Mann-Kaplan, R; Moertel, CG; Nave, H; Novak, JW; O'Connell, MJ; Ramming, K; Reitemeier, RJ; Rubin, J; Schutt, AJ; Spiro, H; Thomas, P; Weiland, LH; Zamcheck, N, 1981) |
| "Data on 162 women (90 premenopausal and 72 postmenopausal) with metastatic breast cancer randomized to receive cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF) on two Eastern Cooperative Oncology Group (ECOG) protocols were analyzed." | 5.05 | The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Carbone, PP; Cummings, FJ; Falkson, G; Falkson, HC; Gelman, RS; Tormey, DC, 1985) |
| "As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF)." | 5.05 | A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Bennett, JM; Byrne, P; DeConti, R; Desai, A; Doroshow, J; Krementz, E; Muggia, F; Plotkin, D; Vogel, C; White, C, 1985) |
| "One hundred eighteen patients with metastatic carcinoid tumor were randomized to treatment with streptozotocin combined with cyclophosphamide or with 5-fluorouracil (5-FU)." | 5.04 | Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. ( Hanley, JA; Moertel, CG, 1979) |
| "One hundred and sixteen patients with advanced and metastatic adenocarcinoma of the pancreas were randomized to treatment with combined Streptozotocin and 5-fluorouracil or combined Streptozotocin and cyclophosphamide." | 5.04 | Treatment of advanced adenocarcinoma of the pancreas with combinations of streptozotocin plus 5-fluorouracil and streptozotocin plus cyclophosphamide. ( Carbone, PP; Douglas, HO; Hanley, J; Moertel, CG, 1977) |
| " The incidence of nausea and vomiting in benzquinamide-treated patients was equal to that in placebo-treated patients and significantly higher than that in patients treated with prochlorperazine, 10 mg 3 times daily." | 5.04 | Oral benzquinamide in the treatment of nausea and vomiting. ( Hahn, RG; Moertel, CG; O'Fallon, JR; Schutt, AJ, 1975) |
| "An electronic search was undertaken to identify randomized controlled trials comparing raltitrexed-based regimen to 5-fluorouracil-based regimen in patients with advanced colorectal cancer." | 4.90 | Raltitrexed-based chemotherapy for advanced colorectal cancer. ( Hong, W; Huang, Q; Liu, Y; Sun, X; Wu, J; Wu, W, 2014) |
| " A phase III randomized trial, Xeloda in Adjuvant Colorectal Cancer Treatment, demonstrated that treatment with single-agent capecitabine was equivalent to bolus 5-fluorouracil with leucovorin with respect to disease-free survival and overall survival, with significantly less diarrhea, stomatitis, neutropenia, nausea and vomiting, and alopecia." | 4.83 | Capecitabine: a new adjuvant option for colorectal cancer. ( Berg, DT, 2006) |
| " This study evaluated the percentages of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) undergoing second-line therapy with 5-fluorouracil (5-FU)-based regimens that experienced AEs during treatment and received medication to manage those AEs." | 4.12 | Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma. ( Cockrum, P; Kim, G; Surinach, A; Wainberg, Z; Wang, S, 2022) |
| "The use of FOLFIRINOX (a combination of oxaliplatin, irinotecan, fluorouracil, and leucovorin) is one of the therapeutic standards in pancreatic adenocarcinoma." | 4.02 | Survival and Predictive Factors of Chemotherapy With FOLFIRINOX as First-Line Therapy in Metastatic Pancreatic Cancer: A Retrospective Multicentric Analysis. ( Ben Abdelghani, M; Caron, B; Duclos, B; Kurtz, JE; Nguimpi-Tambou, M; Noirclerc, M; Reimund, JM; Sondag, D, 2021) |
| "To evaluate the impact of sex on toxicity and efficacy outcomes among patients with metastatic colorectal cancer receiving first-line 5-fluorouracil-based regimens." | 3.91 | Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials. ( Abdel-Rahman, O, 2019) |
| "Although efficacy of aprepitant for suppressing emesis associated with single-dose cisplatin has been demonstrated, there are limited data on the antiemetic effect of this oral neurokinin-1 receptor antagonist during daily administration of cisplatin." | 3.80 | Efficacy of aprepitant for nausea in patients with head and neck cancer receiving daily cisplatin therapy. ( Ishimaru, K; Kaneko, K; Katsura, M; Takahashi, H; Takano, A; Yamaguchi, N, 2014) |
| "To evaluate the efficacy of reduction of dexamethasone with a single-dose of palonosetron in preventing acute and delayed nausea and vomiting in patients receiving highly emetogenic chemotherapy (HEC) for early breast cancer." | 3.79 | Single-dose palonosetron and dose-reduced regimen of dexamethasone in preventing nausea and vomiting by anthracycline-including chemotherapy in patients with early breast cancer. ( Cardillo, FD; Cognetti, F; Evangelista, S; Fabi, A; Fattoruso, SI; Pacetti, U; Veltri, E, 2013) |
| ", drug-adverse event pairs, found in 1,644,220 AERs from 2004 to 2009, it was suggested that leukopenia, neutropenia, and thrombocytopenia were more frequently accompanied by the use of 5-FU than capecitabine, whereas diarrhea, nausea, vomiting, and hand-foot syndrome were more frequently associated with capecitabine." | 3.78 | Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations. ( Brown, JB; Kadoyama, K; Miki, I; Okuno, Y; Sakaeda, T; Tamura, T, 2012) |
| " In this retrospective study, we assessed the efficacy of palonosetron versus granisetron for the incidence of CINV induced by mFOLFOX6 and FOLFIRI in patients with advanced colorectal cancer." | 3.78 | [Antiemetic effect of palonosetron in advanced colorectal cancer patients receiving mFOLFOX6 and FOLFIRI: a retrospective survey]. ( Hayakawa, Y; Muro, K; Noma, H; Okamoto, H; Sato, Y; Tatematsu, M, 2012) |
| " The aim of the present report was to evaluate real-life drug adherence in a prospective cohort analysis of patients with gastrointestinal or breast cancer treated with capecitabine-based chemotherapy." | 3.77 | Self-reported compliance with capecitabine: findings from a prospective cohort analysis. ( Bressoud, A; Delmore, G; Hermann, F; Hoesli, P; Pederiva, S; von Moos, R; Winterhalder, R, 2011) |
| "The aim of the study was to evaluate the role of ramosetron for the prevention of chemoradiotherapy-induced nausea and vomiting (CRINV) in patients receiving upper abdominal irradiation with concurrent 5-fluorouracil chemotherapy." | 3.75 | Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer. ( Bang, YJ; Chie, EK; Ha, SW; Im, SA; Jang, JY; Kim, K; Kim, SW; Kim, TY; Oh, DY, 2009) |
| " We performed retrospective study that examined the efficacy of preventive treatment (granisetron+dexamethasone+domperidone) for delayed emesis induced by FOLFOX4 chemotherapy for advanced and recurrent colorectal cancer." | 3.75 | [Efficacy of preventive treatment for delayed emesis induced by FOLFOX4 chemotherapy]. ( Hama, T; Hatake, K; Imada, H; Kamisugi, K; Kawakami, K; Matsusaka, S; Mizunuma, N; Nakamoto, E; Shinozaki, E; Shirai, T; Shouji, D; Suenaga, M; Suzuki, W; Takahashi, G; Yokokawa, T, 2009) |
| "Short-term infusion of 5-fluorouracil with leucovorin in combination with irinotecan or oxaliplatin has been considered as standard treatment for metastatic colorectal cancer." | 3.74 | Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan. ( Boku, N; Fukutomi, A; Hasuike, N; Hironaka, S; Machida, N; Ono, H; Onozawa, Y; Yamaguchi, Y; Yamazaki, K; Yoshino, T, 2007) |
| " We evaluated the toxicity and efficacy of a Hypofractionated and intensively Accelerated RT regimen supported with amifostine Cytoprotection (HypoARC) in a cohort of 72 high-risk breast cancer patients treated with modified mastectomy or conservative surgery and FEC (5-fluorouracil/epirubicin/cyclophosphamide) chemotherapy." | 3.71 | Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients. ( Frangiadaki, C; Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Koukourakis, MI; Kouroussis, C; Retalis, G; Sivridis, E, 2002) |
| "A two-stage retrospective audit of the efficacy of antiemetics used with intravenous cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2 and 5-fluorouracil 600 mg/m2 (CMF) chemotherapy for breast cancer has been performed in a single centre." | 3.70 | An audit of antiemetic use with CMF chemotherapy. ( Brown, RS; Brown, TK; Gaze, MN; Hoare, D, 1998) |
| "The antiemetic efficacy of granisetron in repeated CAF chemotherapy after breast cancer operation was investigated." | 3.69 | [Antiemetic efficacy of granisetron in repeated CAF chemotherapy after breast cancer operation]. ( Hatano, Y; Kato, N; Okuyama, N; Park, Y; Sasamoto, S; Yamazaki, S, 1997) |
| "Multiple studies have shown that leucovorin-fluorouracil regimens are modestly superior to fluorouracil alone in the treatment of advanced colorectal cancer." | 3.69 | Biochemical modulation in the treatment of advanced cancer: a study of combined leucovorin, fluorouracil, and iododeoxyuridine. ( DeLap, RJ; Marshall, JL; Richmond, E, 1996) |
| "Seventy-five female patients suffering from advanced breast cancer were treated with toilet mastectomy, radiotherapy and oophorectomy (if premenopausal) or tamoxifen therapy (if postmenopausal) as well as chemotherapy with cyclophosphamide, methotrexate, 5-fluorouracil and prednisone." | 3.68 | Toxicity and side-effects of combination chemohormonal therapy of advanced breast cancer. ( Dandapat, MC; Mohapatro, SK; Padhi, NC, 1992) |
| "A total of 60 patients with advanced breast cancer were treated with a combination of prednimustine (P: 110 mg/m2, days 1-5), mitoxantrone (M: 12 mg/m2, day 1) and 5-fluorouracil (F: 500 mg/m2, day 1) (PMF)." | 3.68 | Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer. ( Dusleag, J; Kasparek, AK; Lechner, P; Pfeiffer, K; Samonigg, H; Schmid, M; Smola, M; Steindorfer, P; Stöger, H, 1991) |
| "Twenty-nine patients with metastatic breast cancer were treated with fluorouracil, adriamycin, cyclophosphamide (FAC), and methotrexate (MTX), with or without leukovorin rescue." | 3.67 | Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate. ( Aboud, A; Blumenschein, GR; Buzdar, AU; Hortobagyi, GN; Yap, HY, 1984) |
| "As adverse reactions to the combination treatment by the digestive system, we observed the occurrence of nausea and vomiting in 15% of the cases who received FTP treatment consisting of 5-FU, toyomicin and prednisone, 25% of the cases who received MFU treatment consisting of MMC, 5-FU and ACNU, and in 64% of the cases who received PPQ treatment consisting of CDDP, Carboquone (CQ) and prednisone." | 3.67 | [Adverse reactions to carcinostatics and countermeasures]. ( Nakao, I, 1989) |
| "Thirty patients with advanced breast cancer, not pretreated with chemotherapy, received a polychemotherapy regimen containing mitoxantrone, fluorouracil and cyclophosphamide at the dose of 10 mg/m2, 500 mg/m2 and 500 mg/m2 i." | 3.67 | Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer. ( Canova, N; Ercolino, L; Martoni, A; Pannuti, F; Rani, P, 1988) |
| "Forty-six outpatients with breast cancer who had experienced severe emesis as a result of chemotherapy were evaluated for the antiemetic efficacy of high-dose metoclopramide (HD-MCP) and dexamethasone (DXM)." | 3.67 | High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second study. ( Ben-Baruch, N; Ben-Yosef, R; Biran, S; Brufman, G; Gez, E; Uziely, B; Warner-Efraty, E; Yitzhaki, N, 1987) |
| "We employed a structured interview to retrospectively study tastes and vomiting associated with the parenteral components of cyclophosphamide, methotrexate, and 5-FU in 45 patients with stage II-IV breast cancer." | 3.67 | Tastes associated with parenteral chemotherapy for breast cancer. ( Donehower, RC; Enterline, JP; Fetting, JH; Grochow, LB; Sheidler, VR; Wilcox, PM, 1985) |
| "In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose." | 3.67 | Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer. ( Armand, JP; Cappelaere, P; Delgado, M; Grimbert, J; Keiling, R; Mathe, G; Metz, R; Misset, JL; Prevot, G, 1985) |
| "A total of 65 patients with advanced colorectal or breast cancer were given oral tegafur in the phase I study." | 3.66 | Phase I-II studies of oral tegafur (ftorafur). ( Ansfield, FJ; Kallas, GJ; Singson, JP, 1983) |
| "A group of 47 patients with advanced breast cancer were treated with a combination of prednimustine, methotrexate, 5-FU, and tamoxifen." | 3.66 | Prednimustine in combination with methotrexate and 5-FU (PMF): a pilot study. ( Boesen, E; Mouridsen, HT, 1982) |
| "Overall, nausea was reported by 86% (n=129) of the patients during the ten-day period from the start of cancer treatment." | 3.30 | Single Nucleotide Polymorphism Directed Antiemetic Treatment in Women With Breast Cancer Treated With Neo- or Adjuvant Chemotherapy: A Randomised Multicentre Phase II Study. (EudraCT: 2015-000658-39). ( Andersson, BÅ; Åsenlund, U; Elinder, E; Fust, L; Lewin, F; Lewin, N; Nilsson, MP; Oliva, D; Schildt, EB; Sellerstam, G; Shamoun, L; Sharp, L, 2023) |
| " The studies demonstrated a significant benefit from the triplet at the price of an increased incidence of chemotherapy-related adverse events (AEs)." | 2.90 | Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. ( Allegrini, G; Aprile, G; Bergamo, F; Boccaccino, A; Boni, L; Borelli, B; Buonadonna, A; Cordio, S; Cremolini, C; Dell'Aquila, E; Falcone, A; Latiano, TP; Libertini, M; Lonardi, S; Marmorino, F; Masi, G; Moretto, R; Passardi, A; Pella, N; Randon, G; Ratti, M; Ricci, V; Ronzoni, M; Rossini, D; Tamburini, E; Urbano, F; Zucchelli, G, 2019) |
| "vomiting, anorexia and infection) were recorded, and short-term effect of chemotherapy was evaluated regularly." | 2.84 | Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms. ( Deng, B; Jia, L; Li, X; Li, Y; Lou, Y; Tan, H; Yu, L, 2017) |
| "In mouse models of pancreatic cancer, IPI-926, an oral Hedgehog inhibitor, increases chemotherapy delivery by depleting tumor-associated stroma." | 2.82 | A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. ( Catenacci, DV; Chang, WC; Kantoff, E; Kate Kelley, R; Kindler, HL; Ko, AH; Lewis, S; LoConte, N; Tempero, MA; Vannier, MW; Venook, AP; Walker, EJ, 2016) |
| "In 2594 patients with complete adverse event (AE) data, the incidence of grade 3 or greater 5FU-AEs in DPYD*2A, I560S, and D949V carriers were 22/25 (88." | 2.79 | DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). ( Alberts, SR; Berenberg, JL; Diasio, RB; Goldberg, RM; Lee, AM; Pavey, E; Sargent, DJ; Shi, Q; Sinicrope, FA, 2014) |
| "To evaluate the efficacy and safety of trastuzumab in combination with chemotherapy versus chemotherapy alone in the first-line treatment of HER-2-positive advanced gastric or gastro-oesophageal junction cancer." | 2.78 | [Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport]. ( Feng, FY; Guan, ZZ; Jiao, SC; Jin, YN; Li, J; Pan, LX; Qin, SK; Shen, L; Tao, M; Wang, JJ; Wang, LW; Wang, YJ; Xu, JM; Yu, SY; Zheng, LZ, 2013) |
| "Patients with stage II and III esophageal cancer were enrolled." | 2.77 | Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer. ( Chak, A; Chang, KJ; Hanna, N; Pinto, H; Reid, T; Senzer, N; Soetikno, R; Swisher, S, 2012) |
| "Gemcitabine was administered intravenously at 1,000 mg/m(2)/week (days 1, 8 and 15) and oral capecitabine from day 1 to day 21 at 1,660 mg/m(2)/day." | 2.77 | Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. ( Bennouna, J; Chamorey, E; Douillard, JY; Etienne-Grimaldi, MC; Follana, P; Francois, E; Mari, V; Michel, C; Milano, G; Renée, N; Senellart, H, 2012) |
| " We designed a pilot study in order to explore the optimal dosing period for indisetron during modified FOLFOX6 (mFOLFOX6)." | 2.77 | Optimal dose period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with modified FOLFOX6: a randomized pilot study. ( Asaka, M; Kato, K; Komatsu, Y; Kudo, M; Meguro, T; Miyagishima, T; Muto, S; Nakatsumi, H; Oba, K; Sogabe, S; Tateyama, M; Uebayashi, M; Yuki, S, 2012) |
| "Survival time for metastatic breast cancer (MBC) can be substantially improved by combination chemotherapy in the adjuvant setting." | 2.75 | A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines. ( Alexopoulos, A; Ardavanis, A; Ioannidis, G; Kandylis, C; Malliou, S; Orphanos, G; Rigatos, G; Stavrakakis, J, 2010) |
| "To explore the efficacy, time to disease progression (TTP), overall survival (OS) and toxicity of paclitaxel liposome versus paclitaxel combined with 5-fluorouracil (5-Fu) for patients with advanced gastric cancer." | 2.75 | [Comparison of the therapeutic effects of paclitaxel liposome-5-Fu versus paclitaxel-5-Fu on 67 patients with advanced gastric cancer]. ( Chen, SC; Lu, ZH; Wu, F; Xiong, JP, 2010) |
| "5, or 50 mg) was administered orally once daily on three dosing schedules: 4 weeks on treatment, 2 weeks off treatment (Schedule 4/2); 2 weeks on treatment, 1 week off treatment (Schedule 2/1); and continuous daily dosing (CDD schedule)." | 2.75 | A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. ( Bello, A; Burris, HA; Chao, R; Chiorean, EG; Jones, S; Lee, FC; Liau, KF; Royce, M; Sweeney, CJ; Tye, L; Verschraegen, CF, 2010) |
| "To evaluate the safety and efficacy of preoperative radiotherapy (RT) in combination with cetuximab, capecitabine, and irinotecan in patients with locally advanced rectal cancer." | 2.74 | Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial. ( Barreto-Miranda, M; Dinter, D; Erben, P; Hochhaus, A; Hofheinz, RD; Horisberger, K; Kähler, G; Kienle, P; Mai, S; Post, S; Ströbel, P; Treschl, A; Wenz, F; Willeke, F; Woernle, C, 2009) |
| "This oxaliplatin combined with ELF regimen shows good efficacy and acceptable safety in advanced gastric cancer patients." | 2.74 | [Oxaliplatin combined with ELF regimen in the treatment of patients with advanced gastric cancer]. ( Lou, F; Pan, HM; Zhu, YH, 2009) |
| "Of the 96 patients with gastric cancers, 21 underwent R0 resection and afterward received adjuvant FOLFOX chemotherapy." | 2.74 | [FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer]. ( Dai, H; Yan, D, 2009) |
| "Irinotecan 180 mg/m2 was administered biweekly on D1, LV 200 mg/m2 by intravenous infusion in 2 hours before bolus intravenous injection of 5-Fu 400 mg/m2, then followed immediately by intravenous infusion of 5-Fu 2." | 2.73 | [Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer]. ( Bai, Y; Chu, YP; Jin, ML; Li, J; Liu, DQ; Shen, L; Wang, YH; Xu, JM; Zhang, XD, 2008) |
| "Capecitabine combined with fractionated cisplatin is highly effective and well tolerated as a first-line treatment for advanced gastric cancer, with comparable results to 5-Fu plus cisplatin combination therapy." | 2.73 | [Capecitabine combined with cisplatin as first-line therapy in Chinese patients with advanced gastric carcinoma-a phase II clinical study]. ( Bai, YX; Chen, L; Chen, S; Cheng, Y; Hu, B; Jia, TZ; Jin, ML; Li, J; Liang, J; Shen, L; Shu, YQ; Wan, DS; Wang, BC; Wen, ZZ; Yin, HR; Yu, JR; Zhang, HG; Zhou, Y, 2008) |
| " In conclusion, capecitabine can safely be combined with docetaxel (40 mg m(-2)) and mitomycin C (4 mg m(-2))." | 2.73 | Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial. ( Ernst, T; Gnad-Vogt, U; Hochhaus, A; Hofheinz, RD; Kripp, M; Lukan, N; Merx, K; Schultheis, B, 2007) |
| "Complete surgical resection of gastric cancer is potentially curative, but long-term survival is poor." | 2.73 | Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. ( Antimi, M; Antonuzzo, L; Arcangeli, A; Banducci, S; Bellini, V; Biagioni, F; Bianchini, D; Bilancia, D; Bisagni, G; Biscottini, B; Boni, C; Bracci, R; Bravi, S; Bruno, L; Cabassi, A; Camera, S; Camisa, R; Canaletti, R; Carboni, M; Carlini, P; Carroccio, R; Cascinu, S; Catalano, G; Catalano, V; Cavalli, C; Cesari, M; Cognetti, F; Contu, A; Corgna, E; Cortesi, E; Croce, E; Dalla Mola, A; De Filippis, S; De Stefanis, M; Di Costanzo, F; Dinota, A; Enzo, MR; Farris, A; Figoli, F; Floriani, I; Foa, P; Fornarini, G; Francavilla, F; Frignano, M; Gasperoni, S; Gilli, G; Giunta, A; Grigniani, F; Ionta, MT; Italia, M; Labianca, R; Lastraioli, E; Leoni, M; Lungarotti, F; Luppi, G; Manzione, L; Masoni, L; Massidda, B; Mela, M; Messerini, L; Monzio Compagnoni, B; Muscogiuri, A; Natalini, G; Nelli, F; Nicolosi, A; Oldani, S; Olgiati, A; Olivetti, A; Orselli, G; Pandolfi, U; Papiani, G; Pazzola, A; Piga, A; Pisani Leretti, A; Porrozzi, S; Recchia, F; Romiti, A; Rondini, E; Rossetti, R; Rovei, R; Saggese, M; Sarobba, MG; Scipioni, L; Strafiuso, G; Tomao, S; Tonato, M; Torri, V; Trignano, M; Zironi, S, 2008) |
| " The most frequent common adverse events were nausea, Grades 1 - 2 in 13 patients (81." | 2.72 | Chronomodulated chemotherapy with oxaliplatin, 5-FU and sodium folinate in metastatic gastrointestinal cancer patients: original analysis of non-hematological toxicity and patient characteristics in a pilot investigation. ( Farker, K; Hippius, M; Höffken, K; Hoffmann, A; Merkel, U; Wedding, U, 2006) |
| "Grade 2/3 neutropenia was observed in 4 (3%) treatment cycles." | 2.71 | Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors. ( Agelaki, S; Amarantidis, K; Androulakis, N; Georgoulias, V; Kakolyris, S; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N; Xenidis, N, 2004) |
| "Advanced pancreatic cancer has limited treatment options." | 2.71 | Phase II clinical trial of 5-fluorouracil, trimetrexate, and leucovorin (NFL) in patients with advanced pancreatic cancer. ( Baranda, J; Garcia, AA; Leichman, CG; Leichman, L; Lenz, HJ; Pandit, L, 2003) |
| "Dex combined with GS markedly decreased the occurrence ratio and lasting time of the symptoms such as nausea, vomiting, fever and pain, and protected the function of liver as compared with the placebo (P<0." | 2.71 | [Ginsenosides combined with dexamethasone in preventing and treating postembolization syndrome following transcatheter arterial chemoembolization: a randomized, controlled and double-blinded prospective trial]. ( Chen, Z; Feng, YL; Li, B; Ling, CQ; Yu, CQ; Zhu, DZ, 2005) |
| "Heptaplatin is a newly developed platinum derivative which has been reported to be less toxic than cisplatin." | 2.70 | Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer. ( Ahn, JH; Bahng, H; Chang, HM; Kang, WC; Kang, YK; Kim, TW; Kim, WK; Lee, JS; Park, JS, 2002) |
| " We investigated the therapeutic and adverse drug reaction of intensive chemotherapy using cisplatin (CDDP), 5-FU and dl-leucovorin (LV) (PFL-therapy), which may be producing dual biochemical modulation effect of 5-FU for advanced colorectal carcinoma." | 2.70 | Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer. ( Arai, T; Fukahara, T; Ishikawa, T; Iwai, T; Kuwabara, H; Maruyama, S; Murase, N; Okabe, S; Ootsukasa, S; Tanami, H; Udagawa, M; Yamashita, H, 2002) |
| "Capecitabine is a novel fluoropyrimidine carbamate, orally administered and selectively activated to fluorouracil by a sequential triple-enzyme pathway in liver and tumor cells." | 2.70 | Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. ( Kramer, G; Locker, GJ; Mader, R; Marberger, M; Rauchenwald, M; Schmidinger, M; Steger, GG; Wenzel, C; Zielinski, CC, 2002) |
| ", Carlsbad, CA) when administered in combination with 5-fluorouracil (5-FU) and leucovorin (LV)." | 2.70 | Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. ( Dorr, FA; Geary, RS; Holmlund, JT; Kindler, HL; Kunkel, K; Mani, S; Ratain, MJ; Rudin, CM, 2002) |
| "Levamisole was administered to 38 patients orally three times a day for 5 days concurrently with a course of 5-FU administered daily by rapid intravenous injection for 5 days." | 2.69 | Clinical and pharmacokinetic studies of high-dose levamisole in combination with 5-fluorouracil in patients with advanced cancer. ( Bagniewski, PG; Kovach, JS; Moertel, CG; O'Connell, MJ; Reid, JM, 1998) |
| "Patients with a squamous cell carcinoma of the oropharynx for whom curative radiotherapy or surgery was considered feasible were entered in a multicentric randomized trial comparing neoadjuvant chemotherapy followed by loco-regional treatment to the same loco-regional treatment without chemotherapy." | 2.69 | Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC). ( Coche-Dequeant, B; De Raucourt, D; Domenge, C; Hill, C; Lefebvre, JL; Luboinski, B; Marandas, P; Rhein, B; Sancho-Garnier, H; Stromboni-Luboinski, M; Wibault, P, 2000) |
| "N&V and leukopenia were the major side effects." | 2.68 | Salvage chemotherapy with PEM and long-CF regimen in CDDP refractory advanced head and neck cancer. ( Ichikawa, G; Inuyama, Y; Kawaida, M; Kohno, N; Ohnuma, T; Shirasaka, T, 1995) |
| " Dosing decisions in older patients are difficult and must integrate assessments of organ function, comorbidities, overall physical status, and goals of treatment, in an effort to ensure the best possible outcome for these patients." | 2.68 | Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. ( Arcangeli, G; Douglass, HO; Driscoll, DL; Meropol, NJ; Petrelli, NJ; Stein, BN, 1995) |
| "Forty-eight patients with unresectable gastric cancer were enrolled for a randomized trial of FP (n = 24) vs FEP (n = 24) combination chemotherapy with respect to their effects on survival period." | 2.68 | [Combination chemotherapy with FP versus FEP in patients with advanced gastric cancer. Research group of gastric cancer chemotherapy]. ( Horiuchi, Y; Ina, K; Iwase, H; Kaneko, H; Kuroiwa, A; Kusugami, K; Morise, K; Oka, Y; Shinoda, M; Suga, S, 1995) |
| "Sixty chemotherapy-naive breast cancer patients of 30 to 71 years in age, P." | 2.68 | Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy. ( Ionta, MT; Massidda, B, 1996) |
| "Eleven patients with metastatic renal cell carcinoma received combination therapy with 5-fluorouracil (5-FU), Cisplatin (CDDP) and Interferon alpha-2b (IFN alpha-2b)." | 2.68 | [Combination therapy with 5-fluorouracil (5-FU), cisplatin (CDDP) and interferon alpha-2B (IFN alpha-2B) for advanced renal cell carcinoma]. ( Fujinami, K; Ikeda, I; Kondo, I; Miura, T, 1996) |
| "Grade 4 leukopenia was observed in 1 case and grade 3 to 4 thrombocytopenia was observed in two cases, respectively." | 2.68 | The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD). ( Antón-Torres, A; Aranda, E; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fernández-Martos, C; Massutí, T, 1996) |
| " Intolerance to single dosing was clearly demonstrated, and only the split dosing was advanced to 500 mg/m2/day." | 2.68 | Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil. ( Chan, KK; Groshen, S; Jeffers, S; Leichman, CG; Leichman, L; Muggia, FM; Spicer, D; Wu, X, 1996) |
| "Vomiting was not consistently related to the excretion of either catecholamine." | 2.67 | Delayed chemotherapy-induced nausea is augmented by high levels of endogenous noradrenaline. ( Börjesson, S; Fredrikson, M; Fürst, CJ; Hursti, TJ; Peterson, C; Steineck, G, 1994) |
| "56 female patients with breast carcinoma and treated with polychemotherapy: adriamycin, vindesine, ciclophosphamide and 5-fluorouracil were studied, divided in three groups with different antiemetic schedule: group A 40 mg/iv of metoclopramide; group B 40 mg iv of metoclopramide and 125 mg/iv of methylprednisolone before beginning chemotherapy; and group C 2 mg/oral of lorazepam, 125 mg/iv methyl-prednisolone and 1 mg/kg/oral of metoclopramide previously to begin chemotherapy; at two and four hours of the first dose, metoclopramide was repeated the same doses (really) three doses each two hours." | 2.67 | [Antiemetic treatments associated with antineoplastic chemotherapy]. ( Guillén Lloveria, G; Mayordomo Cámara, JJ; Sáenz Cusi, A; Sáez Martínez, MJ; Tres Sánchez, A, 1990) |
| "Mitoxantrone (Novantrone), is an anthracenedione which in preclinical studies demonstrated a spectrum of antitumor activity similar to the anthracyclines, but with less cardiotoxicity." | 2.66 | Mitoxantrone: an overview of safety and toxicity. ( Bernstein, T; Cartwright, K; Dukart, G; Goldberg, J; Posner, LE, 1985) |
| "Stomatitis was more frequent on the infusion arm but it was mild and reversible." | 2.66 | A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. ( Al-Sarraf, M; Cummings, G; Ensley, JF; Jacobs, J; Kish, JA; Weaver, A, 1985) |
| "Women with breast carcinoma and four or more involved ipsilateral axillary lymph nodes were randomly assigned to receive an induction course and 2 yr of maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF, 150 patients), CMF plus vincristine and prednisone (CMFVP, 166 patients), or chemoimmunotherapy with CMF plus the methanol extraction residue of BCG (CMF-MER, 85 patients)." | 2.65 | A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer. ( Falkson, G; Falkson, HC; Glidewell, OJ; Henry, PH; Holland, JF; Leone, LA; Perloff, M; Tormey, DC; Weinberg, VE; Weiss, RB, 1983) |
| " Weekly oral 5-FU results in comparable response and survival to 5-FU given intravenously, consistent with a relatively low dose-response relationship for 5-FU in breast carcinoma." | 2.65 | Treatment of advanced breast carcinoma with 5-fluorouracil: a randomized comparison of two routes of delivery. ( Bateman, JR; Chlebowski, RT; Pugh, RP; Weiner, JM, 1981) |
| " With the dosage and schedule we used, and in our patient population of largely elderly adults, THC therapy resulted in an overall more unpleasant treatment experience than that noted with prochlorperazine or placebo." | 2.65 | Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. ( Creagan, ET; Frytak, S; Moertel, CG; O'Connell, MJ; O'Fallon, JR; Rubin, J; Schutt, AJ; Schwartau, NW, 1979) |
| "Leukopenia was the dose-limiting toxicity with all three regimens." | 2.64 | Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study. ( Bonnet, JD; Braine, H; Costanzi, JJ; George, SL; Hoogstraten, B; Rivkin, SE; Samal, B; Thigpen, T, 1976) |
| "Colorectal cancer is one of the most common cancers affecting men and women in the United States." | 2.43 | Advanced colorectal cancer: current treatment and nursing management with economic considerations. ( Fung, A; Viale, PH; Zitella, L, 2005) |
| "The severity of emesis is dependent on the dose of cyclophosphamide and on the addition of other cytotoxic drugs." | 2.39 | Optimal control of cyclophosphamide-induced emesis. ( Stewart, A, 1996) |
| "Advanced pancreatic cancer (APC) disproportionately impacts older adults." | 1.72 | Treatment Patterns, Toxicity, and Outcomes of Older Adults With Advanced Pancreatic Cancer Receiving First-line Palliative Chemotherapy. ( Dawe, DE; Kim, CA; Lambert, P; McAndrew, EN; Rittberg, R; Zhang, H, 2022) |
| "Capecitabine is an oral anticancer drug which can cause some adverse reactions and the great challenge for its use is to ensure the medication adherence." | 1.72 | Adverse reactions and adherence to capecitabine: A prospective study in patients with gastrointestinal cancer. ( Barbosa, CR; Cobaxo, TS; de Souza, RN; Dias, LP; Duarte, NC; Lima, CS; Lima, TM; Moriel, P; Pincinato, EC; Tavares, MG; Teixeira, JC; Visacri, MB, 2022) |
| "The outbreak of coronavirus disease 2019 (COVID-19) has affected the treatment of cancer patients, with particular regard to the management of both chemotherapy and side effects." | 1.62 | NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study. ( Caputo, V; Cicero, G; De Luca, R; Ferrera, G; Mistretta, O; Paci, R; Rosati, G; Volpe, C, 2021) |
| "Among patients with colorectal cancer (CRC) treated with oxaliplatin (L-OHP)-based chemotherapy, delayed chemotherapy-induced nausea and vomiting (CINV) have not been well controlled." | 1.62 | Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk. ( Fukunaga, M; Hayashi, T; Kogawa, T; Matsui, R; Mizuki, F; Nishimura, J; Satoh, T; Shimokawa, M; Tsuji, Y, 2021) |
| " Given the known sex differences in fluoropyrimidine pharmacokinetics, sex-specific dosing of fluoropyrimidines warrants further investigation." | 1.62 | Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database. ( Alberts, SR; Allegra, CJ; Andre, T; Blanke, CD; de Gramont, A; Dixon, JG; Francini, E; George, TJ; Goldberg, RM; Grothey, A; Haller, DG; Kerr, R; Marsoni, S; O'Connell, MJ; Saltz, LB; Seitz, JF; Shi, Q; Taieb, J; Twelves, C; VanCutsem, E; Wagner, AD; Wolmark, N; Yothers, G, 2021) |
| "Among the advanced colorectal cancer patients who received treatment with FOLFOX or FOLFIRI at Koyama Memorial Hospital, patients older than 65 years of age were selected in order to assess the effectiveness of aprepitant as an antiemetic supportive therapy." | 1.43 | [Study of the Efficacy of Aprepitant in FOLFOX/FOLFIRI for Elderly Patients with Advanced Colorectal Cancer]. ( Hanaka, J; Nakayama, H; Takahashi, M; Terashima, T, 2016) |
| "Febrile neutropenia was not reported." | 1.43 | Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients. ( Caparello, C; Falcone, A; Fornaro, L; Lencioni, M; Musettini, G; Pasquini, G; Petrini, I; Vasile, E; Vivaldi, C, 2016) |
| "025) in the toxic group (n = 12) compared to the non-toxic group (n = 19)." | 1.42 | Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in patients with esophageal cancer: a pilot study. ( Bowen, JM; Game, PA; Hussey, DJ; Irvine, T; Karapetis, CS; Keefe, DM; Kristaly, K; Smith, L; Tan, H; Thompson, SK; Tsykin, A; Watson, DI; White, I, 2015) |
| "Capecitabine is a complex chemotherapeutic agent with many side effects that might affect patient adherence to treatment." | 1.40 | Adherence to capecitabine treatment and contributing factors among cancer patients in Malaysia. ( Hassan, NB; Norazwany, Y; Norhayati, I; Norsa'adah, B; Roslan, MH; Wan Nazuha, WR; Zahrina, AK, 2014) |
| "All patients scheduled for breast cancer surgery at Danderyd Hospital, Stockholm, Sweden during 1 year (March 2003-March 2004) were asked to participate in this prospective, observational study." | 1.39 | Is there an association between PONV and chemotherapy-induced nausea and vomiting? ( Eksborg, S; Lönnqvist, PA; Öbrink, E; Oddby-Muhrbeck, E; Rotstein, S, 2013) |
| " Gastro-intestinal adverse events graded according to the WHO criteria were recorded after the first cycle." | 1.38 | Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity. ( Bocci, G; Ciccolini, J; Danesi, R; Di Paolo, A; Iliadis, A; Lacarelle, B; Marouani, H; Woloch, C, 2012) |
| "Colorectal carcinomas are among the most common tumor types and are generally treated with palliative chemotherapy in case of metastatic disease." | 1.37 | Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin. ( Peters, GJ; Schneiders, FL; van den Berg, HP; van der Vliet, HJ; Verheul, HM, 2011) |
| "Aprepitant is a very active antiemetic drug for the prevention of delayed nausea and vomiting induced by mFOLFOX6 regimen." | 1.36 | [Clinical usefulness of oral aprepitant for alleviation of delayed nausea and vomiting induced by mFOLFOX6--report of a case]. ( Abe, T; Hachiro, Y; Kunimoto, M, 2010) |
| "The growing number of patients with head and neck cancer is a reason to search for new effective treatment strategies." | 1.36 | [Taxan induction chemotherapy and concomitant chemoradiotherapy with cisplatin in patients with locally advanced head and neck cancer--early results]. ( Chilimoniuk, M; Maksimowicz, T; Olszewska, E, 2010) |
| "While hiccups are usually benign, severe attacks may lead to exhaustion, eating difficulties, and affect quality of life." | 1.35 | Severe hiccups during chemotherapy: corticosteroids the likely culprit. ( Gilbar, P; McPherson, I, 2009) |
| "104 patients with advanced gastric cancers were treated with capecitabine-based chemotherapy regimens from Sept." | 1.35 | [Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer]. ( Li, J; Li, Y; Lu, M; Shen, L; Xiao, Y; Zhang, J; Zhang, XD, 2009) |
| "Pretreatment distress and posttreatment nausea, vomiting, and fatigue were assessed at the 1st, 4th, 6th and last cycles of chemotherapy." | 1.34 | Chemotherapy-induced nausea, vomiting, and fatigue--the role of individual differences related to sensory perception and autonomic reactivity. ( Jensen, AB; Johansson, A; Mehlsen, M; Paulsen, K; von der Maase, H; Zachariae, R, 2007) |
| " This could account for both the toxic effects and the response." | 1.32 | Is drug-induced toxicity a good predictor of response to neo-adjuvant chemotherapy in patients with breast cancer?--a prospective clinical study. ( Bansal, A; Lyall, A; Saxena, S; Singh, JP; Singhal, V, 2004) |
| "Patients with high risk breast carcinoma were conditioned with high dose carmustine, cisplatin, and cyclophosphamide followed by autologous PSCT." | 1.30 | Prolonged nausea and vomiting after high dose chemotherapy and autologous peripheral stem cell transplantation in the treatment of high risk breast carcinoma. ( Chap, L; Hecht, JR; Lembo, T, 1997) |
| "Tegafur was administered orally in two or three divided doses." | 1.27 | Phase I evaluation of oral tegafur. ( Bedikian, AY; Bodey, GP; Burgess, MA; Valdivieso, M, 1983) |
| " Reduced clearance of FU by MISO was associated with an earlier onset of the period of nonlinearity of FU pharmacokinetics and an increased half-life of elimination." | 1.27 | Pharmacokinetic rationale for the interaction of 5-fluorouracil and misonidazole in humans. ( Martin, WM; McDermott, BJ; Murphy, RF; Van den Berg, HW, 1983) |
| "Diphenhydramine was administered intramuscularly 30 minutes before and 5 hours after chemotherapy." | 1.27 | [The prevention of CDDP-induced emesis with a combination regimen including metoclopramide, dexamethasone, droperidol and diphenhydramine]. ( Arihiro, T; Dozono, H; Morimoto, O; Ochiai, K; Sasaki, H; Takahashi, S; Terashima, Y; Tsuruoka, M; Yasuda, M; Yokoyama, S, 1987) |
| "Six patients with an upper gastrointestinal hemorrhage or a small bowel obstruction all had local recurrence." | 1.27 | Results in the management of locally unresectable pancreatic carcinoma. ( Parker, RG; Selch, MT, 1986) |
| "Twenty-one patients were treated with sequential doses of MTX and 5-FU so as to be classified by MTX dosage into an intermediate MTX-dose group and a high MTX-dose group." | 1.27 | [Therapeutic effect of sequential doses of methotrexate (MTX) and 5-fluorouracil (5-FU) in advanced gastric cancer: comparison of intermediate-dose MTX with high-dose MTX]. ( Akazawa, S; Futatsuki, K; Honda, T; Kanda, Y; Kitagawa, H; Nakagawa, T; Nakajima, T; Suda, Y; Yoshida, S, 1985) |
| "Sixteen patients with advanced colo-rectal cancer were treated with the combination methyl-CCNU, vincristin, 5-fluorouracil and streptozotocin (MOF-Strepto)." | 1.26 | [The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma]. ( Cavalli, F; Sessa, C; Togni, P; Varini, M, 1982) |
| " The recommended dosage for daily oral administration of FD-1 is 6-12 mg/kg/day." | 1.26 | Review of a new antimetabolic agent, 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione (FD-1). ( Taguchi, T, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 90 (30.10) | 18.7374 |
| 1990's | 61 (20.40) | 18.2507 |
| 2000's | 66 (22.07) | 29.6817 |
| 2010's | 70 (23.41) | 24.3611 |
| 2020's | 12 (4.01) | 2.80 |
| Authors | Studies |
|---|---|
| De Luca, R | 1 |
| Volpe, C | 1 |
| Mistretta, O | 1 |
| Paci, R | 1 |
| Ferrera, G | 1 |
| Caputo, V | 1 |
| Rosati, G | 1 |
| Cicero, G | 1 |
| Shimokawa, M | 1 |
| Hayashi, T | 1 |
| Nishimura, J | 2 |
| Satoh, T | 2 |
| Fukunaga, M | 2 |
| Matsui, R | 1 |
| Tsuji, Y | 1 |
| Mizuki, F | 1 |
| Kogawa, T | 1 |
| McAndrew, EN | 1 |
| Zhang, H | 1 |
| Lambert, P | 1 |
| Rittberg, R | 1 |
| Dawe, DE | 1 |
| Kim, CA | 1 |
| De Francia, S | 1 |
| Berchialla, P | 1 |
| Armando, T | 1 |
| Storto, S | 1 |
| Allegra, S | 1 |
| Sciannameo, V | 1 |
| Soave, G | 1 |
| Sprio, AE | 1 |
| Racca, S | 1 |
| Caiaffa, MR | 1 |
| Ciuffreda, L | 1 |
| Mussa, MV | 1 |
| Kim, G | 1 |
| Cockrum, P | 1 |
| Surinach, A | 1 |
| Wang, S | 1 |
| Wainberg, Z | 1 |
| Oliva, D | 1 |
| Andersson, BÅ | 1 |
| Shamoun, L | 1 |
| Lewin, N | 1 |
| Nilsson, MP | 1 |
| Schildt, EB | 1 |
| Fust, L | 1 |
| Åsenlund, U | 1 |
| Sellerstam, G | 1 |
| Elinder, E | 1 |
| Sharp, L | 1 |
| Lewin, F | 1 |
| Marmorino, F | 1 |
| Rossini, D | 1 |
| Lonardi, S | 1 |
| Moretto, R | 1 |
| Zucchelli, G | 1 |
| Aprile, G | 1 |
| Dell'Aquila, E | 1 |
| Ratti, M | 1 |
| Bergamo, F | 1 |
| Masi, G | 2 |
| Urbano, F | 1 |
| Ronzoni, M | 1 |
| Libertini, M | 1 |
| Borelli, B | 1 |
| Randon, G | 1 |
| Buonadonna, A | 1 |
| Allegrini, G | 3 |
| Pella, N | 1 |
| Ricci, V | 1 |
| Boccaccino, A | 1 |
| Latiano, TP | 1 |
| Cordio, S | 1 |
| Passardi, A | 1 |
| Tamburini, E | 1 |
| Boni, L | 1 |
| Falcone, A | 5 |
| Cremolini, C | 1 |
| Matsumoto, K | 1 |
| Takahashi, M | 2 |
| Sato, K | 1 |
| Osaki, A | 1 |
| Takano, T | 1 |
| Naito, Y | 1 |
| Matsuura, K | 1 |
| Aogi, K | 1 |
| Fujiwara, K | 1 |
| Tamura, K | 1 |
| Baba, M | 1 |
| Tokunaga, S | 3 |
| Hirano, G | 1 |
| Imoto, S | 2 |
| Miyazaki, C | 1 |
| Yanagihara, K | 1 |
| Imamura, CK | 1 |
| Chiba, Y | 1 |
| Saeki, T | 1 |
| Wagner, AD | 1 |
| Grothey, A | 1 |
| Andre, T | 2 |
| Dixon, JG | 1 |
| Wolmark, N | 1 |
| Haller, DG | 1 |
| Allegra, CJ | 1 |
| de Gramont, A | 2 |
| VanCutsem, E | 1 |
| Alberts, SR | 2 |
| George, TJ | 1 |
| O'Connell, MJ | 5 |
| Twelves, C | 1 |
| Taieb, J | 1 |
| Saltz, LB | 1 |
| Blanke, CD | 1 |
| Francini, E | 1 |
| Kerr, R | 2 |
| Yothers, G | 1 |
| Seitz, JF | 1 |
| Marsoni, S | 2 |
| Goldberg, RM | 2 |
| Shi, Q | 2 |
| Visacri, MB | 1 |
| Duarte, NC | 1 |
| Lima, TM | 1 |
| de Souza, RN | 1 |
| Cobaxo, TS | 1 |
| Teixeira, JC | 1 |
| Barbosa, CR | 1 |
| Dias, LP | 1 |
| Tavares, MG | 1 |
| Pincinato, EC | 1 |
| Lima, CS | 1 |
| Moriel, P | 1 |
| Wang, DS | 1 |
| Hu, MT | 1 |
| Wang, ZQ | 2 |
| Ren, C | 1 |
| Qiu, MZ | 1 |
| Luo, HY | 1 |
| Jin, Y | 1 |
| Fong, WP | 1 |
| Wang, SB | 1 |
| Peng, JW | 1 |
| Zou, QF | 1 |
| Tan, Q | 1 |
| Wang, FH | 2 |
| Li, YH | 2 |
| Watts, K | 1 |
| Wills, C | 1 |
| Madi, A | 1 |
| Palles, C | 1 |
| Maughan, TS | 1 |
| Kaplan, R | 1 |
| Al-Tassan, NA | 1 |
| Kerr, D | 1 |
| Gray, V | 1 |
| West, H | 1 |
| Houlston, RS | 1 |
| Escott-Price, V | 1 |
| Cheadle, JP | 1 |
| Caron, B | 1 |
| Reimund, JM | 1 |
| Ben Abdelghani, M | 1 |
| Sondag, D | 1 |
| Noirclerc, M | 1 |
| Duclos, B | 1 |
| Kurtz, JE | 1 |
| Nguimpi-Tambou, M | 1 |
| Fang, M | 1 |
| Song, T | 1 |
| Liang, X | 1 |
| Lv, S | 1 |
| Li, J | 7 |
| Xu, H | 1 |
| Luo, L | 1 |
| Jia, Y | 1 |
| Chao, YL | 1 |
| Anders, CK | 1 |
| Bubalo, JS | 1 |
| Herrington, JD | 1 |
| Takemoto, M | 1 |
| Willman, P | 1 |
| Edwards, MS | 1 |
| Williams, C | 1 |
| Fisher, A | 1 |
| Palumbo, A | 1 |
| Chen, E | 1 |
| Blanke, C | 1 |
| Lopez, CD | 1 |
| Liu, GY | 1 |
| Lv, X | 1 |
| Wu, YS | 1 |
| Mao, MJ | 1 |
| Ye, YF | 1 |
| Yu, YH | 1 |
| Liang, H | 1 |
| Yang, J | 1 |
| Ke, LR | 1 |
| Qiu, WZ | 1 |
| Huang, XJ | 1 |
| Li, WZ | 1 |
| Guo, X | 2 |
| Xiang, YQ | 2 |
| Xia, WX | 2 |
| Deng, B | 1 |
| Jia, L | 1 |
| Tan, H | 2 |
| Lou, Y | 1 |
| Li, X | 1 |
| Li, Y | 3 |
| Yu, L | 1 |
| Abdel-Rahman, O | 1 |
| Iwazu, Y | 1 |
| Kotani, K | 1 |
| Yamada, T | 1 |
| Pacetti, U | 1 |
| Veltri, E | 1 |
| Fattoruso, SI | 1 |
| Cardillo, FD | 1 |
| Evangelista, S | 1 |
| Cognetti, F | 2 |
| Fabi, A | 1 |
| Koch, S | 1 |
| Wein, A | 2 |
| Siebler, J | 1 |
| Boxberger, F | 1 |
| Neurath, MF | 1 |
| Harich, HD | 1 |
| Hohenberger, W | 2 |
| Dörje, F | 1 |
| Ejlertsen, B | 1 |
| Jensen, MB | 1 |
| Elversang, J | 1 |
| Rasmussen, BB | 1 |
| Andersson, M | 1 |
| Andersen, J | 1 |
| Nielsen, DL | 1 |
| Cold, S | 1 |
| Mouridsen, HT | 2 |
| Martin, M | 3 |
| Bonneterre, J | 4 |
| Geyer, CE | 2 |
| Ito, Y | 1 |
| Ro, J | 1 |
| Lang, I | 1 |
| Kim, SB | 1 |
| Germa, C | 1 |
| Vermette, J | 1 |
| Wang, K | 2 |
| Awada, A | 1 |
| Silvestris, N | 1 |
| Brunetti, AE | 1 |
| Russano, M | 1 |
| Nardulli, P | 1 |
| Shen, L | 5 |
| Xu, JM | 2 |
| Feng, FY | 1 |
| Jiao, SC | 1 |
| Wang, LW | 1 |
| Guan, ZZ | 1 |
| Qin, SK | 1 |
| Wang, JJ | 1 |
| Yu, SY | 1 |
| Wang, YJ | 1 |
| Jin, YN | 1 |
| Tao, M | 1 |
| Zheng, LZ | 1 |
| Pan, LX | 1 |
| Yamashita, H | 2 |
| Omori, M | 1 |
| Okuma, K | 2 |
| Kobayashi, R | 1 |
| Igaki, H | 1 |
| Nakagawa, K | 1 |
| Kajiura, S | 1 |
| Hosokawa, A | 1 |
| Yoshita, H | 1 |
| Ueda, Y | 1 |
| Ueda, A | 1 |
| Mihara, H | 1 |
| Ando, T | 1 |
| Fujinami, H | 1 |
| Nishikawa, J | 1 |
| Ogawa, K | 1 |
| Minemura, M | 1 |
| Sugiyama, T | 1 |
| Gozzo, Tde O | 1 |
| Moysés, AM | 1 |
| da Silva, PR | 1 |
| de Almeida, AM | 1 |
| Liu, Y | 1 |
| Wu, W | 1 |
| Hong, W | 1 |
| Sun, X | 1 |
| Wu, J | 1 |
| Huang, Q | 1 |
| Babacan, T | 1 |
| Turkbeyler, IH | 1 |
| Dag, MS | 1 |
| Dilli, I | 1 |
| Balakan, O | 1 |
| Altundag, K | 1 |
| Bayoglu, IV | 1 |
| Varol, U | 1 |
| Yildiz, I | 1 |
| Muslu, U | 1 |
| Alacacioglu, A | 1 |
| Kucukzeybek, Y | 1 |
| Akyol, M | 1 |
| Demir, L | 1 |
| Dirican, A | 1 |
| Cokmert, S | 1 |
| Yildiz, Y | 1 |
| Karabulut, B | 1 |
| Uslu, R | 1 |
| Tarhan, MO | 1 |
| Soveri, LM | 1 |
| Hermunen, K | 1 |
| Poussa, T | 1 |
| Quinaux, E | 1 |
| Bono, P | 1 |
| Österlund, P | 1 |
| Lee, AM | 1 |
| Pavey, E | 1 |
| Sargent, DJ | 1 |
| Sinicrope, FA | 1 |
| Berenberg, JL | 1 |
| Diasio, RB | 1 |
| Zahrina, AK | 1 |
| Norsa'adah, B | 1 |
| Hassan, NB | 1 |
| Norazwany, Y | 1 |
| Norhayati, I | 1 |
| Roslan, MH | 1 |
| Wan Nazuha, WR | 1 |
| Kim, JE | 2 |
| Hong, YS | 2 |
| Lee, JL | 1 |
| Kim, KP | 2 |
| Park, SJ | 1 |
| Sym, SJ | 1 |
| Shin, DB | 2 |
| Lee, J | 3 |
| Park, YS | 2 |
| Ahn, JS | 1 |
| Kim, TW | 3 |
| Ishimaru, K | 1 |
| Takano, A | 1 |
| Katsura, M | 1 |
| Yamaguchi, N | 1 |
| Kaneko, K | 1 |
| Takahashi, H | 1 |
| Bowen, JM | 1 |
| White, I | 1 |
| Smith, L | 1 |
| Tsykin, A | 1 |
| Kristaly, K | 1 |
| Thompson, SK | 1 |
| Karapetis, CS | 1 |
| Game, PA | 1 |
| Irvine, T | 1 |
| Hussey, DJ | 1 |
| Watson, DI | 1 |
| Keefe, DM | 1 |
| Takemoto, H | 1 |
| Nakata, K | 1 |
| Ide, Y | 1 |
| Fukuzaki, T | 1 |
| Kudo, T | 1 |
| Miyake, Y | 1 |
| Yasui, M | 1 |
| Morita, S | 1 |
| Sakai, D | 1 |
| Uemura, M | 1 |
| Hata, T | 1 |
| Takemasa, I | 1 |
| Mizushima, T | 1 |
| Ohno, Y | 3 |
| Yamamoto, H | 1 |
| Sekimoto, M | 1 |
| Nezu, R | 1 |
| Doki, Y | 1 |
| Mori, M | 2 |
| Miwa, K | 1 |
| Oki, E | 2 |
| Emi, Y | 2 |
| Saeki, H | 2 |
| Kusumoto, T | 1 |
| Akagi, Y | 2 |
| Ogata, Y | 2 |
| Samura, H | 1 |
| Ishikawa, H | 1 |
| Tanaka, T | 3 |
| Sueyoshi, S | 1 |
| Higashi, H | 1 |
| Matsuda, H | 2 |
| Touyama, T | 1 |
| Maehara, Y | 2 |
| Ko, AH | 1 |
| LoConte, N | 1 |
| Tempero, MA | 1 |
| Walker, EJ | 1 |
| Kate Kelley, R | 1 |
| Lewis, S | 1 |
| Chang, WC | 2 |
| Kantoff, E | 1 |
| Vannier, MW | 1 |
| Catenacci, DV | 1 |
| Venook, AP | 1 |
| Kindler, HL | 2 |
| Arslan, M | 1 |
| Ozdemir, L | 1 |
| Wang-Gillam, A | 1 |
| Li, CP | 1 |
| Bodoky, G | 1 |
| Dean, A | 1 |
| Shan, YS | 1 |
| Jameson, G | 1 |
| Macarulla, T | 1 |
| Lee, KH | 1 |
| Cunningham, D | 2 |
| Blanc, JF | 1 |
| Hubner, RA | 1 |
| Chiu, CF | 1 |
| Schwartsmann, G | 1 |
| Siveke, JT | 1 |
| Braiteh, F | 1 |
| Moyo, V | 1 |
| Belanger, B | 1 |
| Dhindsa, N | 1 |
| Bayever, E | 1 |
| Von Hoff, DD | 2 |
| Chen, LT | 1 |
| Tebbutt, NC | 1 |
| Price, TJ | 1 |
| Ferraro, DA | 1 |
| Wong, N | 1 |
| Veillard, AS | 1 |
| Hall, M | 1 |
| Sjoquist, KM | 1 |
| Pavlakis, N | 1 |
| Strickland, A | 1 |
| Varma, SC | 1 |
| Cooray, P | 1 |
| Young, R | 1 |
| Underhill, C | 1 |
| Shannon, JA | 1 |
| Ganju, V | 1 |
| Gebski, V | 1 |
| Zhao, L | 1 |
| Liu, R | 1 |
| Zhang, Z | 1 |
| Li, T | 1 |
| Li, F | 1 |
| Liu, H | 1 |
| Li, G | 1 |
| Hanaka, J | 1 |
| Nakayama, H | 1 |
| Terashima, T | 1 |
| Pasquini, G | 1 |
| Vasile, E | 1 |
| Caparello, C | 1 |
| Vivaldi, C | 1 |
| Musettini, G | 1 |
| Lencioni, M | 1 |
| Petrini, I | 1 |
| Fornaro, L | 1 |
| Kim, JW | 1 |
| Lee, KW | 1 |
| Lee, JH | 1 |
| Kim, SY | 1 |
| Park, SR | 1 |
| Nam, BH | 1 |
| Cho, SH | 1 |
| Chung, IJ | 1 |
| Oh, HS | 1 |
| Lee, MA | 1 |
| Kang, HJ | 1 |
| Park, YI | 1 |
| Song, EK | 1 |
| Han, HS | 1 |
| Lee, KT | 1 |
| Kang, JH | 1 |
| Zang, DY | 1 |
| Kim, JH | 1 |
| Nomura, H | 1 |
| Kawakami, H | 1 |
| Nagai, S | 1 |
| Shinohara, T | 1 |
| Isaka, H | 1 |
| Zhang, XD | 3 |
| Bai, Y | 1 |
| Chu, YP | 1 |
| Wang, YH | 1 |
| Liu, DQ | 1 |
| Jin, ML | 2 |
| Wang, ZH | 1 |
| Guo, J | 1 |
| Chen, Z | 3 |
| Li, CZ | 1 |
| Sheng, LJ | 1 |
| Zhou, DG | 1 |
| Liu, B | 1 |
| Liu, J | 1 |
| Wang, QC | 1 |
| Zhang, EN | 1 |
| Kim, K | 2 |
| Chie, EK | 1 |
| Jang, JY | 1 |
| Kim, SW | 1 |
| Oh, DY | 1 |
| Im, SA | 1 |
| Kim, TY | 1 |
| Bang, YJ | 1 |
| Ha, SW | 1 |
| Horisberger, K | 1 |
| Treschl, A | 1 |
| Mai, S | 1 |
| Barreto-Miranda, M | 1 |
| Kienle, P | 1 |
| Ströbel, P | 1 |
| Erben, P | 1 |
| Woernle, C | 1 |
| Dinter, D | 1 |
| Kähler, G | 1 |
| Hochhaus, A | 2 |
| Post, S | 1 |
| Willeke, F | 1 |
| Wenz, F | 1 |
| Hofheinz, RD | 2 |
| Zhang, JD | 1 |
| Shao, ZY | 1 |
| Hu, B | 1 |
| Yu, JR | 1 |
| Wen, ZZ | 1 |
| Shu, YQ | 1 |
| Wang, BC | 1 |
| Yin, HR | 1 |
| Chen, L | 2 |
| Bai, YX | 1 |
| Liang, J | 1 |
| Cheng, Y | 1 |
| Zhou, Y | 1 |
| Zhang, HG | 1 |
| Wan, DS | 1 |
| Chen, S | 1 |
| Jia, TZ | 1 |
| Kiba, T | 1 |
| Oikawa, M | 1 |
| Hokkoku, K | 1 |
| Watanabe, Y | 1 |
| Nakagawa, T | 2 |
| Shintaku, K | 1 |
| Yoshimitsu, Y | 1 |
| Sakuma, H | 1 |
| Ueda, H | 1 |
| Nakai, M | 2 |
| Moore, S | 1 |
| Gilbar, P | 1 |
| McPherson, I | 1 |
| Raoul, JL | 1 |
| Van Laethem, JL | 1 |
| Peeters, M | 1 |
| Brezault, C | 1 |
| Husseini, F | 1 |
| Cals, L | 1 |
| Nippgen, J | 1 |
| Loos, AH | 1 |
| Rougier, P | 1 |
| Lou, F | 1 |
| Zhu, YH | 1 |
| Pan, HM | 1 |
| Yan, D | 1 |
| Dai, H | 1 |
| Zhang, J | 2 |
| Xiao, Y | 1 |
| Lu, M | 2 |
| Yokokawa, T | 1 |
| Matsusaka, S | 1 |
| Shouji, D | 1 |
| Imada, H | 1 |
| Nakamoto, E | 1 |
| Kamisugi, K | 1 |
| Suzuki, W | 1 |
| Shirai, T | 1 |
| Takahashi, G | 1 |
| Kawakami, K | 1 |
| Shinozaki, E | 1 |
| Suenaga, M | 1 |
| Mizunuma, N | 1 |
| Hatake, K | 1 |
| Hama, T | 1 |
| Orphanos, G | 1 |
| Alexopoulos, A | 1 |
| Malliou, S | 1 |
| Ioannidis, G | 1 |
| Ardavanis, A | 1 |
| Kandylis, C | 1 |
| Stavrakakis, J | 1 |
| Rigatos, G | 1 |
| Zhang, DS | 1 |
| Feng, F | 1 |
| Zhang, L | 2 |
| Xu, RH | 1 |
| Jiang, WQ | 1 |
| He, YJ | 1 |
| Mastoraki, A | 1 |
| Papanikolaou, IS | 1 |
| Kanakis, D | 1 |
| Safioleas, P | 1 |
| Sakorafas, G | 1 |
| Safioleas, M | 1 |
| Lu, X | 1 |
| Hong, MH | 1 |
| Chen, QY | 1 |
| Zeng, Q | 1 |
| Bao, HY | 1 |
| Fang, WJ | 1 |
| Zhang, XC | 1 |
| Shi, GM | 1 |
| Huang, S | 1 |
| Yu, LF | 1 |
| Chen, J | 1 |
| Mou, HB | 1 |
| Deng, J | 1 |
| Shen, P | 1 |
| Xu, N | 1 |
| Wu, F | 1 |
| Chen, SC | 1 |
| Lu, ZH | 1 |
| Xiong, JP | 2 |
| Schneiders, FL | 1 |
| van den Berg, HP | 1 |
| Peters, GJ | 1 |
| Verheul, HM | 1 |
| van der Vliet, HJ | 1 |
| Rades, D | 1 |
| Kronemann, S | 1 |
| Meyners, T | 1 |
| Bohlen, G | 1 |
| Tribius, S | 1 |
| Kazic, N | 1 |
| Schroeder, U | 1 |
| Hakim, SG | 1 |
| Schild, SE | 1 |
| Dunst, J | 1 |
| Sweeney, CJ | 1 |
| Chiorean, EG | 1 |
| Verschraegen, CF | 1 |
| Lee, FC | 1 |
| Jones, S | 1 |
| Royce, M | 1 |
| Tye, L | 1 |
| Liau, KF | 1 |
| Bello, A | 1 |
| Chao, R | 1 |
| Burris, HA | 1 |
| Malik, I | 1 |
| Bernal, P | 1 |
| Byrd, J | 1 |
| Chon, YE | 1 |
| Seong, J | 1 |
| Kim, BK | 1 |
| Cha, J | 1 |
| Kim, SU | 1 |
| Park, JY | 2 |
| Ahn, SH | 2 |
| Han, KH | 2 |
| Chon, CY | 2 |
| Shin, SK | 1 |
| Kim, DY | 1 |
| Abe, T | 1 |
| Hachiro, Y | 1 |
| Kunimoto, M | 1 |
| Gallerani, E | 1 |
| Bauer, J | 2 |
| Hess, D | 1 |
| Boehm, S | 1 |
| Droege, C | 1 |
| Jeckelmann, S | 1 |
| Miani, M | 1 |
| Herrmann, R | 1 |
| Sperka, S | 1 |
| Sessa, C | 2 |
| Chilimoniuk, M | 1 |
| Olszewska, E | 1 |
| Maksimowicz, T | 1 |
| Hesketh, PJ | 1 |
| Sanz-Altamira, P | 1 |
| Bushey, J | 1 |
| Hesketh, AM | 1 |
| Cao, KJ | 1 |
| Zhang, AL | 1 |
| Ma, WJ | 1 |
| Huang, PY | 1 |
| Luo, DH | 1 |
| Li, JH | 1 |
| Li, B | 2 |
| Jiang, HR | 1 |
| Zhong, MZ | 1 |
| Winterhalder, R | 1 |
| Hoesli, P | 1 |
| Delmore, G | 1 |
| Pederiva, S | 1 |
| Bressoud, A | 1 |
| Hermann, F | 1 |
| von Moos, R | 1 |
| Sato, Y | 2 |
| Tatematsu, M | 2 |
| Ishikawa, K | 1 |
| Okamoto, H | 2 |
| Muro, K | 2 |
| Noma, H | 3 |
| Kim, YJ | 1 |
| Goh, PG | 1 |
| Kim, ES | 1 |
| Lee, SY | 1 |
| Moon, HS | 1 |
| Lee, ES | 1 |
| Sung, JK | 1 |
| Kim, SH | 2 |
| Lee, BS | 1 |
| Jeong, HY | 1 |
| Kadoyama, K | 1 |
| Miki, I | 1 |
| Tamura, T | 1 |
| Brown, JB | 1 |
| Sakaeda, T | 1 |
| Okuno, Y | 1 |
| Xiang, XJ | 1 |
| Qiu, F | 1 |
| Yu, F | 1 |
| Zhan, ZY | 1 |
| Feng, M | 1 |
| Yan, J | 1 |
| Zhao, JG | 1 |
| Oshiro, C | 1 |
| Kamigaki, S | 1 |
| Nakamura, Y | 1 |
| Arai, T | 2 |
| Kanai, Y | 1 |
| Fujino, M | 1 |
| Fujii, C | 1 |
| Hamaguchi, Y | 1 |
| Iseki, C | 1 |
| Hachino, Y | 1 |
| Furukawa, H | 1 |
| Chang, KJ | 1 |
| Reid, T | 1 |
| Senzer, N | 1 |
| Swisher, S | 1 |
| Pinto, H | 1 |
| Hanna, N | 1 |
| Chak, A | 1 |
| Soetikno, R | 1 |
| Farid, M | 1 |
| Chowbay, B | 1 |
| Chen, X | 1 |
| Tan, SH | 1 |
| Ramasamy, S | 1 |
| Koo, WH | 1 |
| Toh, HC | 1 |
| Choo, SP | 1 |
| Ong, SY | 1 |
| Qi, WX | 1 |
| Tang, LN | 1 |
| He, AN | 1 |
| Shen, Z | 1 |
| Yao, Y | 1 |
| Hayakawa, Y | 1 |
| Woloch, C | 1 |
| Di Paolo, A | 3 |
| Marouani, H | 1 |
| Bocci, G | 2 |
| Ciccolini, J | 1 |
| Lacarelle, B | 1 |
| Danesi, R | 3 |
| Iliadis, A | 1 |
| Schwartzman, AD | 1 |
| Sethi, R | 1 |
| Smith, R | 1 |
| Bi, LW | 1 |
| Zhang, LZ | 1 |
| Zhao, HF | 1 |
| Francois, E | 1 |
| Bennouna, J | 1 |
| Chamorey, E | 1 |
| Etienne-Grimaldi, MC | 1 |
| Renée, N | 1 |
| Senellart, H | 1 |
| Michel, C | 1 |
| Follana, P | 1 |
| Mari, V | 1 |
| Douillard, JY | 1 |
| Milano, G | 1 |
| Oddby-Muhrbeck, E | 1 |
| Öbrink, E | 1 |
| Eksborg, S | 1 |
| Rotstein, S | 1 |
| Lönnqvist, PA | 1 |
| Wu, S | 1 |
| Chen, MY | 1 |
| Luo, JC | 1 |
| Wei, L | 1 |
| Nakatsumi, H | 1 |
| Komatsu, Y | 1 |
| Yuki, S | 1 |
| Sogabe, S | 1 |
| Tateyama, M | 1 |
| Muto, S | 1 |
| Kudo, M | 1 |
| Kato, K | 1 |
| Miyagishima, T | 1 |
| Uebayashi, M | 1 |
| Meguro, T | 1 |
| Oba, K | 1 |
| Asaka, M | 1 |
| Sadanaga, N | 1 |
| Kakeji, Y | 1 |
| Baba, H | 1 |
| Nishimaki, T | 1 |
| Natsugoe, S | 1 |
| Shirouzu, K | 1 |
| Ahn, JH | 1 |
| Kang, YK | 1 |
| Bahng, H | 1 |
| Chang, HM | 1 |
| Kang, WC | 1 |
| Kim, WK | 1 |
| Lee, JS | 1 |
| Park, JS | 1 |
| Carlomagno, C | 1 |
| Lauria, R | 1 |
| De Laurentiis, M | 1 |
| Arpino, G | 1 |
| Massarelli, E | 1 |
| Ferrara, C | 1 |
| Milano, A | 1 |
| Vernaglia Lombardi, A | 1 |
| Costanzo, R | 1 |
| Catalano, G | 2 |
| Bianco, AR | 1 |
| De Placido, S | 1 |
| Calvo, E | 1 |
| Cortés, J | 1 |
| González-Cao, M | 1 |
| Rodríguez, J | 1 |
| Aramendía, JM | 1 |
| Fernández-Hidalgo, O | 1 |
| Martín-Algarra, S | 1 |
| Salgado, JE | 1 |
| Martínez-Monge, R | 1 |
| de Irala, J | 1 |
| Brugarolas, A | 1 |
| Liaw, CC | 2 |
| Chang, HK | 1 |
| Liau, CT | 2 |
| Huang, JS | 2 |
| Lin, YC | 2 |
| Chen, JS | 2 |
| Innocenti, F | 1 |
| Conte, PF | 1 |
| Del Tacca, M | 2 |
| Okabe, S | 1 |
| Ishikawa, T | 1 |
| Tanami, H | 1 |
| Kuwabara, H | 1 |
| Fukahara, T | 1 |
| Udagawa, M | 1 |
| Ootsukasa, S | 1 |
| Maruyama, S | 2 |
| Murase, N | 1 |
| Iwai, T | 1 |
| MOERTEL, CG | 13 |
| REITEMEIER, RJ | 6 |
| GAGE, RP | 1 |
| ANSFIELD, FJ | 3 |
| CURRERI, AR | 1 |
| HARTMANN, JR | 1 |
| ORIGENES, ML | 1 |
| MURPHY, ML | 1 |
| SITARZ, A | 1 |
| ERLANDSON, M | 1 |
| CUDMORE, JT | 1 |
| GROESBECK, HP | 1 |
| SCHELL, HW | 1 |
| HAHN, RG | 6 |
| JUSTIN-BESANCON, L | 1 |
| GRIVAUX, M | 2 |
| CORNET, A | 1 |
| TOURNEUR, R | 2 |
| GUERRE, J | 1 |
| LAMOTTE-BARRILLON, S | 1 |
| Stickel, F | 1 |
| Jüngert, B | 1 |
| Brueckl, V | 1 |
| Schirner, I | 1 |
| Brueckl, WM | 1 |
| Männlein, G | 1 |
| Hegewald, J | 1 |
| Mühldorfer, S | 1 |
| Bittorf, B | 1 |
| Hahn, EG | 1 |
| Ura, T | 1 |
| Shirao, K | 1 |
| Antón, A | 1 |
| Aranda, E | 2 |
| Carrato, A | 2 |
| Marcuello, E | 1 |
| Massutti, B | 1 |
| Cervantes, A | 2 |
| Abad, A | 1 |
| Sastre, J | 2 |
| Fenández-Martos, C | 1 |
| Gallén, M | 1 |
| Díaz-Rubio, E | 6 |
| Huarte, L | 1 |
| Balcells, M | 1 |
| Chua, DT | 1 |
| Sham, JS | 1 |
| Au, GK | 1 |
| Barbara, C | 1 |
| Cupini, S | 1 |
| Kakolyris, S | 2 |
| Souglakos, J | 1 |
| Kouroussis, C | 2 |
| Androulakis, N | 1 |
| Samonis, G | 1 |
| Vardakis, N | 1 |
| Amarantidis, K | 1 |
| Agelaki, S | 1 |
| Mavroudis, D | 1 |
| Xenidis, N | 1 |
| Georgoulias, V | 2 |
| Singhal, V | 1 |
| Singh, JP | 1 |
| Lyall, A | 1 |
| Saxena, S | 1 |
| Bansal, A | 1 |
| Garcia, AA | 1 |
| Leichman, L | 2 |
| Baranda, J | 1 |
| Pandit, L | 1 |
| Lenz, HJ | 1 |
| Leichman, CG | 2 |
| Schena, M | 1 |
| Barone, C | 1 |
| Birocco, N | 1 |
| Dongiovanni, D | 1 |
| Numico, G | 1 |
| Colantonio, I | 1 |
| Bertetto, O | 1 |
| Feng, YL | 1 |
| Ling, CQ | 1 |
| Zhu, DZ | 1 |
| Yu, CQ | 1 |
| Steiner, M | 1 |
| Seule, M | 1 |
| Steiner, B | 1 |
| Bauer, I | 1 |
| Freund, M | 1 |
| Köhne, CH | 1 |
| Schuff-Werner, P | 1 |
| Kotake, K | 1 |
| Ohashi, Y | 1 |
| Kodaira, S | 1 |
| Koyama, Y | 1 |
| Prévost, A | 1 |
| Mérol, JC | 1 |
| Aimé, P | 1 |
| Moutel, K | 1 |
| Roger-Liautaud, F | 1 |
| Nasca, S | 1 |
| Legros, M | 1 |
| Coninx, P | 1 |
| Abali, H | 1 |
| Oyan, B | 1 |
| Guler, N | 1 |
| Fakih, MG | 1 |
| Creaven, PJ | 1 |
| Ramnath, N | 1 |
| Trump, D | 1 |
| Javle, M | 1 |
| Strychor, S | 1 |
| Repinski, TV | 1 |
| Zamboni, BA | 1 |
| Schwarz, JK | 1 |
| French, RA | 1 |
| Zamboni, WC | 1 |
| Lee, KE | 1 |
| Im, YH | 1 |
| Kang, WK | 1 |
| Park, K | 1 |
| Shim, YM | 1 |
| Viale, PH | 1 |
| Fung, A | 1 |
| Zitella, L | 1 |
| Ferrari, V | 1 |
| Valcamonico, F | 1 |
| Amoroso, V | 1 |
| Simoncini, E | 1 |
| Vassalli, L | 1 |
| Marpicati, P | 1 |
| Rangoni, G | 1 |
| Grisanti, S | 1 |
| Pasinetti, N | 1 |
| Marini, G | 1 |
| Farker, K | 1 |
| Merkel, U | 1 |
| Wedding, U | 1 |
| Hippius, M | 1 |
| Höffken, K | 1 |
| Hoffmann, A | 1 |
| Rivera, E | 1 |
| Meyers, C | 1 |
| Groves, M | 1 |
| Valero, V | 1 |
| Francis, D | 1 |
| Arun, B | 1 |
| Broglio, K | 1 |
| Yin, G | 1 |
| Hortobagyi, GN | 4 |
| Buchholz, T | 1 |
| Berg, DT | 1 |
| Yamamoto, K | 2 |
| Nohara, K | 1 |
| Yamatodani, A | 1 |
| Yoon, YJ | 1 |
| Kim, JK | 1 |
| Lee, HW | 1 |
| Lee, DY | 1 |
| Moon, YM | 1 |
| Yoshino, T | 1 |
| Boku, N | 1 |
| Onozawa, Y | 1 |
| Hironaka, S | 1 |
| Fukutomi, A | 1 |
| Yamaguchi, Y | 2 |
| Hasuike, N | 1 |
| Yamazaki, K | 1 |
| Machida, N | 1 |
| Ono, H | 1 |
| Zachariae, R | 1 |
| Paulsen, K | 1 |
| Mehlsen, M | 1 |
| Jensen, AB | 1 |
| Johansson, A | 1 |
| von der Maase, H | 1 |
| Ernst, T | 1 |
| Merx, K | 1 |
| Gnad-Vogt, U | 1 |
| Lukan, N | 1 |
| Kripp, M | 1 |
| Schultheis, B | 1 |
| Oh, SY | 1 |
| Kwon, HC | 1 |
| Lee, S | 1 |
| Lee, DM | 1 |
| Yoo, HS | 1 |
| Jang, JS | 1 |
| Kim, MC | 1 |
| Jeong, JS | 1 |
| Kim, HJ | 1 |
| Di Costanzo, F | 2 |
| Gasperoni, S | 1 |
| Manzione, L | 1 |
| Bisagni, G | 1 |
| Labianca, R | 4 |
| Bravi, S | 1 |
| Cortesi, E | 2 |
| Carlini, P | 1 |
| Bracci, R | 1 |
| Tomao, S | 1 |
| Messerini, L | 1 |
| Arcangeli, A | 1 |
| Torri, V | 1 |
| Bilancia, D | 1 |
| Floriani, I | 1 |
| Tonato, M | 3 |
| Dinota, A | 1 |
| Strafiuso, G | 1 |
| Corgna, E | 1 |
| Porrozzi, S | 1 |
| Boni, C | 1 |
| Rondini, E | 1 |
| Giunta, A | 1 |
| Monzio Compagnoni, B | 1 |
| Biagioni, F | 1 |
| Cesari, M | 1 |
| Fornarini, G | 1 |
| Nelli, F | 1 |
| Carboni, M | 1 |
| Enzo, MR | 1 |
| Piga, A | 1 |
| Romiti, A | 1 |
| Olivetti, A | 1 |
| Masoni, L | 1 |
| De Stefanis, M | 1 |
| Dalla Mola, A | 1 |
| Camera, S | 1 |
| Recchia, F | 1 |
| De Filippis, S | 1 |
| Scipioni, L | 1 |
| Zironi, S | 1 |
| Luppi, G | 1 |
| Italia, M | 1 |
| Banducci, S | 1 |
| Pisani Leretti, A | 1 |
| Massidda, B | 2 |
| Ionta, MT | 2 |
| Nicolosi, A | 1 |
| Canaletti, R | 1 |
| Biscottini, B | 1 |
| Grigniani, F | 1 |
| Rovei, R | 1 |
| Croce, E | 1 |
| Carroccio, R | 1 |
| Gilli, G | 1 |
| Cavalli, C | 1 |
| Olgiati, A | 1 |
| Pandolfi, U | 1 |
| Rossetti, R | 1 |
| Natalini, G | 1 |
| Foa, P | 1 |
| Oldani, S | 1 |
| Bruno, L | 1 |
| Cascinu, S | 1 |
| Catalano, V | 1 |
| Lungarotti, F | 1 |
| Farris, A | 1 |
| Sarobba, MG | 1 |
| Trignano, M | 1 |
| Muscogiuri, A | 1 |
| Francavilla, F | 1 |
| Figoli, F | 1 |
| Leoni, M | 1 |
| Papiani, G | 1 |
| Orselli, G | 1 |
| Antimi, M | 1 |
| Bellini, V | 1 |
| Cabassi, A | 1 |
| Contu, A | 1 |
| Pazzola, A | 1 |
| Frignano, M | 1 |
| Lastraioli, E | 1 |
| Saggese, M | 1 |
| Bianchini, D | 1 |
| Antonuzzo, L | 1 |
| Mela, M | 1 |
| Camisa, R | 1 |
| Hui, R | 1 |
| Zhang, M | 1 |
| Hao, XM | 1 |
| Punt, CJ | 1 |
| Koopman, M | 1 |
| Kemeny, NE | 1 |
| Ahmed, T | 1 |
| Michaelson, RA | 1 |
| Harper, HD | 1 |
| Yip, LC | 1 |
| Togni, P | 1 |
| Varini, M | 1 |
| Cavalli, F | 2 |
| Legha, SS | 1 |
| Ajani, JA | 1 |
| Blumenschein, GR | 4 |
| Buzdar, AU | 4 |
| Singer, Z | 1 |
| Kozaczka, A | 1 |
| Wilk, J | 1 |
| Janas, J | 1 |
| Tormey, DC | 3 |
| Weinberg, VE | 1 |
| Holland, JF | 2 |
| Weiss, RB | 1 |
| Glidewell, OJ | 1 |
| Perloff, M | 1 |
| Falkson, G | 5 |
| Falkson, HC | 3 |
| Henry, PH | 1 |
| Leone, LA | 1 |
| Presant, CA | 1 |
| Denes, AE | 1 |
| Liu, C | 1 |
| Bartolucci, AA | 1 |
| Vogel, CL | 1 |
| Smalley, RV | 2 |
| Raney, M | 1 |
| Krauss, S | 2 |
| Carpenter, J | 2 |
| Velez-Garcia, E | 1 |
| Fishkin, E | 1 |
| Raab, S | 1 |
| Moore, MR | 1 |
| Stagg, M | 1 |
| Bedikian, AY | 1 |
| Bodey, GP | 2 |
| Valdivieso, M | 2 |
| Burgess, MA | 2 |
| Kallas, GJ | 1 |
| Singson, JP | 1 |
| Bukowski, RM | 2 |
| Abderhalden, RT | 1 |
| Hewlett, JS | 1 |
| Weick, JK | 1 |
| Groppe, CW | 1 |
| Pinnamaneni, K | 1 |
| Yap, HY | 2 |
| Distefano, A | 1 |
| Aboud, A | 1 |
| McDermott, BJ | 1 |
| Van den Berg, HW | 1 |
| Martin, WM | 2 |
| Murphy, RF | 1 |
| Windschitl, H | 1 |
| Scott, M | 1 |
| Schutt, A | 1 |
| McCormack, G | 1 |
| Everson, L | 1 |
| Cullinan, S | 1 |
| Gerstner, J | 1 |
| Krook, J | 1 |
| Laurie, J | 1 |
| Shreck, R | 1 |
| Fishman, ML | 1 |
| Thirlwell, MP | 1 |
| Daly, DS | 1 |
| Kotake, T | 1 |
| Usami, M | 1 |
| Miki, T | 1 |
| Kuroda, M | 1 |
| Obata, K | 1 |
| Osafune, M | 1 |
| Fujioka, H | 1 |
| Takasugi, Y | 1 |
| Taguchi, T | 2 |
| Lee, YT | 1 |
| Vaughn, CB | 1 |
| Maniscalco-Greb, E | 1 |
| Lockhard, C | 1 |
| Groshko, G | 1 |
| Enochs, K | 1 |
| Duffin, H | 1 |
| Demitrish, M | 1 |
| McCracken, JD | 1 |
| Ray, P | 1 |
| Heilbrun, LK | 1 |
| Vaitkevicius, VK | 1 |
| Saiki, JH | 1 |
| Rivkin, SE | 3 |
| Rossof, AH | 1 |
| Moore, TN | 1 |
| Wilcox, PM | 2 |
| Fetting, JH | 2 |
| Nettesheim, KM | 1 |
| Abeloff, MD | 1 |
| Boesen, E | 1 |
| Chlebowski, RT | 1 |
| Pugh, RP | 1 |
| Weiner, JM | 1 |
| Bateman, JR | 1 |
| Frytak, S | 2 |
| Rubin, J | 3 |
| Schutt, AJ | 5 |
| Weiland, LH | 1 |
| Childs, DS | 1 |
| Holbrook, MA | 1 |
| Lavin, PT | 1 |
| Livstone, E | 1 |
| Spiro, H | 1 |
| Knowlton, A | 1 |
| Kalser, M | 1 |
| Barkin, J | 1 |
| Lessner, H | 1 |
| Mann-Kaplan, R | 1 |
| Ramming, K | 1 |
| Douglas, HO | 2 |
| Thomas, P | 1 |
| Nave, H | 1 |
| Bateman, J | 1 |
| Lokich, J | 1 |
| Brooks, J | 1 |
| Chaffey, J | 1 |
| Corson, JM | 1 |
| Zamcheck, N | 1 |
| Novak, JW | 1 |
| Kohno, N | 1 |
| Ichikawa, G | 1 |
| Shirasaka, T | 2 |
| Inuyama, Y | 1 |
| Kawaida, M | 1 |
| Ohnuma, T | 1 |
| Tsukuda, M | 1 |
| Kohno, H | 1 |
| Enomoto, H | 1 |
| Kawai, S | 1 |
| Yago, T | 1 |
| Ikema, Y | 1 |
| Makino, Y | 1 |
| Kubota, A | 1 |
| Furukawa, M | 1 |
| Hebbar, M | 1 |
| Hecquet, B | 1 |
| Vanlemmens, L | 1 |
| Lecomte, S | 1 |
| Pion, JM | 1 |
| Adenis, A | 1 |
| Sugihara, K | 1 |
| Stein, BN | 1 |
| Petrelli, NJ | 1 |
| Douglass, HO | 3 |
| Driscoll, DL | 1 |
| Arcangeli, G | 1 |
| Meropol, NJ | 1 |
| Shinoda, M | 1 |
| Morise, K | 1 |
| Kusugami, K | 1 |
| Iwase, H | 1 |
| Ina, K | 1 |
| Kaneko, H | 1 |
| Horiuchi, Y | 1 |
| Kuroiwa, A | 1 |
| Suga, S | 1 |
| Oka, Y | 1 |
| Nakai, Y | 1 |
| Furuse, K | 1 |
| Ohta, M | 1 |
| Fujii, M | 3 |
| Asakawa, M | 1 |
| Fukuoka, M | 1 |
| Yoshida, K | 1 |
| Niitani, H | 1 |
| Fredrikson, M | 1 |
| Hursti, TJ | 1 |
| Steineck, G | 1 |
| Fürst, CJ | 1 |
| Börjesson, S | 1 |
| Peterson, C | 1 |
| Domaradzka-Woźniak, A | 1 |
| Wojtacki, J | 1 |
| Dziewulska-Bokiniec, A | 1 |
| Tan, EH | 1 |
| Ang, PT | 1 |
| Khoo, KS | 1 |
| Rosso, R | 4 |
| Mazzei, T | 1 |
| Sobrero, A | 2 |
| Mini, E | 1 |
| Cartei, G | 2 |
| Conte, P | 1 |
| Cartei, F | 1 |
| Pancera, G | 1 |
| Tomio, L | 1 |
| Zorat, PL | 1 |
| Paccagnella, A | 1 |
| Segati, R | 1 |
| Loreggian, L | 1 |
| Lora, O | 1 |
| Friso, ML | 1 |
| Chiarion-Sileni, V | 1 |
| Favaretto, A | 1 |
| Fede, A | 1 |
| Wang, HM | 2 |
| Wang, CH | 1 |
| Buser, KS | 1 |
| Joss, RA | 1 |
| Piquet, D | 1 |
| Aapro, MS | 1 |
| Haefliger, JM | 1 |
| Jungi, WF | 1 |
| Obrist, R | 1 |
| Brunner, KW | 1 |
| Levitt, M | 1 |
| Warr, D | 1 |
| Yelle, L | 1 |
| Rayner, HL | 1 |
| Lofters, WS | 1 |
| Perrault, DJ | 1 |
| Wilson, KS | 1 |
| Latreille, J | 1 |
| Potvin, M | 1 |
| Warner, E | 1 |
| Singh, G | 1 |
| Singh, DP | 1 |
| Gupta, D | 1 |
| Muralikrishna, BV | 1 |
| Coombes, RC | 1 |
| Bliss, JM | 1 |
| Wils, J | 1 |
| Morvan, F | 1 |
| Espié, M | 1 |
| Amadori, D | 1 |
| Gambrosier, P | 1 |
| Richards, M | 1 |
| Aapro, M | 1 |
| Villar-Grimalt, A | 1 |
| McArdle, C | 1 |
| Pérez-López, FR | 1 |
| Vassilopoulos, P | 1 |
| Ferreira, EP | 1 |
| Chilvers, CE | 1 |
| Coombes, G | 1 |
| Woods, EM | 1 |
| Marty, M | 1 |
| Feliu, J | 2 |
| González Barón, M | 2 |
| García-Girón, C | 1 |
| Espinosa, E | 2 |
| García-Alfonso, P | 1 |
| Belón, J | 1 |
| Blanco, E | 1 |
| Garrido, P | 1 |
| Ordónez, A | 2 |
| Gómez-Navarro, J | 1 |
| Zamora, P | 1 |
| Katsumata, K | 1 |
| Ohno, M | 1 |
| Shibata, K | 1 |
| Yamashita, S | 1 |
| Stewart, A | 1 |
| Wang, R | 1 |
| Fan, Q | 1 |
| Wang, Z | 1 |
| Hisano, C | 1 |
| Nakano, S | 1 |
| Masumoto, N | 1 |
| Fujishima, H | 1 |
| Nakamura, M | 1 |
| Niho, Y | 1 |
| Barrenetxea, G | 1 |
| Schneider, J | 1 |
| Centeno, MM | 1 |
| Romero, H | 1 |
| de la Rica, M | 1 |
| Rodríguez-Escudero, FJ | 1 |
| Bosnjak, SM | 2 |
| Neskovic-Konstantinovic, ZB | 2 |
| Jovanovic-Micic, DJ | 1 |
| Mitrovic, LB | 1 |
| Radulovic, SS | 2 |
| du Bois, A | 1 |
| Vach, W | 1 |
| Holy, R | 1 |
| Kriesinger-Schröder, H | 1 |
| Fujinami, K | 1 |
| Ikeda, I | 1 |
| Miura, T | 1 |
| Kondo, I | 1 |
| García Girón, C | 1 |
| Vicent, JM | 1 |
| Gómez Navarro, J | 1 |
| Berrocal, A | 1 |
| Vilches, Y | 1 |
| de Castro, J | 1 |
| Díaz, J | 1 |
| Park, Y | 1 |
| Hatano, Y | 1 |
| Sasamoto, S | 1 |
| Kato, N | 1 |
| Okuyama, N | 1 |
| Yamazaki, S | 1 |
| Kobayashi, F | 1 |
| Yamanouchi, T | 1 |
| Shimizu, T | 1 |
| Sato, H | 1 |
| Adachi, I | 1 |
| Sakamoto, T | 1 |
| Fujimaki, M | 1 |
| Horikoshi, I | 1 |
| Hecht, JR | 1 |
| Lembo, T | 1 |
| Chap, L | 1 |
| Kimura, E | 1 |
| Niimi, S | 1 |
| Watanabe, A | 1 |
| Antón-Torres, A | 1 |
| Massutí, T | 1 |
| Fernández-Martos, C | 1 |
| Tokumaru, Y | 2 |
| Imanishi, Y | 2 |
| Kanke, M | 2 |
| Kanzaki, J | 2 |
| Iop, A | 1 |
| Vigevani, E | 1 |
| Clocchiatti, L | 1 |
| Mansutti, M | 1 |
| Sibau, AM | 1 |
| Hoshino, K | 1 |
| Ono, K | 1 |
| Kimura, O | 1 |
| Kawaguchi, H | 1 |
| Fukui, H | 1 |
| Ikeda, M | 1 |
| Shimamoto, Y | 1 |
| Kato, T | 1 |
| Fukushima, M | 1 |
| Shinohara, H | 1 |
| Yonekawa, H | 1 |
| Machimura, T | 1 |
| Furukawa, T | 1 |
| Nishihori, H | 1 |
| Kurihara, N | 1 |
| Urakami, H | 1 |
| Nemoto, Y | 1 |
| Reid, JM | 1 |
| Kovach, JS | 1 |
| Bagniewski, PG | 1 |
| Jan, YY | 1 |
| Steyn, RS | 1 |
| Vijeyasingam, R | 1 |
| Darnton, SJ | 1 |
| Cullen, MH | 1 |
| Matthews, HR | 1 |
| Muggia, FM | 1 |
| Wu, X | 1 |
| Spicer, D | 1 |
| Groshen, S | 1 |
| Jeffers, S | 1 |
| Chan, KK | 1 |
| Marshall, JL | 1 |
| Richmond, E | 1 |
| DeLap, RJ | 1 |
| Brown, RS | 1 |
| Brown, TK | 1 |
| Hoare, D | 1 |
| Gaze, MN | 1 |
| Rothenberg, ML | 1 |
| Cox, JV | 1 |
| DeVore, RF | 1 |
| Hainsworth, JD | 1 |
| Pazdur, R | 1 |
| Macdonald, JS | 1 |
| Sandbach, J | 1 |
| Wolf, DL | 1 |
| Mohrland, JS | 1 |
| Elfring, GL | 1 |
| Miller, LL | 1 |
| Sigsgaard, T | 1 |
| Herrstedt, J | 1 |
| Andersen, LJ | 1 |
| Havsteen, H | 2 |
| Langer, SW | 1 |
| Kjaerbøl, AG | 1 |
| Lund, H | 1 |
| Kjaer, M | 2 |
| Dombernowsky, P | 1 |
| Tsukamoto, F | 1 |
| Watanabe, T | 1 |
| Yoneda, K | 1 |
| Takamura, Y | 1 |
| Hojo, S | 1 |
| Shiba, E | 1 |
| Noguchi, S | 1 |
| Susnjar, S | 1 |
| Mitrovi, LB | 1 |
| Domenge, C | 1 |
| Hill, C | 1 |
| Lefebvre, JL | 1 |
| De Raucourt, D | 1 |
| Rhein, B | 1 |
| Wibault, P | 1 |
| Marandas, P | 1 |
| Coche-Dequeant, B | 1 |
| Stromboni-Luboinski, M | 1 |
| Sancho-Garnier, H | 1 |
| Luboinski, B | 1 |
| Santini, D | 1 |
| Tonini, G | 1 |
| Salerno, A | 1 |
| Vincenzi, B | 1 |
| Patti, G | 1 |
| Battistoni, F | 1 |
| Dicuonzo, G | 1 |
| Guglielmi, A | 1 |
| Cirillo, M | 1 |
| Recaldin, E | 1 |
| Frassineti, GL | 1 |
| Aschele, C | 1 |
| Ravaioli, A | 1 |
| Testore, P | 1 |
| Caroti, C | 1 |
| Gallo, L | 1 |
| Pessi, MA | 1 |
| Turci, D | 1 |
| Grossi, F | 1 |
| Olencki, T | 1 |
| Peereboom, D | 1 |
| Wood, L | 1 |
| Budd, GT | 1 |
| Novick, A | 1 |
| Finke, J | 1 |
| McLain, D | 1 |
| Elson, P | 1 |
| Tomita, T | 1 |
| Patt, YZ | 1 |
| Hassan, MM | 1 |
| Lozano, RD | 1 |
| Waugh, KA | 1 |
| Hoque, AM | 1 |
| Frome, AI | 1 |
| Lahoti, S | 1 |
| Ellis, L | 1 |
| Vauthey, JN | 1 |
| Curley, SA | 1 |
| Schnirer, II | 1 |
| Raijman, I | 1 |
| Chau, I | 1 |
| Webb, A | 1 |
| Hill, M | 1 |
| Waters, JS | 1 |
| Norman, A | 1 |
| Massey, A | 1 |
| Wenzel, C | 1 |
| Locker, GJ | 1 |
| Schmidinger, M | 1 |
| Mader, R | 1 |
| Kramer, G | 1 |
| Marberger, M | 1 |
| Rauchenwald, M | 1 |
| Zielinski, CC | 1 |
| Steger, GG | 1 |
| Koukourakis, MI | 1 |
| Giatromanolaki, A | 1 |
| Sivridis, E | 1 |
| Frangiadaki, C | 1 |
| Retalis, G | 1 |
| Mani, S | 1 |
| Rudin, CM | 1 |
| Kunkel, K | 1 |
| Holmlund, JT | 1 |
| Geary, RS | 1 |
| Dorr, FA | 1 |
| Ratain, MJ | 1 |
| Shinchi, H | 1 |
| Takao, S | 1 |
| Matsuo, Y | 1 |
| Mataki, Y | 1 |
| Mori, S | 1 |
| Aikou, T | 1 |
| Enck, RE | 1 |
| Scanni, A | 1 |
| Tomirotti, M | 1 |
| Margulis, A | 1 |
| Biraghi, M | 1 |
| Curtarelli, G | 1 |
| Hanley, JA | 1 |
| Hanley, J | 1 |
| Carbone, PP | 3 |
| Lavin, P | 1 |
| Pretorius, FJ | 1 |
| Bartolucci, A | 1 |
| Vogel, C | 2 |
| Tashima, CK | 1 |
| Livingston, RB | 1 |
| Gutterman, JU | 1 |
| Hersh, EM | 1 |
| Williams, SD | 1 |
| Einhorn, LH | 1 |
| Donohue, JP | 1 |
| Jones, KD | 1 |
| Hughes, LE | 1 |
| O'Fallon, JR | 2 |
| Creagan, ET | 1 |
| Schwartau, NW | 1 |
| Cedermark, BJ | 1 |
| Kaufman, JH | 1 |
| Mittelman, A | 1 |
| Posey, LE | 1 |
| Morgan, LR | 1 |
| Hoogstraten, B | 1 |
| George, SL | 1 |
| Samal, B | 1 |
| Costanzi, JJ | 1 |
| Bonnet, JD | 1 |
| Thigpen, T | 1 |
| Braine, H | 1 |
| Pouillart, P | 1 |
| Schwarzenberg, L | 1 |
| Amiel, JL | 1 |
| Mathé, G | 2 |
| Huguenin, P | 1 |
| Morin, P | 1 |
| Baron, A | 1 |
| Laparre, Ch | 1 |
| Parrot, R | 1 |
| Mohapatro, SK | 1 |
| Dandapat, MC | 1 |
| Padhi, NC | 1 |
| Casado, A | 1 |
| Dominguez, S | 1 |
| Gez, E | 3 |
| Strauss, N | 1 |
| Vitzhaki, N | 1 |
| Cass, Y | 2 |
| Edelmann, DZ | 1 |
| Tohnai, I | 1 |
| Kawabe, Y | 1 |
| Nakashima, T | 1 |
| Yamagiwa, M | 1 |
| Suzuki, T | 1 |
| Mizuno, A | 1 |
| Mineda, H | 1 |
| Kerbrat, P | 1 |
| Fargeot, P | 2 |
| Metz, R | 4 |
| Roche, H | 1 |
| Bastit, P | 2 |
| Chevrier, A | 1 |
| Tubiana-Hulin, M | 2 |
| Geyer, G | 1 |
| Cappelaere, P | 3 |
| Campora, E | 3 |
| Oliva, C | 1 |
| Mammoliti, S | 1 |
| Cetto, GL | 1 |
| Fosser, V | 1 |
| Marangolo, M | 1 |
| Samonigg, H | 1 |
| Stöger, H | 1 |
| Kasparek, AK | 1 |
| Schmid, M | 1 |
| Dusleag, J | 1 |
| Pfeiffer, K | 1 |
| Smola, M | 1 |
| Steindorfer, P | 1 |
| Lechner, P | 1 |
| Baldini, E | 1 |
| Rubagotti, A | 1 |
| Chiara, S | 2 |
| Bruzzi, P | 2 |
| Sertoli, MR | 1 |
| Tres Sánchez, A | 1 |
| Sáez Martínez, MJ | 1 |
| Mayordomo Cámara, JJ | 1 |
| Guillén Lloveria, G | 1 |
| Sáenz Cusi, A | 1 |
| Chevallier, B | 1 |
| Pujade-Lauraine, E | 1 |
| Spielmann, M | 1 |
| Paes, D | 1 |
| Bons, J | 1 |
| Fumoleau, P | 1 |
| Horner, D | 1 |
| Chauvergne, J | 1 |
| Bugat, R | 1 |
| Lowenthal, RM | 1 |
| Jestrimski, KW | 1 |
| Nakao, I | 1 |
| Pollera, CF | 1 |
| Nardi, M | 1 |
| Marolla, P | 1 |
| Pinnaró, P | 1 |
| Terzoli, E | 1 |
| Giannarelli, D | 1 |
| Sasaki, T | 1 |
| Ota, K | 1 |
| Ibayashi, J | 1 |
| Sakata, Y | 1 |
| Matsuoka, T | 1 |
| Ishikawa, M | 1 |
| Wakui, A | 1 |
| Ogoshi, K | 1 |
| Akazawa, S | 2 |
| Sakai, Y | 1 |
| Sulkes, A | 1 |
| Ochayon, L | 1 |
| Gera, C | 1 |
| Nathan, S | 1 |
| Rubello, E | 1 |
| Biran, S | 2 |
| Engstrom, PF | 1 |
| MacIntyre, JM | 1 |
| Martin-Jimenez, M | 2 |
| Silvey, L | 1 |
| Carpenter, JT | 1 |
| Wheeler, RH | 1 |
| Conolley, C | 1 |
| Martoni, A | 1 |
| Rani, P | 1 |
| Ercolino, L | 1 |
| Canova, N | 1 |
| Pannuti, F | 1 |
| Lionetto, R | 1 |
| Roila, F | 2 |
| Basurto, C | 2 |
| Minotti, V | 2 |
| Ballatori, E | 2 |
| del Favero, A | 2 |
| Shiu, W | 1 |
| Tsang, V | 1 |
| Lam, YM | 1 |
| Zacharia, A | 1 |
| Sangro, B | 1 |
| Dionet, C | 1 |
| Rozan, R | 1 |
| Achard, JL | 1 |
| Verrelle, P | 1 |
| Dumesnil, Y | 1 |
| Russier, M | 1 |
| Lemesle, P | 1 |
| Theron, H | 1 |
| de Latour, M | 1 |
| Mondie, JM | 1 |
| Zhao, TP | 1 |
| He, GF | 1 |
| Dozono, H | 1 |
| Yasuda, M | 1 |
| Yokoyama, S | 1 |
| Takahashi, S | 1 |
| Ochiai, K | 1 |
| Tsuruoka, M | 1 |
| Morimoto, O | 1 |
| Sasaki, H | 1 |
| Arihiro, T | 1 |
| Terashima, Y | 1 |
| Selch, MT | 1 |
| Parker, RG | 1 |
| Kvols, LK | 1 |
| Merlano, M | 1 |
| Grimaldi, A | 1 |
| Brunetti, I | 1 |
| Modenesi, M | 1 |
| Scala, M | 1 |
| Margarino, G | 1 |
| Scasso, F | 1 |
| Santelli, A | 1 |
| Castiglia, G | 1 |
| Pallestrini, E | 1 |
| Warner-Efraty, E | 1 |
| Ben-Yosef, R | 1 |
| Ben-Baruch, N | 1 |
| Yitzhaki, N | 1 |
| Uziely, B | 1 |
| Brufman, G | 1 |
| Adelstein, DJ | 1 |
| Sharan, VM | 1 |
| Earle, AS | 1 |
| Shah, AC | 1 |
| Vlastou, C | 1 |
| Haria, CD | 1 |
| Carter, SG | 1 |
| Damm, C | 1 |
| Hines, JD | 1 |
| Gelman, RS | 1 |
| Cummings, FJ | 1 |
| Sheidler, VR | 1 |
| Enterline, JP | 1 |
| Donehower, RC | 1 |
| Grochow, LB | 1 |
| Page, JP | 1 |
| Levi, JA | 1 |
| Woods, RL | 1 |
| Tattersall, MN | 1 |
| Fox, RM | 1 |
| Coates, AS | 1 |
| Posner, LE | 1 |
| Dukart, G | 1 |
| Goldberg, J | 1 |
| Bernstein, T | 1 |
| Cartwright, K | 1 |
| Bennett, JM | 1 |
| Byrne, P | 1 |
| Desai, A | 1 |
| White, C | 1 |
| DeConti, R | 1 |
| Krementz, E | 1 |
| Muggia, F | 1 |
| Doroshow, J | 1 |
| Plotkin, D | 1 |
| Kish, JA | 1 |
| Ensley, JF | 1 |
| Jacobs, J | 1 |
| Weaver, A | 1 |
| Cummings, G | 1 |
| Al-Sarraf, M | 1 |
| Nakajima, T | 1 |
| Kitagawa, H | 1 |
| Kanda, Y | 1 |
| Futatsuki, K | 1 |
| Suda, Y | 1 |
| Yoshida, S | 1 |
| Honda, T | 1 |
| Delgado, M | 1 |
| Keiling, R | 1 |
| Armand, JP | 1 |
| Prevot, G | 1 |
| Misset, JL | 1 |
| Grimbert, J | 1 |
| Gailani, S | 2 |
| Leone, L | 2 |
| van Eden, EB | 1 |
| Cichy, A | 1 |
| Jurga, L | 1 |
| Klvana, M | 1 |
| Burningham, R | 1 |
| Larsen, V | 1 |
| Nadler, SH | 2 |
| Moore, GE | 1 |
| Piro, AJ | 1 |
| Wilson, RE | 1 |
| Hall, TC | 1 |
| Aliapoulios, MA | 1 |
| Nevinny, HB | 1 |
| Moore, FD | 1 |
| Hill, GJ | 1 |
| Grage, TB | 1 |
| Wilson, W | 1 |
| White, RS | 1 |
| Fuqua, WB | 1 |
| Barrett, O | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of Breast Cancer Chemotherapy-induced Nausea and Vomiting: a Single-center, Randomized Controlled Clinical Trial[NCT05841849] | Phase 4 | 1,028 participants (Anticipated) | Interventional | 2023-07-31 | Not yet recruiting | ||
| Efficacy of Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Nondrinking Women Younger Than 50 Years Who Received Moderately Emetogenic Chemotherapy: A Randomized, Double-blind, Phase Ⅲ Trial[NCT03674294] | Phase 3 | 248 participants (Actual) | Interventional | 2015-08-04 | Completed | ||
| A Multicenter Randomized Dble-Blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin and 5-FU/LV Combination in First-Line Treatment of Patients With Metastatic Colorectal Carcinoma(MCRC)[NCT00272051] | Phase 3 | 620 participants | Interventional | 2002-07-31 | Completed | ||
| A Multicenter, Randomized Double-blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Preventing the Neurotoxicity of Oxaliplatin in First-line Treatment of Patients With Metastatic Colorectal Cancer Treated With Oxaliplatin / 5-FU/LV[NCT00305188] | Phase 3 | 879 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| PACCE: A Randomized, Open-Label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab With and Without Panitumumab in the First-Line Treatment of Subjects With Metastatic Colorectal Cancer[NCT00115765] | Phase 3 | 1,053 participants (Actual) | Interventional | 2005-06-01 | Completed | ||
| A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Pat[NCT00384176] | Phase 2/Phase 3 | 1,814 participants (Actual) | Interventional | 2006-08-30 | Completed | ||
| A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Oxaliplatin/ 5-fluorouracil/ Leucovorin to the Efficacy of Oxaliplatin/ 5-fluorouracil/ Leucovorin Alone in Patients With Previously Untreated Metastatic C[NCT00364013] | Phase 3 | 1,183 participants (Actual) | Interventional | 2006-08-01 | Completed | ||
| A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer[NCT00777101] | Phase 2 | 233 participants (Actual) | Interventional | 2009-02-04 | Completed | ||
| An Open Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With HER2+ Breast Cancer Treated With Neratinib With or Without Trastuzumab[NCT03094052] | Phase 2 | 11 participants (Actual) | Interventional | 2018-10-09 | Completed | ||
| Randomized Study of the Efficacy and Safety of Transdermal Granisetron Compared With Intravenous and Oral Agent in the Control of Nausea and Vomiting Induced by Moderately Emetogenic Chemotherapy[NCT01662687] | Phase 4 | 276 participants (Anticipated) | Interventional | 2012-02-29 | Recruiting | ||
| A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy[NCT01494506] | Phase 3 | 417 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer: a Phase I Study[NCT05277766] | Phase 1 | 45 participants (Anticipated) | Interventional | 2022-11-21 | Recruiting | ||
| Multicenter Phase I/IIa Study of NASOX (Nal-IRI + S-1 + Oxaliplatin) as First-line Treatment for Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma[NCT04662112] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2021-06-15 | Active, not recruiting | ||
| A Phase Ib/II Study of Ramucirumab (Cyramza®), Nal-IRI (ONIVYDE®) and Trifluridine/Tipiracil (Lonsurf®) in Second Line Metastatic Gastric Cancer (COOL Study).[NCT05927857] | Phase 1/Phase 2 | 45 participants (Anticipated) | Interventional | 2023-09-01 | Not yet recruiting | ||
| An Open-label, Randomized, Multicenter, Phase II Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers[NCT06135896] | Phase 2 | 98 participants (Anticipated) | Interventional | 2023-12-10 | Not yet recruiting | ||
| Randomized Phase II Trial of Fluorouracil and Folinic Acid With or Without Liposomal Irinotecan (ONIVYDE) for Patients With Metastatic Biliary Tract Cancer Which Progressed Following Gemcitabine Plus Cisplatin[NCT03524508] | Phase 2 | 178 participants (Actual) | Interventional | 2018-09-04 | Completed | ||
| Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| Survival Rate and Treatment Cost in Patients With Pancreatic Cancer With the Advent of New Chemotherapeutic Agents in Korea: An Analysis Using NHIS Database and K-PaC Registry Focusing on the Newest One, Liposomal Irinotecan[NCT04984174] | 54,000 participants (Anticipated) | Observational | 2021-08-04 | Recruiting | |||
| Phase III Prospective Randomized Trial Comparing Ramosetron Versus Ondansetron for Radiotherapy Induced Nausea and Vomiting in the Treatment of Gastrointestinal Cancer[NCT00971399] | Phase 3 | 172 participants (Anticipated) | Interventional | 2009-09-30 | Completed | ||
| A Single Arm, Phase II Study of TNFerade™ Biologic Gene Therapy + Radiation + 5-FU and Cisplatin in Locally Advanced, Resectable, Esophageal Cancer[NCT00051480] | Phase 2 | 0 participants | Interventional | Completed | |||
| Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT01479348] | Early Phase 1 | 5 participants (Actual) | Interventional | 2011-11-01 | Terminated (stopped due to Slow, insufficient accrual.) | ||
| A Phase II Trial of Gemcitabine, Herceptin, and Radiation for Regionally Confined Adenocarcinoma of the Pancreas[NCT00005926] | Phase 2 | 50 participants | Interventional | 2000-06-30 | Completed | ||
| 09.017 - A Phase I Study of Tolfenamic Acid With Gemcitabine and Radiation in Patients With Locally Advanced or Metastatic Pancreatic Cancer Requiring Definitive or Palliative Radiation Therapy[NCT02159248] | Phase 1 | 0 participants (Actual) | Interventional | 2014-03-31 | Withdrawn (stopped due to The study closed prior to enrolling any participants.) | ||
| Phase I Study of Cabazitaxel - Platinum Fluorouracil Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck[NCT01379339] | Phase 1 | 40 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Best overall response of complete or partial response within irinotecan stratum (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 49 |
| Irinotecan and Bevacizumab Without Panitumumab | 46 |
Best overall response of complete or partial response in participants treated with irinotecan and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 14 |
| Irinotecan and Bevacizumab Without Panitumumab | 15 |
Best overall response of complete or partial response within oxaliplatin stratum (NCT00115765)
Timeframe: Overall study
| Intervention | Participant (Number) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 190 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 196 |
Best overall response of complete or partial response in participants treated with irinotecan and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 31 |
| Irinotecan and Bevacizumab Without Panitumumab | 28 |
Objective tumor response (complete or partial) rate through week 12 based on central review in the Irinotecan stratum (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 29 |
| Irinotecan and Bevacizumab Without Panitumumab | 27 |
Incidence of mortality from any cause in groups treated with Irinotecan. Incidence is provided in lieu of the median time to death since the median or its measure of dispersion was not estimable for at least one treatment arm. (NCT00115765)
Timeframe: Overall study
| Intervention | Participant (Number) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 26 |
| Irinotecan and Bevacizumab Without Panitumumab | 18 |
Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS). Since the measure of dispersion could not be estimated for at least one treatment arm, participant incidence is provided in lieu of the median. (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 47 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 45 |
Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin (NCT00115765)
Timeframe: Overall study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 19.4 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 24.5 |
Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS). Since the measure of dispersion could not be estimated for at least one treatment arm, participant incidence is provided in lieu of the median (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 71 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 46 |
Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 10.1 |
| Irinotecan and Bevacizumab Without Panitumumab | 11.7 |
Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression in groups treated with oxaliplatin and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 10.4 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 11.0 |
Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression (NCT00115765)
Timeframe: Overall study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 10.0 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 11.4 |
Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression in groups treated with oxaliplatin and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 9.8 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 11.5 |
Kaplan-Meier estimate of the median time from randomization to disease progression or death due to disease progression within the irinotecan stratum (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 11.1 |
| Irinotecan and Bevacizumab Without Panitumumab | 11.9 |
Kaplan-Meier estimate of the median time from randomization to disease progression or death due to disease progression within the oxaliplatin stratum (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 10.8 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 11.4 |
Kaplan-Meier estimate of the median time from randomization to the date the decision was made to discontinue treatment for a reason other than a complete response to treatment within the irinotecan stratum (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 6.6 |
| Irinotecan and Bevacizumab Without Panitumumab | 6.0 |
Kaplan-Meier estimate of the median time from randomization to the date the decision was made to discontinue treatment for a reason other than a complete response to treatment within the oxaliplatin stratum. (NCT00115765)
Timeframe: Overall study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 5.7 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 5.9 |
Duration of Response is calculated as the time from the first recording of CR/PR until the patient progresses, regardless of whether the patient was still taking study medication. Only confirmed responses are included in the calculation. For patients who had not progressed, the end date used in the calculation of duration of response is the data cut-off date of 15th November 2009. (NCT00384176)
Timeframe: Up until data cut-off date of 15/11/2007
| Intervention | Months (Median) |
|---|---|
| Cediranib 20 mg | 8.6 |
| Bevacizumab 5 mg/kg | 9.6 |
"Objective response rate is Complete Response (CR) + Partial Response (PR) as defined below:~CR = Disappearance of all target lesions. PR = At least a 30% decrease in the sum of longest diameters (LDs) of target lesions, taking as reference the baseline sum of LDs." (NCT00384176)
Timeframe: Up until data cut-off
| Intervention | Participants (Number) |
|---|---|
| Cediranib 20 mg | 328 |
| Bevacizumab 5 mg/kg | 337 |
Number of months from randomisation to the date of death from any cause (NCT00384176)
Timeframe: Randomisation until data cut-off
| Intervention | Months (Median) |
|---|---|
| Cediranib 20 mg | 22.8 |
| Bevacizumab 5 mg/kg | 21.3 |
Percentage change in tumour size from baseline to first RECIST assessment (Week 8) ((Week 8 - baseline)/baseline)*100 (NCT00384176)
Timeframe: Baseline to Week 8
| Intervention | Percentage change in tumour size (Mean) |
|---|---|
| Cediranib 20 mg | -23.2 |
| Bevacizumab 5 mg/kg | -22.1 |
Progression is defined as the number of months from randomisation until progressive disease based on RECIST (progression of target lesions, clear progression of existing non-target lesions or the appearance of one or more new lesions) or death in the absence of progression. (NCT00384176)
Timeframe: Baseline then at Weeks 8, 16, 24 and then every 12 weeks until progression
| Intervention | Months (Median) |
|---|---|
| Cediranib 20 mg | 9.9 |
| Bevacizumab 5 mg/kg | 10.3 |
Time to worsening of symptoms, as measured by the FACT colorectal symptom index (FCSI), will be defined as the time when a sustained clinically important deterioration in the total score from the FCSI has been recorded. (NCT00384176)
Timeframe: Baseline through to data cut-off
| Intervention | Days (Median) |
|---|---|
| Cediranib 20 mg | 170 |
| Bevacizumab 5 mg/kg | 245 |
Duration of response was calculated only for those participants with a confirmed CR or PR, as the time from the first CR or PR (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified RECIST criteria, based on a blinded central review. (NCT00364013)
Timeframe: Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 11.1 |
| Wild-type KRAS - FOLFOX | 8.8 |
| Mutant KRAS - FOLFOX + Panitumumab | 7.4 |
| Mutant KRAS - FOLFOX | 8.0 |
The definition of overall survival is the time from randomization to death; participants who were alive at the analysis data cutoff were censored at their last contact date. (NCT00364013)
Timeframe: From randomization until the data cutoff date of 28 August 2009. Maximum time on follow-up was 153 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 23.9 |
| Wild-type KRAS - FOLFOX | 19.7 |
| Mutant KRAS - FOLFOX + Panitumumab | 15.5 |
| Mutant KRAS - FOLFOX | 19.3 |
Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response by central radiological assessment was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on the first-line treatment, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders. (NCT00364013)
Timeframe: Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 55.21 |
| Wild-type KRAS - FOLFOX | 47.68 |
| Mutant KRAS - FOLFOX + Panitumumab | 39.53 |
| Mutant KRAS - FOLFOX | 40.28 |
Progression-free survival (PFS), assessed by central radiological assessment, was defined as the time from randomization to disease progression per modified response evaluation criteria in solid tumors (RECIST) criteria or death. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions. (NCT00364013)
Timeframe: From randomization until the data cutoff date of 30 September 2008. Maximum follow-up time was 109 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 9.6 |
| Wild-type KRAS - FOLFOX | 8.0 |
| Mutant KRAS - FOLFOX + Panitumumab | 7.3 |
| Mutant KRAS - FOLFOX | 8.8 |
Time to progression was defined as time from randomization date to date of disease progression per the modified RECIST criteria. (NCT00364013)
Timeframe: From randomization until the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 10.8 |
| Wild-type KRAS - FOLFOX | 9.2 |
| Mutant KRAS - FOLFOX + Panitumumab | 7.5 |
| Mutant KRAS - FOLFOX | 9.0 |
"A serious adverse event (SAE) is defined as an AE that • is fatal • is life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: Is there a reasonable possibility that the event may have been caused by the study treatment?" (NCT00364013)
Timeframe: From randomization until the data cut-off date of 28 August 2009; Maximum time on follow-up was 153 weeks.
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any adverse event | Serious adverse event | Leading to discontinuation of any study drug | Treatment-related adverse event (TRAE) | Serious treatment-related adverse event | TRAE leading to discontinuation of any study drug | |
| FOLFOX + Panitumumab | 583 | 262 | 136 | 581 | 162 | 117 |
| FOLFOX Alone | 579 | 198 | 84 | 565 | 89 | 63 |
"Clinical benefit rate (CR, PR, or SD = 24 weeks) for women For ErbB2 Positive Advanced Breast Cancer. Clinical benefit rate was the percentage of subjects who achieved overall tumor response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.~Clinical Benefit (CB) = CR + PR + SD >= 24 weeks." (NCT00777101)
Timeframe: From randomization date to progression or last tumor assessment, assessed up to 69 months
| Intervention | percentage of participants (Median) |
|---|---|
| Neratinib | 44.4 |
| Lapatinib+Capecitabine | 63.8 |
Duration of response was measured from the time at which response criteria were met for complete response (CR) or partial response (PR) (whichever status was recorded first) until the first date of recurrence or progressive disease (PD) or death. For subjects without death or progression, censorship was at the last valid tumor assessment per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions. (NCT00777101)
Timeframe: From start date of response to first PD, assessed up to 69 months after the first subject was randomized.
| Intervention | months (Median) |
|---|---|
| Neratinib | 12.48 |
| Lapatinib+Capecitabine | 7.98 |
The percent of patients with symptomatic or progressive CNS lesions was the proportion of subjects who had PD considering CNS lesions only, according to RECIST criteria. (NCT00777101)
Timeframe: From randomization date to first CNS symptom or lesions
| Intervention | percentage of participants (Number) |
|---|---|
| Neratinib | 9.4 |
| Lapatinib+Capecitabine | 12.9 |
Objective Response Rate, investigator assessment. The ORR was defined as the percentage of participants demonstrating a confirmed objective response, either Complete Response (CR) or Partial Response (PR) during the study per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v.1.0: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; and Non-PD for non-target lesions, and no new lesions. (NCT00777101)
Timeframe: From randomization date to progression or last tumor assessment, assessed up to 69 months
| Intervention | percentage of participants (Number) |
|---|---|
| Neratinib | 29.1 |
| Lapatinib+Capecitabine | 40.5 |
Overall Survival (OS) was defined as the time from randomization to death due to any cause. Subjects last known to be alive were censored at the last date of last contact or the data cutoff employed for the analysis, whichever was earlier. (NCT00777101)
Timeframe: From randomization date to death, assessed up to 69 months
| Intervention | months (Median) |
|---|---|
| Neratinib | 19.74 |
| Lapatinib+Capecitabine | 23.62 |
Progression Free Survival, Measured in Months, for Subjects Randomized. Investigator assessment. The time interval from the date of randomization until the earliest date of progression per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) or death due to any cause. For subjects without death or progression, censorship was at the last valid tumor assessment. (NCT00777101)
Timeframe: From randomization date to progression or death, assessed up to 69 months
| Intervention | months (Median) |
|---|---|
| Neratinib | 4.53 |
| Lapatinib+Capecitabine | 6.83 |
Time to symptomatic or progressive Central nervous system (CNS) lesions. Time to symptomatic or progressive CNS lesions was the time from the date of randomization until the date of progressive disease (PD) considering CNS lesions only (ie, appearance of newly diagnosed CNS lesions or progressive CNS lesions). (NCT00777101)
Timeframe: From randomization date to first CNS symptom or lesions
| Intervention | months (Median) |
|---|---|
| Neratinib | 19.68 |
| Lapatinib+Capecitabine | NA |
The number of participants who discontinued neratinib earlier than expected during the course of study therapy will be reported (NCT03094052)
Timeframe: Up to 55 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Neratinib) | 1 |
The number of participants who experienced a dose hold of neratinib during the course of study therapy will be reported (NCT03094052)
Timeframe: Up to 55 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Neratinib) | 0 |
The number of participants whose dose was reduced at any time during the course of therapy will be reported (NCT03094052)
Timeframe: Up to 55 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Neratinib) | 5 |
Percentage of participants with clinically assessed grade 3 or greater diarrhea reported within the first 2 cycles (each cycle is 21 days) of neratinib while using anti-diarrheal strategies. Reports of diarrhea will be graded according to NCI CTCAE version 4.0. (NCT03094052)
Timeframe: Up to 6 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Treatment (Neratinib) | 36.3 |
Percentage of patients requiring multiple anti-diarrheal medications will be reported (NCT03094052)
Timeframe: Up to 55 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Neratinib) | 7 |
Percentage of participants with reported serious adverse events and adverse events of interest of any grade that have been determined to be related to the anti-diarrhea treatment will be reported by worst grade and associated toxicity. (NCT03094052)
Timeframe: Up to 55 weeks
| Intervention | participants (Number) |
|---|---|
| Treatment (Neratinib) | 100 |
The objective response rate was a secondary efficacy endpoint of the study and was defined by the percentage of patients in the study population with a best overall response of Complete Response (CR) or Partial Response (PR) as assessed by the investigator. Best overall response was defined per RECIST (version 1.1) recorded from randomization until progression or end of study. RECIST (v 1.1) criteria does not require confirmation of response, but an additional, more stringent analysis was also conducted, with designation of CR (or PR) requiring confirmation of response at least 4 weeks following the initial assessment of CR (or PR). Stable disease (SD) required an assessment of SD at least 6 weeks after starting treatment. Subjects with insufficient data for response classification were classified as Not Evaluable for best overall response, and as a non-responder for objective response, in the ITT population. Treatment groups are as indicated for the primary outcome of OS. (NCT01494506)
Timeframe: Assessment every 6 weeks after initial response; Day 1 to data cut off of 14 Feb 2014; maximum time on study 25 months.
| Intervention | percentage with confirmed response (Number) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 3.31 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 0.67 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 7.69 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 0.84 |
"Overall survival was the primary efficacy endpoint of the study and was defined as the time from the date of patient randomization to the date of death or the date the patient was last known to be alive. OS was summarized by Kaplan-Meier methodology for each treatment group. Pairwise treatment group comparisons were carried out using unstratified log rank analyses on the ITT population. Hazard ratio estimates are from Cox regression analysis.~The comparison of Arm C is based only on patients who were randomized under the 3-arm version of the protocol. Consequently, the 5-FU+Leucovorin (Combo Therapy Comparison) group is a subset of all patients randomized to 5-FU+Leucovorin, which is the Mono Therapy Comparison control and contains patients randomized under both the 2-arm and 3-arm versions of the protocol." (NCT01494506)
Timeframe: From randomization to death; until the data cut off 14 Feb 2014. The maximum time in follow up was 25 months.
| Intervention | months (Median) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 4.9 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 4.2 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 6.1 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 4.2 |
"Composite measure based on patient-reported pain (per VAS), patient-reported pain medication, KPS, and weight. Clinical benefit is indicated by either:~(a) improvement in pain (less pain intensity with stable or decreased pain medication; or less pain medication with stable or decreased pain intensity) with stable or improved KPS; or (b) improvement in KPS with stable or improved pain.~With stable for KPS and pain, clinical benefit may be indicated with an observation of positive weight change.~Clinical benefit response (CBR) was classified weekly and a patient was considered a clinical benefit responder if clinical benefit was observed and maintained over a 4 week period." (NCT01494506)
Timeframe: Randomization to treatment discontinuation.The maximum time in follow up was 25 months
| Intervention | percentage of participants with CBR (Number) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 14 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 13 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 14 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 12 |
Tumor marker response (TMR) was evaluated by the change in CA19-9 serum levels. Response was defined as a decrease of 50% of CA19-9 in relation to the baseline level at least once during the treatment period. (NCT01494506)
Timeframe: Baseline to treatment discontinuation every 6 weeks; The maximum time in follow up was 25 months
| Intervention | percent of participants with TMR (Number) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 23.6 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 11.4 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 28.9 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 8.6 |
"Progression-free survival was defined as the time from the date of randomization to the date of disease progression, or death (any cause) on or prior to the clinical cutoff date, whichever occurred earlier. Participants who did not have disease progression or had not died were censored at the date of the last tumor assessment. Patients with two or more consecutive missing response assessments prior to a visit with documented progression (or death) were censored at the last date of tumor assessment when the patient was documented to be progression free. PFS was summarized using Kaplan-Meier methods.~The comparison of Arm C is based only on patients who were randomized under the 3-arm version of the protocol. Consequently, the 5-FU+Leucovorin (Combo Therapy Comparison) group is a subset of all patients randomized to 5-FU+Leucovorin, which is the Mono Therapy Comparison control and contains patients randomized under both the 2-arm and 3-arm versions of the protocol." (NCT01494506)
Timeframe: Randomization until disease progression or death from any cause; Until the data cut off of 14 Feb 2014. The maximum time in follow up was 25 months.
| Intervention | months (Median) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 2.7 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 1.6 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 3.1 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 1.5 |
Time from randomization to discontinuation of treatment for any reason, including disease progression, treatment toxicity or death. (NCT01494506)
Timeframe: Randomization to treatment discontinuation (any cause). The maximum time in follow up was 25 months
| Intervention | months (Median) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 1.7 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 1.4 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 2.3 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 1.4 |
This patient recorded outcome consists of 15 subscales in 3 independent domains: global health-related quality of life (HRQoL), functional scales (cognitive, emotional, physical, role and social functioning), and symptom scales (appetite loss, constipation, diarrhea, dyspnea, fatigue, insomnia, nausea and vomiting, and pain). For each subscale, patients were classified as improved, worsened or stable. Improvement is indicated by achievement of subscale score at least 10% improved from baseline and maintained for at least 6 weeks. Worsened is indicated by subscale score at least 10% worse than baseline. Stable is indicated by neither improvement nor worsened. Achievement of improvement prior to worsening was classified as improvement. (NCT01494506)
Timeframe: Baseline to treatment discontinuation every 6 weeks; The maximum time in follow up was 25 months
| Intervention | percent of patients in category (Number) | ||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Health Status: Improved | Global Health Status: Stable | Global Health Status: Worsened | Physical Functioning: Improved | Physical Functioning: Stable | Physical Functioning: Worsened | Role Functioning: Improved | Role Functioning: Stable | Role Functioning: Worsened | Emotional Functioning:Improved | Emotional Functioning:Stable | Emotional Functioning:Worsened | Cognitive Functioning:Improved | Cognitive Functioning:Stable | Cognitive Functioning:Worsened | Social Functioning:Improved | Social Functioning:Stable | Social Functioning:Worsened | Fatigue:Improved | Fatigue:Stable | Fatigue:Worsened | Nausea and Vomiting:Improved | Nausea and Vomiting:Stable | Nausea and Vomiting:Worsened | Pain:Improved | Pain:Stable | Pain:Worsened | Dyspnoea:Improved | Dyspnoea:Stable | Dyspnoea:Worsoned | Insomnia:Improved | Insomnia:Stable | Insomnia:Worsened | Appetite Loss:Improved | Appetite Loss:Stable | Appetite Loss:Worsened | Constipation:Improved | Constipation:Stable | Constipation:Worsened | Diarrhoea:Improved | Diarrhoea: Stable | Diarrhoea: Worsened | Financial Difficulties: Improved | Financial Difficulties: Stable | Financial Difficulties: Worsened | |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 11 | 41 | 48 | 11 | 37 | 52 | 10 | 39 | 52 | 8 | 59 | 33 | 6 | 42 | 52 | 11 | 43 | 46 | 11 | 30 | 59 | 6 | 42 | 52 | 10 | 37 | 53 | 6 | 69 | 24 | 4 | 49 | 47 | 6 | 42 | 52 | 4 | 63 | 34 | 4 | 58 | 39 | 1 | 67 | 31 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 12 | 44 | 44 | 11 | 40 | 49 | 11 | 37 | 53 | 9 | 58 | 33 | 7 | 44 | 49 | 11 | 47 | 42 | 12 | 33 | 54 | 4 | 46 | 51 | 11 | 40 | 49 | 5 | 68 | 25 | 5 | 49 | 46 | 5 | 46 | 49 | 4 | 67 | 30 | 4 | 58 | 39 | 0 | 74 | 26 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 17 | 38 | 45 | 10 | 41 | 49 | 15 | 32 | 52 | 20 | 46 | 34 | 11 | 48 | 41 | 13 | 34 | 54 | 14 | 20 | 66 | 13 | 32 | 55 | 27 | 34 | 39 | 7 | 51 | 42 | 18 | 34 | 48 | 11 | 45 | 44 | 13 | 56 | 31 | 6 | 39 | 55 | 8 | 51 | 41 |
| MM-398 Arm A (Mono Therapy Comparison) | 10 | 31 | 57 | 10 | 29 | 61 | 6 | 29 | 66 | 10 | 32 | 56 | 12 | 32 | 54 | 11 | 26 | 62 | 13 | 18 | 69 | 5 | 37 | 58 | 20 | 30 | 50 | 10 | 47 | 44 | 9 | 43 | 48 | 9 | 38 | 53 | 13 | 47 | 39 | 4 | 35 | 59 | 6 | 51 | 42 |
Plasma concentration-time data for MM-398 will be analyzed using population pharmacokinetic methods. (NCT01494506)
Timeframe: 6 weeks after first study drug administration
| Intervention | Total irinotecan = ug/L; SN38= ug/L (Geometric Mean) | |||
|---|---|---|---|---|
| Total Irinotecan-Cavg | Total Irinotecan-Cmax | Total SN38-Cavg | Total SN38-Cmax | |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 2120.00 | 28460.00 | 0.68 | 2.58 |
| MM-398 Arm A (Mono Therapy Comparison) | 2550.00 | 40550.00 | 0.82 | 3.93 |
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01479348)
Timeframe: Date treatment consent signed to date off study, approximately 20 months and 12 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 2 |
[F-18]-5-fluoro-2'-deoxycytidine (FdCyd) was administered intravenously with administration of tetrahydrouridine (THU) and the frequency and severity of adverse events was observed. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 0 is normal, Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or medically significant but not immediately life-threatening, Grade 4 is life-threatening consequences, and Grade 5 is death related to adverse event. (NCT01479348)
Timeframe: Within 5 days after interventions
| Intervention | adverse events (Number) | |||||
|---|---|---|---|---|---|---|
| Day 1 Adverse Events | Day 2, Grade 2 Hypoalbuminemia | Day 2, Grade 3 Anemia | Day 3 Adverse Events | Day 4 Adverse Events | Day 5 Adverse Events | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 0 | 1 | 1 | 0 | 0 | 0 |
Radiation dosimetry was determined based on the first patients. This involved making region of interest measurements on the scan for each major organ and measuring the uptake. Using standard dosimetry software this is converted into mSv/MBq, a standard measure of dosimetry. The software is known as Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA) and is commonly used to generate this kind of data. (NCT01479348)
Timeframe: 1 year
| Intervention | mSv/MBq (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adrenals | Brain | Breasts | Gallbladder wall | Lower large intestine wall | Small intestine | Stomach wall | Upper large intestine wall | Heart wall | Kidneys | Liver | Lungs | Muscle | Ovaries | Pancreas | Red marrow | Osteogenic cells | Skin | Spleen | Testes | Thymus | Thyroid | Urinary bladder wall | Uterus | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.83 | 8.17 | 1.03 | 4.05 | 2.52 | 2.13 | 1.90 | 2.04 | 1.10 | 5.26 | 6.02 | 1.82 | 1.16 | 1.57 | 1.63 | 1.14 | 1.71 | 8.65 | 1.69 | 1.03 | 1.12 | 8.23 | 7.96 | 1.63 |
Participants were scanned by positron emission tomography (PET) and lesions were measured at 4 time points after injection. (NCT01479348)
Timeframe: 9 minutes, 32 minutes, 56 minutes and 2 hours after injection
| Intervention | TBR ratio (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt 1 L. Parotid adenosquam. cell ca at 9 min | Pt 1 L. Parotid adenosquam. cell ca at 32 min | Pt 1 L. Parotid adenosquam. cell ca at 56 min | Pt 1 L. Parotid adenosquam. cell ca at 2 hrs | Pt 2 R. Parapharyngeal Spindle Cell Ca at 9 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 32 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 56 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 2 hrs | Pt 3 Non-small Cell Lung Ca at 9 min | Pt 3 Non-small Cell Lung Ca at 32 min | Pt 3 Non-small Cell Lung Ca at 56 min | Pt 3 Non-small Cell Lung Ca at 2 hrs | Pt 4 Non-small Cell Lung Ca at 9 min | Pt 4 Non-small Cell Lung Ca at 32 min | Pt 4 Non-small Cell Lung Ca at 56 min | Pt 4 Non-small Cell Lung Ca at 2 hrs | Pt 5 Hepatocellular Ca at 9 min | Pt 5 Hepatocellular Ca at 32 min | Pt 5 Hepatocellular Ca at 56 min | Pt 5 Hepatocellular Ca at 2 hrs | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.4 | 1.5 | 1.5 | 1.6 | 1.9 | 1.7 | 1.7 | 1.6 | 1.4 | 1.4 | 1.5 | 1.7 | 2.4 | 2.1 | 1.6 | 2.0 | NA | NA | NA | NA |
13 reviews available for fluorouracil and Vomiting
| Article | Year |
|---|---|
[Acute Kidney Injury in a Patient with Diarrhea and Vomiting Undergoing Chemotherapy for Colorectal Cancer].
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Diarrhea; Fluoroura | 2016 |
Raltitrexed-based chemotherapy for advanced colorectal cancer.
Topics: Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Chemical and Drug Induce | 2014 |
Oxaliplatin/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; D | 2016 |
Unanticipated toxicity to capecitabine.
Topics: Antimetabolites, Antineoplastic; Black or African American; Breast Neoplasms; Capecitabine; Deoxycyt | 2009 |
Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protoco | 2013 |
Multiorgan failure in a patient treated with the 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan regimen.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Duodenal Neoplasms; Fe | 2013 |
[Toxicities associated with chemotherapy in colorectal cancer].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Clinical Trials a | 2003 |
[Complications of hepatic artery chemotherapy for liver metastases in colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arterial Occlusive Diseases; Cholangitis, Sclerosing | 2003 |
Advanced colorectal cancer: current treatment and nursing management with economic considerations.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Campt | 2005 |
Capecitabine: a new adjuvant option for colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Cause of Death; Colorectal Neop | 2006 |
Optimal control of cyclophosphamide-induced emesis.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Epirubic | 1996 |
[Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Topics: Animals; Anorexia; Antimetabolites, Antineoplastic; Diarrhea; Dogs; Drug Combinations; Female; Fluor | 1998 |
Corticosteroid drugs: their role in oncological practice.
Topics: Adrenal Cortex Hormones; Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast | 1986 |
164 trials available for fluorouracil and Vomiting
| Article | Year |
|---|---|
Single Nucleotide Polymorphism Directed Antiemetic Treatment in Women With Breast Cancer Treated With Neo- or Adjuvant Chemotherapy: A Randomised Multicentre Phase II Study. (EudraCT: 2015-000658-39).
Topics: Antiemetics; Antineoplastic Agents; Breast Neoplasms; Female; Fluorouracil; Humans; Nausea; Polymorp | 2023 |
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2019 |
A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophospham
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast | 2020 |
Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial.
Topics: Adult; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aprepitan | 2021 |
Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2017 |
Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepit | 2018 |
Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Camptothecin; Diarrhea; Drugs, Chinese Herbal; Femal | 2017 |
One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherap | 2013 |
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2013 |
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2013 |
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2013 |
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2013 |
Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Benztropine; Camptoth | 2013 |
[Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2013 |
Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisp | 2016 |
Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2014 |
DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients.
Topics: Administration, Cutaneous; Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined | 2015 |
Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Capecitabine; Colorectal Ne | 2015 |
Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801).
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Co | 2016 |
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; | 2016 |
Oral intake of ginger for chemotherapy-induced nausea and vomiting among women with breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; | 2015 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy | 2016 |
[Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diseas | 2008 |
[Preliminary study of biweekly regimen of docetaxel, oxaliplatin, 5-fluorouracil and leucovorin for advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2008 |
Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
[Capecitabine combined with cisplatin as first-line therapy in Chinese patients with advanced gastric carcinoma-a phase II clinical study].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
[Oxaliplatin combined with ELF regimen in the treatment of patients with advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pro | 2009 |
[FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Topics: Adult; Aged; Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm | 2010 |
[Efficacy of FORFIRI regimen on oxaliplatin-based chemotherapy-failed advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic N | 2009 |
Comparison of the short-term efficacy of two inductive chemotherapy regimens for locally advanced nasopharyngeal caricinoma: docetaxal plus carboplatin versus 5-fluorouracil plus carboplatin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Female; Fluorouracil; | 2010 |
Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Colorectal Neoplas | 2011 |
[Comparison of the therapeutic effects of paclitaxel liposome-5-Fu versus paclitaxel-5-Fu on 67 patients with advanced gastric cancer].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Pr | 2010 |
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2010 |
A phase I study of docetaxel, oxaliplatin, & capecitabine (DOC) as first-line therapy of patients with locally advanced or metastatic adenocarcinoma of stomach and GE junction.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2010 |
A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dia | 2011 |
[Nedaplatin or cisplatin combined with 5-fluorouracil for treatment of stage III-IVa nasopharyngeal carcinoma: a randomized controlled study].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans; Lymp | 2011 |
A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine | 2012 |
Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2012 |
Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under C | 2012 |
Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capeci | 2012 |
[Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2012 |
Optimal dose period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with modified FOLFOX6: a randomized pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bridged | 2012 |
Phase II trial of alternating mFOLFOX6 and FOLFIRI regimens in the first-line treatment for unresectable or metastatic colorectal cancer (KSCC0701).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2013 |
Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer.
Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 2002 |
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2002 |
Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2002 |
Reduced maintenance of complete protection from emesis for women during chemotherapy cycles.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 2003 |
Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisp | 2002 |
Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Alopecia; Camptothecin; Chemotherapy, Adjuvant; Colorectal | 2003 |
A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisp | 2004 |
A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2004 |
Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Cap | 2004 |
Phase II clinical trial of 5-fluorouracil, trimetrexate, and leucovorin (NFL) in patients with advanced pancreatic cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Female; Fluoro | 2003 |
Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2005 |
[Ginsenosides combined with dexamethasone in preventing and treating postembolization syndrome following transcatheter arterial chemoembolization: a randomized, controlled and double-blinded prospective trial].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Dexame | 2005 |
A multicenter randomized study comparing 5-fluorouracil continuous infusion (ci) plus 1-hexylcarbamoyl-5-fluorouracil and 5-FU ci alone in colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore | 2005 |
A randomized trial between two neoadjuvant chemotherapy protocols: CDDP + 5-FU versus CDDP + VP16 in advanced cancer of the head and neck.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea; Etoposid | 2005 |
Alprazolam significantly improves the efficacy of granisetron in the prophylaxis of emesis secondary to moderately emetogenic chemotherapy in patients with breast cancer.
Topics: Alprazolam; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 2005 |
Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Cisplat | 2005 |
Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2005 |
An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2005 |
Chronomodulated chemotherapy with oxaliplatin, 5-FU and sodium folinate in metastatic gastrointestinal cancer patients: original analysis of non-hematological toxicity and patient characteristics in a pilot investigation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Chronotherapy; Diarrhe | 2006 |
Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cape | 2006 |
Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisp | 2007 |
Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Di | 2007 |
A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma; Disease-Fre | 2007 |
Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuva | 2008 |
[Comparison of tolerance and toxicity of CEF-100 regimen versus CEF-60 regimen as adjuvant therapy for breast cancer].
Topics: Adult; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransfer | 2007 |
Activity of sequential low-dose methotrexate and fluorouracil in advanced colorectal carcinoma: attempt at correlation with tissue and blood levels of phosphoribosylpyrophosphate.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl | 1984 |
A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; BCG Vaccine; Breast Neoplasms; | 1983 |
Prospective randomized reappraisal of 5-fluorouracil in metastatic colorectal carcinoma. A comparative trial with 6-thioguanine.
Topics: Adenocarcinoma; Bone Marrow; Clinical Trials as Topic; Colonic Neoplasms; Diarrhea; Female; Fluorour | 1984 |
Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials a | 1984 |
Randomized phase II studies in advanced colorectal carcinoma: a North Central Cancer Treatment Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Drug Evalu | 1983 |
5-Fluorouracil, methyl-CCNU, and radiotherapy with or without testolactone for localized adenocarcinoma of the exocrine pancreas: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Aged; Agranulocytosis; Anorexia; Antineoplastic Agents; Clinical Trials as Topic; Do | 1980 |
Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma.
Topics: Activities of Daily Living; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 1982 |
Treatment of advanced breast carcinoma with 5-fluorouracil: a randomized comparison of two routes of delivery.
Topics: Administration, Oral; Breast Neoplasms; Female; Fluorouracil; Humans; Injections, Intravenous; Leuko | 1981 |
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Anemia; Carcinoembryonic Antigen; Female; Fluorouracil; Humans; Male; Middle Aged; N | 1981 |
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Anemia; Carcinoembryonic Antigen; Female; Fluorouracil; Humans; Male; Middle Aged; N | 1981 |
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Anemia; Carcinoembryonic Antigen; Female; Fluorouracil; Humans; Male; Middle Aged; N | 1981 |
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Anemia; Carcinoembryonic Antigen; Female; Fluorouracil; Humans; Male; Middle Aged; N | 1981 |
Salvage chemotherapy with PEM and long-CF regimen in CDDP refractory advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 1995 |
[Comparison of granisetron alone and granisetron plus dexamethasone or hydroxyzine hydrochloride for the prevention of nausea and vomiting during chemotherapy including cisplatin].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; | 1995 |
Continuous hepatic arterial infusion of 5-fluorouracil for unresectable colorectal liver metastases: phase II study.
Topics: Abdominal Pain; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Stu | 1995 |
Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; F | 1995 |
[Combination chemotherapy with FP versus FEP in patients with advanced gastric cancer. Research group of gastric cancer chemotherapy].
Topics: Adenocarcinoma; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Admi | 1995 |
Efficacy of a new 5-fluorouracil derivative, BOF-A2, in advanced non-small cell lung cancer. A multi-center phase II study.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Sm | 1994 |
Delayed chemotherapy-induced nausea is augmented by high levels of endogenous noradrenaline.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Circadian Rhythm; Cis | 1994 |
[Use of dexamethasone as an antiemetic in patients with breast cancer treated with the CMF regimen].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dexamethasone; F | 1994 |
Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide.
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Constipation; Cyclophosphamide; Epirubicin; Fem | 1994 |
Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Female; | 1994 |
Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1993 |
Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophospha | 1993 |
Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collab
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemother | 1996 |
Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Anemia; Antidotes; Antimetabolites, Antineoplast | 1996 |
[Evaluation of chemotherapy in the treatment of advanced colorectal cancer--pilot study of 5-FU by biochemical modulation].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplas | 1996 |
[Comparative trial of granisetron alone and granisetron plus methylprednisolone for prevention of nausea and vomiting during cancer chemotherapy].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Over Stud | 1996 |
Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens.
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1996 |
Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Cost-Benef | 1996 |
Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting.
Topics: Acute Disease; Administration, Oral; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 1996 |
5-Hydroxyindoleacetic acid excretion following combination chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil plus ondansetron compared to ondansetron alone.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antiemetics; Antimetabolites, Antineoplastic; Antineoplast | 1996 |
[Combination therapy with 5-fluorouracil (5-FU), cisplatin (CDDP) and interferon alpha-2B (IFN alpha-2B) for advanced renal cell carcinoma].
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Ce | 1996 |
Phase II study of cisplatin, 5-fluorouracil, and leucovorin in inoperable squamous cell carcinoma of the esophagus. ONCOPAZ Cooperative Group, Spain.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combi | 1996 |
[Clinical evaluation of ondansetron suppository].
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Humans; | 1997 |
[Clinical effect of two azasetron treatment methods against nausea and vomiting induced by anticancer drugs including CDDP].
Topics: Adult; Antiemetics; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cisplatin; Drug | 1997 |
The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD).
Topics: Administration, Oral; Adult; Aged; Anemia; Antidotes; Antimetabolites, Antineoplastic; Carcinoma; Co | 1996 |
[Comparison of effects between single vs five-day injection of granisetron for combination chemotherapy with cisplatin and 5-fluorouracil for head and neck cancer].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 1997 |
[Efficacy of combination of ondansetron injection and tablet in CAF-induced emesis in breast cancer patients].
Topics: Administration, Oral; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 1998 |
Clinical and pharmacokinetic studies of high-dose levamisole in combination with 5-fluorouracil in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Confusion; Drug Synergism; Drug The | 1998 |
Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas.
Topics: Aged; Anorexia; Antidotes; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Bone Marrow; Di | 1998 |
A phase II trial of cisplatin and 5-fluorouracil in adenocarcinoma of the oesophagus.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine | 1998 |
Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Cohor | 1996 |
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; | 1999 |
Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclopho | 1999 |
[Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Al | 1999 |
High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemoth | 2000 |
Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuv | 2000 |
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Conjunctivitis; D | 2001 |
Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Chills; Combined Moda | 2001 |
Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 2001 |
Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols | 2001 |
Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.
Topics: Aged; Anemia; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; D | 2002 |
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Diarrhea; DNA, Antise | 2002 |
Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; | 2002 |
Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoid Tumor; Child; Clinical Trials as Topic; Cy | 1979 |
Treatment of advanced adenocarcinoma of the pancreas with combinations of streptozotocin plus 5-fluorouracil and streptozotocin plus cyclophosphamide.
Topics: Adenocarcinoma; Aged; Bone Marrow; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combina | 1977 |
Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial.
Topics: Adenoma, Bile Duct; Antineoplastic Agents; Bone Marrow; Carcinoma, Hepatocellular; Clinical Trials a | 1978 |
A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: a Southeastern Cancer Study Group project.
Topics: Agranulocytosis; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; | 1977 |
cis-Platinum combination chemotherapy of bladder cancer: an update.
Topics: Adult; Aged; Cisplatin; Clinical Trials as Topic; Doxorubicin; Drug Therapy, Combination; Female; Fl | 1979 |
Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo.
Topics: Adult; Aged; Antiemetics; Double-Blind Method; Dronabinol; Drug Evaluation; Fluorouracil; Gastrointe | 1979 |
Combination with 5-fluorouracil, methyl-CCNU and beta-2-deoxythioguanosine in advanced colo-rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Deoxyribonucleosides; Drug Therapy, Combination; Fem | 1977 |
Methyl-CCNU versus methyl-CCNU and 5-fluorouracil in carcinoma of the large bowel.
Topics: Arylsulfatases; Carcinoembryonic Antigen; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluo | 1977 |
Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study.
Topics: Alopecia; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Evaluation; D | 1976 |
Oral benzquinamide in the treatment of nausea and vomiting.
Topics: Clinical Trials as Topic; Fluorouracil; Humans; Nausea; Prochlorperazine; Quinolizines; Vomiting | 1975 |
Methylprednisolone as antiemetic treatment in breast-cancer patients receiving cyclophosphamide, methotrexate, and 5-fluorouracil: a prospective, crossover, randomized blind study comparing two different dose schedules.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Double-Bl | 1992 |
[Clinical effects and toxicity of chemotherapy with cisplatin for head and neck cancer--the multi-institutional joint research in Tokai district].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Female; Fluoroura | 1990 |
Double-blind randomized cross-over trial comparing methylprednisolone with placebo in chemotherapy-induced nausea and vomiting: a study with special reference to efficacy parameters.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Double-Blind Method; Female; | 1991 |
Tetracosactrin vs. methylprednisolone in the prevention of emesis in patients receiving FEC regimen for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cosyntropin; Cyclophosphamide; Epi | 1991 |
Oral ondansetron (GR 38032F) for the control of CMF-induced emesis in the outpatient.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Brea | 1991 |
Double-blind randomized trial of lorazepam versus placebo with methylprednisolone for control of emesis due to non-cisplatin containing chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Double-Blind Method; | 1990 |
[Antiemetic treatments associated with antineoplastic chemotherapy].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1990 |
A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Brea | 1990 |
A phase III randomised trial of cistplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; F | 1990 |
[Phase II trial as 2nd line chemotherapy with 5 fluorouracil and cisplatin (5FU-CDDP) for advanced breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Cisplatin | 1990 |
Effective control of CMF-related emesis with high-dose dexamethasone: results of a double-blind crossover trial with metoclopramide and placebo.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dex | 1989 |
[Randomized multicenter trial of sequential methotrexate and 5-fluorouracil versus 5-fluorouracil alone in advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Administ | 1989 |
Methylprednisolone versus metoclopramide as antiemetic treatment in patients receiving adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) chemotherapy: a randomized crossover blind study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; F | 1989 |
A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclopho | 1988 |
Chemotherapy of large bowel carcinoma--fluorouracil (FU) + hydroxyurea (HU) vs. methyl-CCNU, oncovin, fluorouracil, and streptozotocin (MOF-Strep). An Eastern Cooperative Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Female; Fluorour | 1985 |
Clinical evaluation of the simultaneous blockade of the dopamine D-2, histamine H-1, and muscarinic cholinergic receptors in cancer chemotherapy-induced emesis: results of a controlled trial.
Topics: Aged; Antidepressive Agents, Tricyclic; Antineoplastic Combined Chemotherapy Protocols; Clinical Tri | 1986 |
A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclopho | 1988 |
Methylprednisolone for the control of CMF-induced emesis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1987 |
Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1987 |
A randomised cross-over trial comparing low-dose metoclopramide and chlorpromazine with high-dose metoclopramide in Chinese patients with advanced cancer receiving cisplatinum and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorpromazine; Cisplatin; Clinical Tri | 1987 |
Results of two controlled studies on antiemetic combination against vomiting induced by 5-fluorouracil.
Topics: Adult; Aged; Amitriptyline; Antiemetics; Clinical Trials as Topic; Diphenhydramine; Drug Therapy, Co | 1987 |
Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized study.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclopho | 1988 |
Clinical trial of cisplatin and intensive course 5-fluorouracil for the treatment of advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Co | 1986 |
The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 1985 |
Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Do | 1985 |
Mitoxantrone: an overview of safety and toxicity.
Topics: Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Clini | 1985 |
A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Anthraquinones; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; | 1985 |
A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 1985 |
Controlled studies of metopimazine for the treatment of nausea and vomiting.
Topics: Antiemetics; Clinical Trials as Topic; Fluorouracil; Humans; Isonipecotic Acids; Nausea; Neoplasms; | 1973 |
Fluorouracil, imidazole carboxamide dimethyl triazeno, vincristine, and bis-chloroethyl nitrosourea in colon cancer.
Topics: Alopecia; Amides; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Colonic Neoplasms; Dr | 1974 |
Experience with furanidyl-fluorouracil in advanced tumours of the breast.
Topics: Adult; Aged; Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation; Feeding and Eating Disorde | 1974 |
Comparison of treatment of metastatic gastrointestinal cancer with 5-fluorouracil (5-FU) to a combination of 5-FU with cytosine arabinoside.
Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Cytarabine; Diabetic Ketoacidosis; Diar | 1972 |
A clinical study of fluorouracil.
Topics: Adult; Aged; Clinical Trials as Topic; Diarrhea; Female; Fluorouracil; Follow-Up Studies; Humans; Le | 1968 |
122 other studies available for fluorouracil and Vomiting
| Article | Year |
|---|---|
NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms | 2021 |
Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Ph | 2021 |
Treatment Patterns, Toxicity, and Outcomes of Older Adults With Advanced Pancreatic Cancer Receiving First-line Palliative Chemotherapy.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; | 2022 |
Colorectal cancer chemotherapy: can sex-specific disparities impact on drug toxicities?
Topics: Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug-Related | 2022 |
Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atropine Derivatives; | 2022 |
Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Camptothecin; Capecit | 2021 |
Adverse reactions and adherence to capecitabine: A prospective study in patients with gastrointestinal cancer.
Topics: Aged; Capecitabine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Nausea; Pro | 2022 |
Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Color | 2021 |
Survival and Predictive Factors of Chemotherapy With FOLFIRINOX as First-Line Therapy in Metastatic Pancreatic Cancer: A Retrospective Multicentric Analysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 2021 |
TYMS Gene Polymorphisms in Breast Cancer Patients Receiving 5-Fluorouracil-Based Chemotherapy.
Topics: Adult; Antimetabolites, Antineoplastic; Breast; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, B | 2018 |
Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Chemoradiotherapy; Ci | 2018 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Single-dose palonosetron and dose-reduced regimen of dexamethasone in preventing nausea and vomiting by anthracycline-including chemotherapy in patients with early breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2013 |
Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2013 |
Longitudinal assessments of quality of life and late toxicities before and after definitive chemoradiation for esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Esophageal Neoplasms | 2014 |
[Nausea, vomiting and quality of life in women with breast cancer receiving chemotherapy].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brea | 2013 |
Cetuximab-induced esophageal ulcer: the first report in literature.
Topics: Abdomen, Acute; Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2014 |
Second-line capecitabine and oxaliplatin combination for gemcitabine-resistant advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Adherence to capecitabine treatment and contributing factors among cancer patients in Malaysia.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Capecitabine; Cross-Sectional Studies; | 2014 |
Efficacy of aprepitant for nausea in patients with head and neck cancer receiving daily cisplatin therapy.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; | 2014 |
Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in patients with esophageal cancer: a pilot study.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2015 |
[Study of the Efficacy of Aprepitant in FOLFOX/FOLFIRI for Elderly Patients with Advanced Colorectal Cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Camptothecin; C | 2016 |
Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asth | 2016 |
Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2017 |
[Predictive factors of nausea/vomiting of breast cancer patients receiving FEC and AC chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 2008 |
Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer.
Topics: Adult; Aged; Antiemetics; Benzimidazoles; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Female; F | 2009 |
[Combination of docetaxel and capecitabine for the treatment of anthracycline-resistant advanced breast carcinoma].
Topics: Adult; Aged; Agranulocytosis; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Combin | 2008 |
[Report of a case effectively treated by appropriate therapy for severe anticipatory nausea and vomiting due to FOLFOX or FOLFIRI].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Leucovorin; Male | 2009 |
Severe hiccups during chemotherapy: corticosteroids the likely culprit.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Adult; Antidotes; Antiemetics; Antimetabolites, Antineoplas | 2009 |
[Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2009 |
[Efficacy of preventive treatment for delayed emesis induced by FOLFOX4 chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dexamethasone; Do | 2009 |
A case of signet ring carcinoma of the appendix: dilemmas in differential diagnosis and management.
Topics: Abdominal Pain; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Appendiceal Neoplasms; | 2010 |
[Oxaliplatin-based regimen for the treatment of advanced or metastatic gastric/esophagogastric junction cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Esophagogastric Junctio | 2009 |
Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ato | 2011 |
Comparison of four cisplatin-based radiochemotherapy regimens for nonmetastatic stage III/IV squamous cell carcinoma of the head and neck.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2011 |
Gastroduodenal complications after concurrent chemoradiation therapy in patients with hepatocellular carcinoma: endoscopic findings and risk factors.
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Chemoradiotherapy; Duodenal Ulcer | 2011 |
[Clinical usefulness of oral aprepitant for alleviation of delayed nausea and vomiting induced by mFOLFOX6--report of a case].
Topics: Adenocarcinoma; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Female; Flu | 2010 |
[Taxan induction chemotherapy and concomitant chemoradiotherapy with cisplatin in patients with locally advanced head and neck cancer--early results].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplat | 2010 |
Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents, Phytogenic; Colorectal Neoplasms | 2012 |
[Weekly regimen of paclitaxel liposome combined with cisplatin and 5-fluorouracil continuous infusion in the treatment of advanced gastric carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 2011 |
Self-reported compliance with capecitabine: findings from a prospective cohort analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Fema | 2011 |
[Induced nausea and vomiting induced by mFOLFOX6 and FOLFIRI with advanced colorectal cancer: a retrospective survey].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2011 |
[Comparison of the toxicities and efficacies of the combination chemotherapy regimens in advanced gastric cancer patients who achieved complete response after chemotherapy].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Ci | 2011 |
Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations.
Topics: Adverse Drug Reaction Reporting Systems; Capecitabine; Data Mining; Deoxycytidine; Diarrhea; Fluorou | 2012 |
[Assessment of nausea and vomiting during FEC regimen for breast cancer after the novel antiemetic agent - introduction using MASCC antiemesis tool].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclopho | 2012 |
[Antiemetic effect of palonosetron in advanced colorectal cancer patients receiving mFOLFOX6 and FOLFIRI: a retrospective survey].
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2012 |
Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity.
Topics: Aged; Biomarkers; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Huma | 2012 |
[Efficacy of docetaxel and nedaplatin combined with concurrent intensity modulated radiation therapy in the treatment of esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2012 |
Is there an association between PONV and chemotherapy-induced nausea and vomiting?
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Betamethasone; Breast Neoplasms; | 2013 |
Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report.
Topics: Alopecia; Antimetabolites, Antineoplastic; Area Under Curve; Diarrhea; Drug Eruptions; Female; Fever | 2002 |
A CONTROLLED CLINICAL EVALUATION OF ANTIEMETIC DRUGS.
Topics: Antiemetics; Benzamides; Fluorouracil; Humans; Pharmacology; Prochlorperazine; Tranquilizing Agents; | 1963 |
FURTHER CLINICAL COMPARISON BETWEEN 5-FLUOROURACIL (5-FU) AND 5-FLUORO-2' -DEOXYURIDINE (5-FUDR).
Topics: Brain Neoplasms; Breast Neoplasms; Diarrhea; Floxuridine; Fluorouracil; Geriatrics; Humans; Liver Ne | 1963 |
EFFECTS OF 2'-DEOXY-5-FLUOROURIDINE (NSC-27640) AND 5-FLUOROURACIL (NSC-19893) ON CHILDHOOD LEUKEMIA.
Topics: Bone Marrow Examination; Child; Floxuridine; Fluorouracil; Leukemia; Leukopenia; Melena; Nausea; Tox | 1964 |
COMPARISON OF HIGH-DOSAGE AND LOW-DOSAGE-MAINTENANCE THERAPY WITH 5-FLUOROURACIL IN SOLID TUMORS.
Topics: Diarrhea; Fluorouracil; Humans; Nausea; Neoplasms; Stomatitis; Toxicology; Vomiting | 1964 |
CURRENT STATUS OF 5-FLUOROURACIL THERAPY IN FAR-ADVANCED NEOPLASTIC DISEASE.
Topics: Alopecia; Chlorpromazine; Diarrhea; Erythema; Fluorouracil; Leukopenia; Nausea; Neoplasms; Thrombocy | 1964 |
FLUORINATED PYRIMIDINE THERAPY OF ADVANCED GASTROINTESTINAL CANCER.
Topics: Alopecia; Colonic Neoplasms; Drug Eruptions; Esophagitis; Fluorouracil; Gallbladder Neoplasms; Human | 1964 |
[RESEARCH ON CERTAIN DIGESTIVE DYSKINESIAS AND FUNCTIONAL DISORDERS].
Topics: Antiemetics; Apomorphine; Cobalt Isotopes; Cyclophosphamide; Digitalis Glycosides; Dyskinesias; Dysp | 1964 |
[DIGESTIVE INTOLERANCE TO DIGITALIN, CYTOSTATIC DRUGS AND VARIOUS THERAPEUTIC DRUGS. THEIR TREATMENT WITH METHOCLOPRAMIDE].
Topics: Antiemetics; Antitubercular Agents; Cobalt Isotopes; Cyclophosphamide; Cytostatic Agents; Digitalis | 1964 |
Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2003 |
Is drug-induced toxicity a good predictor of response to neo-adjuvant chemotherapy in patients with breast cancer?--a prospective clinical study.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X | 2004 |
5-Fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a case.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineopl | 2005 |
The anti-cancer drug-induced pica in rats is related to their clinical emetogenic potential.
Topics: Animals; Anorexia; Antineoplastic Agents; Cisplatin; Dactinomycin; Fluorouracil; Kaolin; Male; Pica; | 2007 |
Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2007 |
Chemotherapy-induced nausea, vomiting, and fatigue--the role of individual differences related to sensory perception and autonomic reactivity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Arousal; Autonomic Nervous Sys | 2007 |
Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; | 2008 |
[The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Combinations; Female; Fluorouracil; Humans; Leu | 1982 |
Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Neoplasms; | 1984 |
[Non-hematologic adverse effects of cytostatic drugs].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Diarrhea; Drug Eruptions; Female; | 1984 |
Phase I evaluation of oral tegafur.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Blood Cell Count; Diarrhea; Dose-Response Relatio | 1983 |
Phase I-II studies of oral tegafur (ftorafur).
Topics: Administration, Oral; Bone Marrow; Breast Neoplasms; Colonic Neoplasms; Dose-Response Relationship, | 1983 |
Phase II trial of streptozotocin, mitomycin C, and 5-fluorouracil in adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Drug Evaluation; Drug Therapy, Combination; Fluorouracil; Humans; Mitomycins; Nausea | 1980 |
Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neopla | 1984 |
Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Breast Neoplasms; Cy | 1984 |
Pharmacokinetic rationale for the interaction of 5-fluorouracil and misonidazole in humans.
Topics: Adult; Aged; Drug Evaluation; Drug Synergism; Female; Fluorouracil; Gastrointestinal Neoplasms; Huma | 1983 |
Mallory-Weiss tear. A complication of cancer chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dimenhydrinate; Doxorub | 1983 |
Combination chemotherapy including adriamycin for advanced transitional cell carcinoma of the urinary tract.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Transitional Ce | 1983 |
Review of a new antimetabolic agent, 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione (FD-1).
Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; Delayed-Action Preparations; Dogs; Drug Evalu | 1980 |
Adjuvant chemotherapy (CMF) for breast carcinoma: hematological side effects.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Carcinoma; Cyclophosp | 1982 |
VP-16 and adriamycin in patients with advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 1982 |
Prednimustine in combination with methotrexate and 5-FU (PMF): a pilot study.
Topics: Aged; Alopecia; Breast Neoplasms; Chlorambucil; Drug Therapy, Combination; Female; Fluorouracil; Hum | 1982 |
[Insufficient efficacy of the use of a single 8 mg tablet of ondansetron in the prevention of nausea and vomiting induced by FEC chemotherapy].
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1995 |
A pilot study of concomitant radiation and chemotherapy in patients with locally advanced head and neck cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 1993 |
Spontaneous gastroduodenal perforation in patients with cancer receiving chemotherapy and steroids. Report of four cases combining 5-fluorouracil infusion and cisplatin with antiemetics dexamethasone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Duodenal Dise | 1993 |
Neoadjuvant chemotherapy in locally advanced breast cancer.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breas | 1996 |
[CF/5-FU-DDP therapy for esophageal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Es | 1995 |
[Antiemetic efficacy of granisetron in repeated CAF chemotherapy after breast cancer operation].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclopho | 1997 |
Prolonged nausea and vomiting after high dose chemotherapy and autologous peripheral stem cell transplantation in the treatment of high risk breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin; Comb | 1997 |
Mitomycin C, cisplatin, and 5-fluorouracil for advanced and/or recurrent head and neck squamous cell carcinomas.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 1997 |
[Usefulness of continuous venous daily chemotherapy of 5-fluorouracil and low-dose cisplatin for patients undergoing noncurative surgery].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Ci | 1997 |
Biochemical modulation in the treatment of advanced cancer: a study of combined leucovorin, fluorouracil, and iododeoxyuridine.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as | 1996 |
An audit of antiemetic use with CMF chemotherapy.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dex | 1998 |
Idiosyncratic reaction after oxaliplatin infusion.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chills; Fever; Fluorouracil; | 2001 |
Manifest Anxiety Scale for evaluation of effects of granisetron in chemotherapy with CDDP and 5FU for head and neck cancer.
Topics: Adult; Aged; Antiemetics; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Prot | 2001 |
Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients.
Topics: Adult; Aged; Alkaline Phosphatase; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Breas | 2002 |
Mallory-Weiss lesion following cancer chemotherapy.
Topics: Drug Therapy, Combination; Fluorouracil; Humans; Lung Neoplasms; Male; Mallory-Weiss Syndrome; Methy | 1977 |
Cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in advanced gastrointestinal cancer.
Topics: Aged; Bone Marrow; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Gastrointestin | 1979 |
Ftorafur, adriamycin, cyclophosphamide and BCG in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; BCG Vaccine; Body Weight; Breast Neoplasms; Central Nervous Syst | 1979 |
Chemotherapy of common solid tumours in a general surgical unit.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Interactions; Drug Syne | 1979 |
[Chemotherapeutic combinations of mutually potentializing drugs. 1-Application to the treatment of breast cancers].
Topics: Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Synergism; Drug Ther | 1975 |
Toxicity and side-effects of combination chemohormonal therapy of advanced breast cancer.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therap | 1992 |
Progressive loss of antiemetic efficacy during subsequent courses of chemotherapy.
Topics: Adult; Aged; Amitriptyline; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclophosph | 1992 |
Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chi-Square Distributi | 1991 |
Emesis during past pregnancy: a new prognostic factor in chemotherapy-induced emesis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin | 1990 |
[Adverse reactions to carcinostatics and countermeasures].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carbazilquinone; Chemical and Drug Indu | 1989 |
Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosph | 1988 |
Sequential combination of 5-fluorouracil, cis-platinum and irradiation. 1. Advanced head and neck cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; E | 1988 |
A phase II clinical trial of flutamide in the treatment of advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Cyclophospha | 1988 |
[The prevention of CDDP-induced emesis with a combination regimen including metoclopramide, dexamethasone, droperidol and diphenhydramine].
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dex | 1987 |
Results in the management of locally unresectable pancreatic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 1986 |
Simultaneous cisplatin and 5-fluorouracil as second-line treatment of head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1987 |
High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplati | 1987 |
Chemoradiotherapy as initial management in patients with squamous cell carcinoma of the head and neck.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1986 |
Tastes associated with parenteral chemotherapy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorour | 1985 |
[Therapeutic effect of sequential doses of methotrexate (MTX) and 5-fluorouracil (5-FU) in advanced gastric cancer: comparison of intermediate-dose MTX with high-dose MTX].
Topics: Adult; Aged; Alopecia; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusio | 1985 |
Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer.
Topics: Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Cycloph | 1985 |
Combination chemotherapy in gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Alopecia; Appendiceal Neoplasms; Diarrhea; Drug Eruptions; Fluorouracil; Gall | 1970 |
Phase II evaluation of BCNU and 5-FU in gastrointestinal carcinomas.
Topics: Adenocarcinoma; Administration, Oral; Carmustine; Colonic Neoplasms; Diarrhea; Fluorouracil; Hematoc | 1974 |
Sequential 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037) and 5-fluorouracil (NSC 19893) therapy of gastrointestinal cancer.
Topics: Cyclohexanes; Fluorouracil; Gastrointestinal Neoplasms; Humans; Leukopenia; Nitroso Compounds; Nitro | 1972 |
Toxicity studies of fluorouracil used with adrenalectomy in breast cancer.
Topics: Adrenalectomy; Adult; Aged; Alopecia; Ataxia; Blood Platelet Disorders; Breast Neoplasms; Diarrhea; | 1972 |
5-fluorouracil intravenous infusion for 48 hours, repeated every two weeks.
Topics: Adult; Aged; Breast Neoplasms; Diarrhea; Evaluation Studies as Topic; Female; Fluorouracil; Gastroin | 1972 |
The effect of 5-fluorouracil on small bowel mucosa.
Topics: Adult; Aged; Biopsy; Diarrhea; Duodenum; Female; Fluorouracil; Humans; Intestinal Mucosa; Intestine, | 1971 |
Oral administration of fluorouracil. A preliminary trial.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Bile Duct Neoplasms; Colonic Neoplasms; Diarrhea; Fluorouraci | 1968 |